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Abstract
.0
Cryptococcal neoformans is the commonest cause of invasive fungal disease in the 
world, causing up to 1.5 million cases of meningitis each year, and 1 million deaths. The 
aims of this thesis were to understand the differences in cryptococcal meningitis in Viet 
Nam in relation to the HIV infection status of the host, focussing on disease clinical 
phenotype, prognostic factors and the molecular epidemiology of the infecting isolates. 
In addition, the thesis examines the antifungal susceptibilities of Vietnamese 
Cryptococcus spp, how these vary by species and time, and the clinical utility of their 
measurement.
Patients drawn from two prospective cohorts (HIV infected and HIV uninfected) form 
the basis of the thesis. The HIV uninfected patients are predominantly 
immunocompetent. Clinical and investigational findings are compared in relation to the 
literature. HIV patients had shorter durations of history and more frequent headache, but 
there were few differences in clinical presentation. Previously published prognostic 
factors were reassessed; only 3 of 40 (altered consciousness, cerebrospinal fluid (CSF) 
white cell count, and CSF cryptococcal antigen titre) were independently associated with 
outcome.
Mortality was significantly higher in HIV infected patients, but the shapes of the 
survival curves were similar for both groups, most deaths occurring in the first 4 weeks 
of treatment.
2
Amplified Fragment Length Polymorphism analysis was used to define the relationships 
between HIV positive and negative strains -  a clade of C. neoformans var grubii with 
increased propensity to cause disease in immunocompetent patients was identified.
The Sensititre® YeastOne® system was used to determine MICs of 7 antifungal drugs. 
The susceptibility of C. neoformans has decreased significantly over a .13 year period. 
No relationship with the rate o f clearance of yeast from CSF and antifungal MIC was 
found, but raised amphotericin B MIC after 48 hours incubation may be associated with 
early death and warrants further investigation.
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Chapter 1 
Introduction
Cryptococcus neoformans is an encapsulated basidiomycetous yeast (figure 1.1). The 
HIV pandemic has raised its profile from obscure fungus to the most important fungal 
cause o f morbidity and mortality in the world. Previously best known as a rare cause of 
meningitis in patients with some form of acquired immunodeficiency such as 
haematological malignancy or organ transplantation, Cryptococcus neoformans is now 
estimated to cause 1 million cases of meningitis per year, and 720 000 deaths, most 
occurring within 3 months of diagnosis [1].
Figure 1.1 Encapsulated yeasts of Cryptococcus neoformans (India ink stain).
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1.1 History
Studies on Cryptococcus neoformans began in 1894, when San Felice first isolated 
Saccharomyces neoformans from peach juice in Italy, and demonstrated that it was 
pathogenic in laboratory animals [2, 3]. He subsequently isolated an encapsulated yeast 
(which he termed Saccharomyces lithogenes) from the lymph node of an ox [4]. In the 
same year the first human infection was described by 2 German physicians, Otto Busse, 
a pathologist, and Abraham Buschke, a surgeon and dermatologist (who later perished 
with other intellectuals in the Theresienstadt concentration camp in 1943). They isolated 
an encapsulated yeast, which they termed Saccharomyces hominis, from the tibia of a 31 
year old woman [4]. The second human case was described by Curtis in France in 1896 
-  he recovered a yeast-like fungus from a hip lesion and named it Saccharomyces
thsubcutaneous tumefaciens [4]. Thus by the end of the 19 century the organism had 
been isolated from the environment, demonstrating that it could be free-living; from 
humans and animals, demonstrating its ability to cause disease; and it had been shown 
that it was possible to propagate the organism in the laboratory and infect laboratory 
animals.
In 1901 Vuillemin re-examined several of the isolates, and finding the ascospore 
characteristics of the Saccharomyces genus to be absent, reclassified the organism in the 
genus Cryptococcus [5]. Cryptococcus hominis was subsequently described as a 
synonym for C. neoformans [6] . During the first half of the 20th century numerous 
names were suggested for C. neoformans, including Torula histolytica (based on the 
mistaken assumption that it caused tissue lysis), Cryptococcus histolytica and 
Debaromyces hominis, but by the 1950s the term Cryptococcus neoformans had come
26
into widespread use and was quickly adopted by both the scientific and medical 
literature [7-9].
Through the beginning of the 20th century numerous case reports of human disease were 
published. The clinical syndromes were varied, including disease of the skin, tumour­
like lesions, brain, bone, spine, lungs and kidneys. The first description of cryptococcal 
meningitis was published in 1905 by von Hansemann, although Freeman has argued that 
a case o f chronic meningitis described in 1861 by Zenker, before the isolation of the 
organism, may represent the first case history [4, 10,11].
1.2 Microbiology
The genus Cryptococcus now contains at least 39 species of yeast, but few are able to 
cause disease in humans [4]. Disease has rarely been attributed to other species such as 
C. flavescens (formerly laurentii) and C. albidus, but almost all human disease is due to 
infection with the C. neoformans species complex [12-15]. The C. neoformans species 
complex consists of C. neoformans var grubii, C. neoformans var neoformans, and C. 
neoformans var gattii. Since the middle of the last century, it was known that different 
isolates could be distinguished using rabbit sera. Evans and Kessel demonstrated 3 
serotypes they termed A, B and C [16-18]. Subsequently a 4 serotype, D, was 
identified, and a hybrid AD strain discovered in the 1980s [19, 20]. In general, 
Cryptococcus neoformans var grubii and var neoformans type as serotype A or D 
respectively, and Cryptococcus neoformans var gattii as serotype B or C, although there 
are occasional inconsistencies reported in the literature [21].
The term C. neoformans var gattii was first used to describe an atypical strain of C. 
neoformans isolated from a leukaemic patient in 1970 [22]. C. neoformans var gattii has
recently been designated as a separate species (C. gattii) because of increasing data 
suggesting its distinctive evolution [23]. Using multigene sequence analysis it has been 
estimated that C. gattii diverged from C. neoformans approximately 49 million years 
ago [24]. C. neoformans and C. gattii can be distinguished by L-canavanine-glycine 
bromothymol blue agar (CGB), serotyping, RAPD patterns, PCR fingerprints, RFLP 
patterns, AFLP patterns and DNA sequencing [21, 25-35]. Additionally, most of these 
methods have shown that C. neoformans can be divided into 2 groups which have been 
described as separate varieties, a suggestion that was first made by Franzot based on 
both phenotypic and genotypic data [36]. These 2 groups are designated C. neoformans 
var grubii (serotype A) and C. neoformans var neoformans (serotype D). The 2 lineages 
are estimated to have diverged some 24.5 million years ago [24]. By far the majority of 
infections world wide are due to C. neoformans var grubii.
Cryptococcus neoformans and C. gattii are usually haploid yeasts that reproduce 
asexually[4]. However, they are dimorphic, and as well as existing in the asexual yeast 
form, characterised by oval to spherical cells with a polysaccharide capsule, have a 
sexual or perfect state which is characterised by the presence of basidiospores. Mating is 
a heterothallic process controlled by the MAT locus which determines the mating type 
(a or a), and consists of over 20 genes [6], The MATa mating type is predominant in 
both clinical specimens and the environment for both C. neoformans var grubii and C. 
neoformans var neoformans, and is considered to be a virulence factor (being 
disproportionately prominent for C. neoformans var neoformans in clinical specimens) 
[37]. The MATa mating type of C. neoformans var grubii was thought to be extinct, and
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has only recently been rediscovered [37]. Each mating type of C. gattii occurs in roughly 
1:1 ratio. Interestingly the a  mating type may play a role in neurotrophism [38].
The perfect state has not been described in association with clinical specimens and is 
observed only during mating, which has only been observed under laboratory conditions 
[6]. The asexual form reproduces through budding, which is frequently seen in clinical 
specimens. Some strains produce pseudohyphal forms that may be seen in tissue 
sections. Additionally, when under physiological stress, such as nitrogen deprivation or 
desiccation, C. neoformans can reproduce by haploid fruiting, a process which is similar 
to mating, although it is less effective in producing basidiospores, and is homothallic [6]. 
Haploid fruiting can occur with either mating type, but C. neoformans var grubii has 
poor fruiting ability, suggesting that it is not haploid fruiting that determines the 
different prevalences o f the mating types within the environment [39]. Mating and 
haploid fruiting are clinically important since the infectious propagule is most likely the 
resultant basidiospores [40, 41].
C. neoformans is readily cultured in the laboratory, producing mucoid colonies within 
36 to 72 hours on blood or Sabouraud’s agar. Colonies are white to cream in colour, but 
characteristic dark brown colonies are formed when grown on birdseed agar (Figure 
1.2a). The organism grows readily in automated blood culture systems. Identification 
can be confirmed through the demonstration of capsule growth on com meal agar, 
development o f characteristic brown mucoid colonies on birdseed agar, and through 
commercially available sugar assimilation test kits. Most strains are urease positive, 
turning urea agar pink (Figure 1.2b).
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Figure 1.2 Cryptococcus neoformans
a) Characteristic brown colonies on 
bird seed agar
b) Blue discolouration of 
canavanine glycine bromothymol 
blue agar with growth of 
Cryptococcus gattii
c) Pink discolouration of urea agar 
due to urease production
a
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Biotyping, to distinguish C. gattii from C. neoformans, can be done relatively cheaply 
using canavanine-glycine-bromothymol blue agar (Figure 1.2c).
1.3 Epidemiology
Neither C. neoformans nor C. gattii are primary pathogens, but are able to cause disease 
as a bystander effect of their adaptations to the environment. Cryptococcus neoformans 
is associated with pigeons, and has been repeatedly isolated from both the birds’ crops 
and their droppings [42-45]. It has also been isolated from soil and decaying wood [46, 
47]. C. gattii is associated with trees, first being associated with eucalypts, but has also 
been isolated from soil and associated with other tree species [48-50].
Antibodies to capsular antigen are ubiquitous in the sera of both HIV infected and 
uninfected asymptomatic individuals, suggesting that exposure to the organism is 
widespread [51]. The association with a bird as common and as widely distributed as the 
pigeon may explain C. neoformans ’ global distribution and the high rates of 
seropositivity. However, disease in otherwise healthy individuals is rare. In California 
the incidence rate of invasive cryptococcal disease in otherwise healthy people has been 
estimated at 0.2/million people/year [52]. Various conditions have been recognised to 
increase the disease risk, including sarcoidosis, lymphoproliferative disorders, 
hypogammaglobulinaemia, corticosteroid therapy, systemic lupus erythematosus, 
idiopathic CD4 lymphopenia, cirrhosis and peritoneal dialysis[4]. In particular, 
immunosuppression for solid organ transplant patients, and the use of monoclonal 
antibody based immunosuppressive therapies, are recognised and important iatrogenic 
risk factors for disease [53-55]. However, the major factor influencing the epidemiology 
of cryptococcal meningitis has been the HIV epidemic. Park et al have estimated the
global burden of disease due to cryptococcal meningitis, and conclude that the 
worldwide number o f infections and deaths due to cryptococcal meningitis is similar to 
that reported for diseases that have achieved greater public health attention [1], They 
estimated that there are almost 1 million cases of cryptococcal meningitis per year 
(range 370 000 -  1.44 million). As might be expected, most of these cases occur where 
there is little capacity to manage severe disease. There are estimated to be 720 000 cases 
annually in Africa, and South and Southeast Asia are the next most affected regions, 
with 120 000 cases per year. The number of deaths, derived from the case fatality rates 
reported for studies from the different regions, is estimated to be 625 000 per year (range 
125 000 -  1 125 000). This approaches the number o f deaths due to pertussis, 
poliomyelitis, diphtheria, measles and tetanus combined (530 000) [1, 56]. In Uganda, 
French reported twenty per cent o f all AIDS deaths to be due to cryptococcal meningitis, 
making it the second most frequent cause of death in HIV infection after tuberculosis, 
similar to the experience at the Hospital for Tropical Diseases, Ho Chi Minh City [57, 
58].
In addition, pulmonary cryptococcosis in HIV infected patients is probably under­
diagnosed. An autopsy series of 8421 miners from South Africa (estimated HIV 
seroprevalence 24%) identified pulmonary cryptococcal infection in 7%. Only 1.9% of 
these cases had an ante-mortem diagnosis, being frequently misdiagnosed as 
tuberculosis (TB), bacterial or Pneumocystis pneumonia [59]. Cryptococcus neoformans 
may be responsible for more deaths than Mycobacterium tuberculosis in sub-Saharan 
Africa, recently estimated to account for 350 000 deaths per year [1, 56]. While most of 
these estimates were derived prior to the current efforts to improve access to anti­
retroviral therapy (ART), in fact rates of cryptococcal meningitis have actually increased 
in South Africa since the introduction o f ART [1]. This could be a result of 
improvements in diagnostics, better case ascertainment, or immune reconstitution 
disease, all related to improved provision of HIV services.
Cryptococcus gattii tends to cause disease in the immunocompetent. In particular, 
disease is associated with male aboriginal people in northern Australia, and it is also an 
important cause of meningitis in Papua New Guinea [60-62]. The incidence of C. gattii 
infection may be increasing - while originally associated with tropical and sub-tropical 
regions, there has been a notable outbreak in British Columbia since 1999, and there is 
now evidence of autochthonous spread within the region [49, 63-69]. However, even in 
tropical regions where the HIV seroprevalence is high, infection with C. gattii remains 
uncommon [70]. As might be expected with a potential pathogen associated with 
eucalypts, disease in koalas is well described [71]. Disease described in wild dolphins 
associated with the British Columbia outbreak suggests that either C. gattii or dolphins 
are adapting their environmental niches in ways that have not been anticipated [72]! 
Despite their marine existence the route of infection in dolphins is likely the same as for 
other mammals -  namely inhalation of air-borne spores.
Recently it has been reported that a large proportion of disease in immunocompetent 
Chinese patients is due to infection with Cryptococcus neoformans var grubii, and that 
these strains are genetically homogeneous. How they relate to strains isolated from HIV 
positive patients has not been elucidated.
At the Hospital for Tropical Diseases (HTD), Ho Chi Minh City, there has been a steady 
rise in the number of cases of cryptococcal meningitis since 1994, as illustrated by the
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rates of its isolation from CSF in comparisons to Streptococcus suis, the commonest 
identified cause of pyogenic bacterial meningitis in our hospital (figure 1.3). This rise in 
cases parallels the AIDS epidemic in Viet Nam. Cryptococcus neoformans is now the 
most frequently isolated organism from both blood and cerebrospinal fluid at HTD. In 
addition, a small number of cases (2 -1 0 )  of cryptococcal meningitis are seen each year 
at HTD in patients who are not HIV infected. Part of my work outlined in this thesis was 
aimed at speciating these strains and determining the relationship of these strains with 
those from HIV infected patients.
Cryptococcus neoformans and Streptococcus 
suis CSF Isolates, Hospital for Tropical Diseases 
1994 -  2006
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Figure 1.3 C. neoformans and S. suis isolates from CSF 1994 -  2006 at the Hospital for Tropical 
Diseases.
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1.4 Human Disease
Infection of almost all organs has been described, but the primary organs of infection are 
believed to be the lungs, since this is the postulated route of infection. However, as the 
South African experience described above demonstrates, it is unusual for a diagnosis of 
pulmonary disease to be made in an HIV infected patient. It is not clear whether clinical 
disease is the result o f recrudescence of latent infection, or the result o f primary 
infection. The recent outbreak in British Columbia has allowed better estimates of the 
incubation period for C. gattii, because it has been possible to define the probable 
exposure periods for non-residents. The median incubation is estimated to be 6-7 months 
(range 2 to 11 months) [73]. It is more difficult to arrive at estimates for C. neoformans, 
since unlike C. gattii it is ubiquitous, and unlike tuberculosis spread is not via person to 
person. In France Dromer found that isolates from African patients were closely related, 
despite them having been resident there for a median of 9 years, suggesting that in HIV 
patients disease due to C. neoformans var grubii can be due to recrudescence of latent 
infection [74]. However, there are also reports of central nervous system (CNS) disease 
occurring short periods after recent exposure to pigeons and pigeon guano (with 
incubation periods as short as 7 to 10 weeks) [75].
1.4.1 Disease phenotypes
The major site o f infection is the central nervous system (CNS), but disease of the lungs, 
skin, eyes, and prostate is also well described [4]. More rarely, infection occurs in bone, 
heart, liver, lymph nodes, joints, muscle, adrenal glands and kidneys [4]. Host immune 
status is thought to have a significant role in determining the disease phenotype, but
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differences have also been ascribed according to the infecting species [4, 64,-76]. For 
example, focal neurological and pulmonary lesions, and visual impairment are more 
common with C. gattii infection [76]. However, by far the majority of cases of 
cryptococcal meningitis in HIV infected or uninfected patients are due to infection with 
Cryptococcus neoformans varieties. Significant co-morbidities are common in the HIV 
uninfected patients with cryptococcal meningitis, so the specific effect of HIV on 
clinical phenotype is not fully defined. The effect of HIV may be significant. Presence 
of a more robust immune response may increase the risk of residual disability, which 
may be reduced by specific adjuvant therapies [76, 77]. However, it is the results of 
treatment in HIV infected patients that are used to guide the treatment in HIV uninfected 
patients [78]. Better understanding the effect of HIV on the clinical phenotype of 
cryptococcal meningitis will help determine whether it s reasonable to extrapolate 
clinical trial results from one set o f patients to another. In chapter 3 of the thesis I will 
examine the impact of HIV on the clinical phenotype of cryptococcal meningitis and 
discuss in more detail the current literature [4, 64]. A brief review of the clinical aspects 
o f cryptococcal meningitis is presented below.
1.4.2 Clinical Features
Cryptococcal meningitis usually presents as a subacute meningitis, which is clinically 
indistinguishable from that due to tuberculosis [79]. Patients with HIV infection are 
most at risk when the CD4 count has fallen below lOOcells/uL. Commonly reported 
symptoms include fever, headache, neck stiffness, malaise and visual disturbance.
Visual loss seems to be particularly associated with C. gattii infection [80]. Nausea and
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vomiting may indicate raised intracranial pressure. Physical examination may reveal 
other signs of severe immunosuppression, such as oral candidiasis and oral hairy 
leukoplakia, and signs characteristic of meningitis such as confusion, neck stiffness, 
papilloedema and cranial nerve palsies (figure 1.4).
Figure 1.4 Left 6th nerve palsy in cryptococcal meningitis*.
Occasionally papular or ulcerated skin lesions are seen, which can be an important 
diagnostic aid where there are no facilities for microbiological confirmation (figure 1.
Figure 1.5 Typical skin lesion in cryptococcosis*.
However, in Asia Penicillium marneffei infection can cause a similar appearance 
(figurel.6).
Figure 1.6 Typical skin lesion due to Penicillium marneffei*.
*all patients provided consent for photography
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While HIV infection increases the risk o f developing cryptococcal meningitis, the effect 
it has on the clinical phenotype is not clear. In tuberculous meningitis the death rate in 
HIV co-infected Vietnamese patients is 2-3 fold higher than in HIV uninfected patients 
[81]. Despite this increase in mortality, the neurological findings in patients with 
tuberculous meningitis with and without HIV co-infection are similar [81]. The 
influence of HIV on the presentation, course and outcome of cryptococcal meningitis is 
less clear, because of the relative rarity o f cryptococcal meningitis in HIV uninfected 
patients, making clinical comparisons in single centres or even single geographical areas 
difficult. Moreover, a large proportion of cases of cryptococcal meningitis in HIV- 
uninfected patients are accounted for by patients with co-existing malignancies, organ 
transplants or other chronic diseases that are associated with morbidities and mortalities 
of their own, or are due to infection with Cryptococcus gattii, a species that probably 
accounts for less than 1% of all associated HIV infections worldwide [53, 70, 82-89]. As 
will be shown in chapter 3, the populations in whom cryptococcal meningitis are 
described are highly heterogeneous. Better understanding the particular effect of HIV 
infection on the disease phenotype of cryptococcal meningitis would allow the 
development of hypotheses regarding the pathophysiology of the disease in both HIV 
infected and uninfected patients (for example, which complications are immune 
mediated), and improve understanding of the generalizability of findings from one 
patient group to another.
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1.4.3 Radiological Findings
Magnetic resonance imaging (MRI) has increased sensitivity in detecting intracranial 
abnormalities compared with computerised tomography (CT) brain scanning. Findings 
are not specific; tuberculous meningitis is the condition highest in the differential 
diagnosis. Hydrocephalus is the most common finding (figure 1.7) [90]. Basal 
meningeal enhancement may be present. Evidence o f both parenchymal and meningeal 
disease can also be seen, but scans are frequently normal [91]. The abnormalities seen 
include cryptococcomas, dilated Virchow-Robin spaces and cortical nodules. The 
commonest parenchymal areas to be involved are the basal ganglia [91]. Cerebral 
infarctions, again usually seen in the basal ganglia but also affecting the thalamus and 
internal capsule, are indistinguishable from those seen in tuberculous meningitis [92]. 
Cryptococcomas are more common in immunocompetent patients, and usually enhance 
with contrast, although this effect can be attenuated in immunocompromised patients 
[90]. A miliary appearance has also been described [90]. Of note, at the Hospital for 
Tropical Diseases, we have seen patients with simultaneous culture confirmed 
cryptococcal and tuberculous meningitis.
Abnormal chest X-rays occur in up to one third of patients who present primarily with 
neurological disease. The manifestations are protean, varying from infiltrative lesions 
through to cavitation and mass lesions, particularly with C. gattii infection [4].
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Figure 1.7 MRI scan showing hydrocephalus in cryptococcal meningitis.
1.4.4 Diagnosis
The definitive diagnosis is made through examination of CSF and the demonstration of 
encapsulated yeasts in cerebrospinal fluid, either through microscopy or culture. 
Microbiological diagnosis is considerably easier than in tuberculous meningitis - 
staining with India ink is usually sufficient, but cells are also easily seen with Gram’s or 
Ziehl-Neelsen’s stains [93]. Cryptococcus spp grow readily on blood and Sabouraud’s 
agars although growth is enhanced for some strains at 30 rather than 35C. The CSF 
opening pressure is frequently raised, typically greater than 40mmCSF, and a mild 
lymphocyte predominant pleocytosis is characteristic, although CSF may be acellular, 
particularly in the immunosuppressed. The CSF to blood glucose ratio may be reduced
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but can be normal. The protein is normal or raised. The CSF lactate is sometimes raised 
(typically 4-6mmols), but less so than is seen in pyogenic meningitis. In addition, 
cryptococcal antigen testing of CSF and serum is highly specific and sensitive, with 
sensitivities and specificities ranging from 83% to 97% and 93% to 100% respectively 
when compared to culture [94-96]. The sensitivity of the India ink test is in the order of 
50% in non-AIDS and 80% in AIDS patients when compared to culture, the lower limit 
of detection being around 1,000 yeast cells/mL CSF, although under experimental 
conditions it performs similarly to antigen testing [97].
1.4.5 Prognostic factors
In tuberculous meningitis, well validated determinants of disease outcome (the United 
Kingdom Medical Research Council grading system) continue to apply well to HIV 
infected patients [98]. In cryptococcal meningitis, determinants of outcome are less 
clear. Individual studies have identified factors associated with outcome including 
fungal load at baseline, clinical features, presence of raised intracranial pressure and 
markers of inflammation in the CSF [61, 99-106]. However, these have rarely been 
tested in other datasets, investigators instead tending to identify further factors within 
their own cohorts. While identified prognostic markers may seem plausible, it cannot be 
discounted that the associations identified are simply chance findings [99, 101, 107, 
108]. Treatment options for cryptococcal meningitis are limited, and have significant 
risks of toxicity. While treatment for all patients needs to be improved, the identification 
of reliable predictors of outcome on presentation may enable the identification of
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patients in whom the use o f intensified, but potentially more toxic, therapy can be 
justified [109].
In Chapter 3 o f this thesis I discuss the literature on prognostic factors in more detail, 
and evaluate previously identified prognostic factors in a cohort of Vietnamese HIV 
infected and uninfected patients.
1.5 Treatment
Antifungal drug options for cryptococcal meningitis are limited. The Infectious Diseases 
Society of America has this year published revised treatment guidelines for cryptococcal 
meningitis [78]. They differ little in the recommended choice of antifungal regime from 
the guidelines published 10 years earlier [110]. The guideline authors suggest that the 
critical factors for successful treatment are host immunity, site of infection, drug toxicity 
and management of underlying disease. However, the lack of change in the guidelines 
perhaps also reflects the lack of trials that have been powered to clinical end-points in 
the last 15 years, which probably reflects the fact that most disease occurs in resource- 
poor settings. It seems surprising that in a disease where the median time to CSF 
sterilisation is in the order o f 2 weeks, choice of antifungal therapy is not considered 
more critical [107].
1.5.1 Antifungals
1.5.1.1 Amphotericin B
Amphotericin B is the mainstay o f treatment. This broad spectrum drug is fungicidal and 
in vitro resistance is extremely rare [111-115]. Amphotericin B causes membrane
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disruption through binding to sterols in the cell membrane, but it probably also has an 
effect through stimulating macrophage function [116-118]. Bioavailability is extremely 
poor via the oral route and amphotericin B must be given intravenously [119]. The 
pharmacokinetics are poorly understood -  it is difficult to detect in CSF but is effective 
in cryptococcal meningitis. Nephrotoxicity is a significant problem, although usually 
reversible if the total dose administered does not exceed 4g [119]. This is exacerbated by 
salt depletion, and a normal saline infusion is recommended prior to drug administration. 
In Vietnamese patients, anaemia is common (unpublished data). The lipid formulations 
of amphotericin B have the advantage of lower toxicities, and can be given in higher 
dosage of up to 10 mg/kg/day. However, they are considerably more expensive. An 
alternative route of administration is intra-thecally.
1.5.1.2 Flucytosine
Flucytosine is a nucleotide analogue. Available in oral and intravenous formulations, it 
appears to have a synergistic action with amphotericin in vitro [120]. Flucytosine is 
converted to fluorouracil within the fungal cell and inhibits RNA biosynthesis [121]. It 
probably directly inhibits DNA synthesis. A randomised trial showed a trend towards 
more rapid CSF sterilisation in patients receiving flucytosine in combination with 
amphotericin compared with amphotericin alone, but flucytosine has not been shown to 
reduce mortality in cryptococcal meningitis [107]. It has the disadvantages of high cost, 
poor tolerability, and rapid development of resistance if used as monotherapy. In 
wealthy countries monitoring of blood levels is usual.
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1.5.1.3 Azole Drugs
The azole drugs have revolutionised the treatment of fungal infections because of their 
potency, tolerability, and oral and intravenous formulations. Fluconazole is the most 
frequently prescribed azole for cryptococcal meningitis. It has good CSF penetration, 
with peaks levels reaching 75-90% of serum levels, is relatively cheap and is widely 
available [122]. The mechanism of action of azoles is inhibition of sterol synthesis by 
the fungal cell and the effect is fungistatic [4]. Initial concerns that they might adversely 
affect the action of amphotericin if used in combination have not been born out in 
animal studies, and there are now data emerging from the treatment of systemic 
candidaemia that suggest this can be a powerful combination [123]. There is most 
experience with fluconazole in the treatment o f cryptococcal meningitis. While it is not 
as potent as itraconazole in vitro, it has better CSF penetration and is more effective in 
clinical trials [107]. The newer azoles such as voriconazole and posaconazole appear to 
have better in vitro activity against C. neoformans than fluconazole, but there are no data 
from controlled trials in cryptococcal meningitis [124],
1.5.1.4 Echinocandins
These drugs, act by inhibiting 1,3-6-D-glucan synthase complex and inhibiting cell wall 
synthesis [125]. They are generally fungicidal and active against azole resistant yeasts. 
Unfortunately, despite their otherwise broad spectrum, they have no activity against 
Cryptococcus spp.
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1.5.2 Other Treatments
1.5.2.1 Interferon Gamma
There is direct in vivo evidence that interferon gamma levels are associated with the 
ability to clear yeast from CSF in HIV infected patients[126]. Pappas reported a small 
randomised trial of recombinant interferon gamma in 75 HIV patients and found 
improved fungal clearance rates in CSF at 2 weeks in patients receiving active drug, 
although the study was too small to detect differences in survival [127].
1.5.2.2 Corticosteroids
There has never been a randomised controlled trial of steroids in the treatment of 
cryptococcal meningitis. Dexamethasone is of proven benefit in tuberculous meningitis, 
although whether this is mediated through immune modulation is not clear [128, 129]. 
Potential mechanisms through which they could improve outcome in cryptococcal 
meningitis would include their anti-inflammatory effects and modulation of raised 
intracranial pressure. Their value in bacterial meningitis seems to vary by geographical 
location [130-132]. There are retrospective data suggesting that their use in C. gattii 
meningitis may reduce the incidence of visual complications and improve outcome[29, 
31]. Seaton reported how the use o f steroids (to treat reactions to amphotericin B 
infusion) was found to be highly associated with a reduced risk of development of visual 
loss or blindness (12.5% versus 70%, p=0.007 steroids versus no-steroids), and a 10-fold 
reduction in the risk of blindness (p = 0.018)[77]. In this study 13 patients received 
hydrocortisone (between 100 and 250mg/day), two received dexamethasone (16mg/day 
for up to 7 weeks) and one received prednisolone (7 weeks). One patient receiving
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hydrocortisone improved, one patient receiving dexamethasone improved and the patient 
who received prednisolone improved. Two patients receiving hydrocortisone had 
deterioration in vision. The data reported by Seaton et al are weakened by the fact that 
they are retrospective and non-randomised, and that there was a change in the 
prescribing practice concerning steroids over time. However, they provide the best 
evidence yet o f a potential disease modifying adjunctive treatment in cryptococcal 
meningitis. Their use in HIV patients in areas of high TB incidence would need to be 
carefully monitored, and a randomised controlled trial is needed.
1.5.2.3 Antiretroviral Therapy
It is not clear when to start antiretroviral therapy in HIV patients with cryptococcal 
meningitis. The potential benefits of immune reconstitution have to be balanced against 
the risks of drug toxicity and immune reconstitution inflammatory syndromes. Like 
tuberculous meningitis, most deaths in cryptococcal meningitis occur within the first 
month of treatment [81, 133]. A randomised trial of timing of initiation of antiretroviral 
therapy in tuberculous meningitis found no difference in mortality between starting 2 
weeks after diagnosis and starting 8 weeks after diagnosis (Torok ME et al, unpublished 
data). A randomised controlled trial of early versus deferred antiretroviral therapy in 280 
patients with a diverse range of opportunistic infections, 12% of which were 
cryptococcal disease, suggested that early introduction of ARVs in cryptococcal 
meningitis might be beneficial, but failed to reach conventional levels of statistical 
significance [134]. Conversely, in a retrospective review of almost 300 patients with 
cryptococcal meningitis in Thailand, Manosuthi found timing of initiation of
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antiretrovirals had no impact on mortality (this dataset included 59 patients who began 
treatment within 1 month of diagnosis [135]. A recent trial from Zimbabwe on the 
timing of ARVs in cryptococcal meningitis was stopped early, ostensibly on the grounds 
o f safety, but in fact had been struggling to recruit patients [136]. Immediate 
introduction of ARVs (within 72 hours of diagnosis) was associated with a worse 
outcome than delayed introduction (10 weeks). The median survival time was 28 days in 
the immediate arm versus 637 days in the delayed ARV arm (Hazard ratio 2.34, 95%CI 
1 .1 2 - 4.89), but the p value was only 0.031, a value much less significant that would 
usually be considered robust enough to stop a trial early.
1.5.3 Treatment for Particular Patient Groups
1.5.3.1 HIV Infected Patients
The current recommendations for HIV infected patients are that treatment is with 
amphotericin B 0.7 -  lmg/kg/day, in combination with flucytosine (lOOmg/kg/day) for 
at least 2 weeks (induction), followed by fluconazole 400mg/day for at least 8 weeks 
(consolidation). Following these 2 stages of treatment, patients require long term 
maintenance therapy with lower dose fluconazole until there has been a degree of 
antiretroviral therapy induced immune reconstitution.
These recommendations are derived from the large (380 patients) Mycoses Study Group 
randomised controlled trial published in 1997 [107]. This was a study carried out in the 
United States in HIV infected patients who, by nature of the study entry criteria, had 
relatively mild disease. Patients received amphotericin B in the dose described, and were 
then randomised to receive flucytosine or placebo. Despite the guidelines’
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recommendation that flucytosine be included in the treatment, this study found no 
difference in outcome according to receipt of flucytosine. There was a non-statistically 
significant trend towards more rapid CSF sterilisation in the patients receiving 
flucytosine. A randomised controlled trial from Thailand compared the effect of 4 
different antifungal regimes on the rate of clearance of yeast from cerebrospinal fluid 
(CSF) [99]. The rate of decline of viable yeast counts in CSF was greatest for the 
combination o f amphotericin B with flucytosine, statistically significantly slower when 
combining amphotericin B with fluconazole 400mg/day or all 3 drugs together, and 
slowest with amphotericin alone. The dose of amphotericin B used was 0.7mg/kg/day, 
fluconazole 400mg/day and flucytosine 1 OOmg/kg/day.
While the dosages of amphotericin B used in the Mycoses Study Group trial were in the 
range o f 0.7 -  lmg/kg/day, the ‘science’ behind this original choice may have been that 
the drug is presented in a 50mg vial, and thus use of a single vial per dose for an average 
sized patient results in a dosage within this range. Recent data do suggest that 
significantly more rapid yeast clearance is achieved with a dosage of lmg/kg/day versus 
0.7 mg/kg/day [137]. The rate of decline of CSF yeast counts has subsequently been 
associated with outcome; these data are discussed in more detail in Chapter 5 [138].
It may be that the effect of flucytosine in combination with amphotericin is greater in 
more severe disease. Cohort data seem to support this -  Dromer found that the treatment 
failure rate in patients receiving the combination of flucytosine and amphotericin was 
significantly lower than for patients receiving any other therapy, including amphotericin 
monotherapy (26% vs. 56%, p <0.001) [139]. Patients receiving combination therapy 
tended to have more severe disease defined using conventional criteria such as the
baseline cryptococcal antigen titre and confusion. However, the presences of other 
markers of severe disease such as renal, liver or haematological failure, that may have 
precluded the use of flucytosine, and been associated with a worse outcome, are not 
mentioned in the study, amphotericin formulations have significantly reduced toxicities 
but much higher cost. In some patient groups, where the risk of renal impairment leading 
to dialysis is higher, it may be more cost effective, but this has not been rigorously tested 
in cryptococcal meningitis, and amphotericin B deoxycholate remains the recommended 
treatment [78, 140, 141].
Fluconazole monotherapy has been disappointing in cryptococcal meningitis [142-144]. 
One study examined escalating doses of fluconazole (800 -  2000mg/day with or without 
flucytosine) [145]. This 8 arm study recruited 88 patients, and patients considered to be 
more severely unwell (likely to die within 2 weeks) were excluded. The primary end 
point was treatment success, defined as surviving to 10 weeks with at least 1 negative 
CSF culture in that time period. The actual number of deaths is not described in the 
paper. The authors report an incremental increase in response as the dose of fluconazole 
increased, and the treatment success rate was higher for patients also receiving 
flucytosine. However, in many resource-poor areas it is the only treatment available. 
Itraconazole very poorly penetrates the blood brain barrier, and it has performed poorly 
in comparison with amphotericin when used as monotherapy, and in comparison with 
fluconazole when used for consolidation therapy [107, 146].
The value of fluconazole in preventing relapse in HIV infected patients who have 
completed treatment has been clearly demonstrated through a double blind randomized 
placebo controlled trial (which also demonstrated the prostate to be a potential site of
latent infection [147]. Alternative treatments are itraconazole or weekly amphotericin, 
but fluconazole has been shown to be superior in randomized controlled trials [148,
149].
Several studies have examined whether it is safe to stop maintenance therapy in HIV 
patients. If the patient has a sustained CD4 count of greater than 100 cells/uL on anti­
retroviral therapy together and is symptom-free then stopping maintenance therapy is 
probably safe, although follow-up remains essential because there is still a real (but 
small) risk of relapse [150, 151].
1.5.3.2 Organ Transplant Patients
Around 2.8% of solid organ transplant recipients will develop cryptococcosis and the 
median time to disease onset is within 2 years [152]. Multi-organ involvement is 
frequent [78]. Because of the renal dysfunction associated with immunotherapy for 
organ transplant recipients, liposomal amphotericin is recommended [78]. Long term 
maintenance therapy with fluconazole is required - in its absence relapse approaches 
100% within 1 year [153].
1.5.3.3 HIV Uninfected Patients
There are few data on which to base the treatment choices for this group of patients. The 
few randomised controlled trials which preceded the HIV epidemic had small numbers 
of patients, and used the low amphotericin B doses (0.3 -  0.4 mg/kg/day) that were 
consistent with the practice of the time [154, 155]. Furthermore, they preceded the 
arrival of the azoles, with their potential for tolerable long term therapy. The study of
Bennett is frequently quoted as the justification for the use of flucytosine in combination 
with amphotericin, although in this randomised controlled trial of amphotericin versus 
amphotericin plus flucytosine, there was no clinical outcome benefit on an intention to 
treat analysis [154]. Dismukes compared 4 versus 6 weeks of treatment with 
amphotericin and flucytosine in a randomized controlled trial, and found better response 
rates with the 6 week regimen. However, again the doses of amphotericin were lower 
than those used today (0.3mg/kg/day). The dose of flucytosine was 150mg/kg/day. Of 
note, the relapse rate was lower in the patients receiving the longer duration of therapy. 
Again, this trial preceded the azole drugs. Data from retrospective studies are suggestive 
that amphotericin and flucytosine are important in determining good outcomes, but are 
complicated by biases in determining treatment allocation [156, 157]. The updated 
treatment guidelines recommend that flucytosine combined with amphotericin (0.7 -  
1 mg/kg/day) for 6 weeks should be the basis o f treatment for this group of patients [78]. 
This is probably safe, given that provided the total dose of amphotericin remains below 
4g, any renal impairment tends to be reversible [119]. However, the value of adding 
flucytosine to this dose of amphotericin in immunocompetent patients has not been 
tested. Given a more robust immune response, its value may be limited.
No prospective studies have addressed the use of maintenance therapy in HIV 
uninfected patients. The relapse rate prior to the azole era was in the order of 15 -  25%, 
most occurring within the first year, and thus it is recommended that patients receive 
fluconazole maintenance therapy for 6-12 months [155].
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1.5.3.4 Cryptococcus gattii meningitis
Cryptococcus gattii infections occur predominantly in immunocompetent hosts [60, 64, 
76]. There is believed to be a lower response to therapy, perhaps as a result of walling 
off of foci of infection due to a more competent immune response. In addition, some 
reports suggest that C. gattii is inherently less sensitive to azole antifungals [158]. There 
has never been a randomised controlled trial of treatment of C. gattii infection. The 
treatment recommendations are essentially the same as for C. neoformans infection, but 
with increased vigilance recommended for the development of cryptococcomas that may 
benefit from surgical intervention.
1.6 Antifungal Sensitivity Testing
Numerous commercial antifungal susceptibility testing methodologies are now available 
for determining the susceptibilities of yeasts to currently available antifungals, and most 
systems have reasonable correlation with results of the standardised protocol (M27A) 
published by the Clinical and Laboratory Standards Institute (CLSI) [159-169]. 
Minimum inhibitory concentrations of antifungal drugs have been shown to have 
reasonable correlation with outcome in infection with Candida species, depending upon 
the site of infection and drug tested. In a murine model, outcome of treatment with 
azoles is related to in vitro azole susceptibility [170]. In humans with Candida albicans 
mucosal infection, breakpoints have been derived for fluconazole, itraconazole, and 
voriconazole that are based upon the outcome o f treatment [171-173].Testing the 
susceptibility of isolates to fluconazole has been demonstrated to correlate with the 
clinical outcome of mucocutaneous disease in HIV infected patients, and thus has
clinical utility [174-176]. However, no relationship between MIC and clinical outcome 
has been demonstrated for caspofungin and oesophageal candidiasis, although this is an 
effective treatment [177]. There has been limited success in correlating antifungal 
susceptibilities with the outcome of candidaemia. A relationship has not been 
demonstrated for amphotericin B, the key therapeutic agent [178]. However, there is 
probably a role for azole testing in this situation, where a relationship between 
fluconazole MICs and outcome has been demonstrated in more than one study in HIV 
uninfected patients [179, 180]. A novel method for determining susceptibility to 
fluconazole using flow cytometry has been shown to correlate with outcome of Candida 
fungaemia in one small study [181]. Interestingly, in this small study of 24 patients, 
there was reasonable correlation between the flow cytometric methodology and results 
obtained using the CLSI protocol, but only the results obtained using flow cytometry 
correlated with clinical outcome.
There are fewer data for cryptococcal disease, and a relationship between the antifungal 
MICs and outcome has not been consistently demonstrated [114, 161, 182, 183]. 
Cryptococcus spp with reduced sensitivity to antifungals have been detected in the 
environment; additionally, the long term use of azole prophylaxis has been associated 
with the development of resistance amongst Candida isolates, and given the evidence 
that cryptococcal disease may represent reactivation o f latent disease, there may be the 
potential for the selection o f resistant strains within patients [158, 184], Currently, the 
American Infectious Diseases Society does not recommend the use of antifungal 
susceptibility testing in first presentations of cryptococcal disease. This is because it is 
not well validated, and detectable resistance at initiation of therapy is uncommon, at
least in the USA [78, 185]. In Chapter 5 o f the thesis I investigate the antifungal 
susceptibilities of Vietnamese Cryptococcus isolates, relate this to rates o f fungal 
clearance and outcome and discuss the literature in more depth regarding antifungal 
susceptibility testing in relation to cryptococcal meningitis.
1.7 Complications
1.7.1 Raised Intracranial Pressure
Raised intracranial pressure is a frequent feature of cryptococcal meningitis in both HIV 
infected and uninfected patients, present at baseline in approximately half of all HIV 
patients and 80% of HIV uninfected patients with C. gattii [62, 186]. Raised intracranial 
pressure seems to be related to yeast burden, and interestingly in one small study was 
not related to the levels of pro-inflammatory cytokines [186]. Management of raised 
intracranial pressure is believed to be crucial, although Seaton did not find it to be 
associated with outcome in C. gattii infection [62]. There has been only one randomised 
controlled trial of an intervention to control pressure. This trial investigated the utility of 
acetazolamide, a carbonic anhydrase inhibitor which reduces CSF production [109], 
Unfortunately the study had to be stopped early because of an excess of deaths in the 
intervention arm, due to metabolic acidosis, considered to be a consequence of renal 
tubular acidosis induced by the drug. However, the dose of acetazolamide was relatively 
high compared with that used to treat and prevent acute mountain sickness. Raised 
intracranial pressure often develops during the course of treatment, and acetazolamide 
may be a useful therapy either in lower dose, or after the induction phase of treatment. 
Further trials are needed. Other possible drug treatments include mannitol or
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corticosteroids, but there are no data to support their use. Repeated drainage by lumbar 
puncture is advocated by most clinicians.
There is limited experience with the use o f lumbar drains. The main concern is the 
introduction o f infection, although the rate was reported to be less than 5% in one case 
series o f bacterial meningitis [187]. A drain was used for 13 days without problem in 
one case report [188]. Where there is access, the insertion of ventricular-peritoneal 
shunts has been used to manage chronic hydrocephalus. Provided the patient is receiving 
antifungal therapy, insertion during acute infection seems to be safe, but the outcome is 
worse if  the Glasgow coma score is less than 9 at the time of insertion [189-191].
1.7.2 Visual Loss
Visual loss is well recognized in cryptococcal meningitis, and appears to be more 
common in the immunocompetent than in HIV patients [192, 193]. The mechanism of 
damage is not clear, but lesions all along the optic tract have been described. Some 
studies have found visual loss to be associated with raised intracranial pressure but this 
relationship is not always present. Direct optic nerve invasion by cryptococci has been 
demonstrated in post-mortem specimens. Other mechanisms suggested include optic 
nerve compression by inflammatory adhesions, endophthalmitis and cryptococcomas 
[80]. The difference in rates of visual loss between HIV positive and negative patients, 
along with the potential disease modifying effect of steroids, lend weight to the 
hypothesis that the damage is in some way immune mediated.
56
1.7.3 Other focal neurological deficits
The most common sequelae in survivors of cryptococcal meningitis are visual 
impairment and hearing loss [62]. The commonest focal neurological deficit is a sixth 
nerve palsy, usually indicating raised intracranial pressure. As in tuberculous meningitis 
cerebral infarction, perhaps due to associated vasculitis, is described. This can occur in 
any vascular territory but characteristically affects the basal ganglia [194]. Disability at 
the end of treatment, with the exception of visual loss, is infrequently described in the 
literature suggesting that these events are uncommon.
1.7.4 Relapse
The major clinical question in patients who relapse is how to effectively retreat the 
patient. There have been no randomised controlled trials of salvage therapy, but there is 
some experience of using later generation azoles, (voriconazole and posaconazole) in 
this situation [78]. The success rates with these agents in salvage is in the order of 40% 
[78]. Fluconazole resistance is associated with treatment relapse, and cross-resistance is 
likely between different azoles, so this low rate of success might be expected [195].
*
1.7.5 Immune Reconstitution Inflammatory Syndrome (IRIS)
The development o f effective antiretroviral therapy has been associated with the
emergence of IRIS as a complication of HIV disease, although a similar immune
phenomenon has been well recognised in tuberculosis for some time [196]. IRIS
describes a condition whereby a disease syndrome arises or deteriorates not directly due
to treatment failure, but due to a rapid improvement in the immune responsiveness of the
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host with resultant inflammation. Usually the pathogen in question is not culturable at 
the time of IRIS. The difficulty is in distinguishing IRIS from treatment failure.
Currently there is no diagnostic test for IRIS, and it remains a clinical diagnosis. The 
incidence of IRIS in cryptococcal meningitis is in the order of 13% [197]. Identified risk 
factors include low CD4 count, no previous anti-retroviral treatment, positive CSF 
cultures at 2 weeks , and rapid response o f viral load to therapy [198]. IRIS occurs not 
only in HIV patients, but also in patients with organ transplantation and the apparently 
immunocompetent [78]. As well as presenting as meningitis, it can present in a body 
tissue that was not the initial site of disease presentation [199, 200]. IRIS can present 
any time from a few weeks after initiation of therapy to several months. The 
consequences of IRIS can be severe, but there are no randomised controlled trials to 
guide management. For IRIS affecting the CNS, steroids are suggested [78]. 
Retrospective data suggest that cryptococcal antigen testing of the serum of patients 
beginning ARV therapy can identify patients at risk of developing cryptococcal disease 
within the first year of treatment [201]. Some of this disease may be IRIS, and it is 
plausible that an antifungal intervention might reduce this risk. A trial is needed.
1.8 Outcome
The outcome in cryptococcal meningitis varies profoundly according to geographical 
location [1]. The mortality rate varies between 100% at 6 months in sub-Saharan Africa, 
to around 10% at 10 weeks in well resourced settings [107]. This is almost certainly 
influenced by the ability to make a timely diagnosis, access to treatment other than 
fluconazole, and the ability to manage complications and raised intracranial pressure
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[78]. In southeast Asia, the mortality rate is in the order o f 40%, and most deaths occur 
within the first month of treatment [202]. The advent of effective antiretroviral therapy 
has done little to impact on the early mortality in cryptococcal meningitis, but the long 
term mortality for patients who survive meningitis and begin antiretroviral therapy has 
improved dramatically [203]. This remains true for patients in less well resourced 
countries [137, 204, 205]. In most infectious diseases, early diagnosis and instigation of 
effective treatment is key in determining a good outcome, and the same is likely to be 
true in cryptococcal disease. One tool that may be useful in identifying patients at risk of 
cryptococcal disease is serum cryptococcal antigen testing. It has been shown that 
asymptomatic cryptococcal antigenaemia precedes the onset of disease, and is an 
independent predictor of mortality in patients in Uganda [206]. Micol found 11% of 
asymptomatic first time attending HIV patients in Cambodia to have positive serum 
cryptococcal antigen tests [207]. All patients were treated in this study, so the natural 
history of antigenaemia in this group is not known. Whether or not asymptomatic 
antigenaemia should be treated is not clear, but it identifies a group of patients in whom 
heightened surveillance for cryptococcal disease is prudent. Primary prophylaxis for 
cryptococcal meningitis with azole drugs has been investigated in randomized controlled 
trials. While it seems to reduce the risk of invasive fungal disease, in the absence of 
antiretroviral therapy it does not seem to be associated with a mortality benefit [208- 
210]. Furthermore, long term use of itraconazole as prophylaxis has been associated 
with reduced azole susceptibilities of Candida albicans strains in HIV patients, and thus 
azole primary prophylaxis is generally not recommended, although it forms part of the 
national guidelines in both Thailand and Viet Nam [211].
1.9 Summary
Thirty years ago the idea that meningitis due to a yeast would be amongst the leading 
infectious causes of death in adults would have been met with incredulity. If Park and 
colleagues are correct, then Cryptococcus neoformans is a more frequent cause of death 
in adults in sub-Saharan Africa than tuberculosis. Cryptococcal meningitis is relatively 
easy to diagnose, but the high mortality rates illustrate the difficulties in its treatment. 
The arrival of the azole drugs, with their tolerability and ease of administration, has had 
an important impact on the ability to manage this disease in the long term, but when 
used as monotherapy their performance has been disappointing, perhaps reflecting the 
fungistatic nature of their action. The mortality rate remains high, particularly in poorly 
resourced countries, and there has not been a major advance in treatment since 1997 
[107]. Effective treatment still relies on 2 drugs, amphotericin B and flucytosine, that 
are over 50 years old, have significant rates of side effects, and are expensive. In 
addition, they are poorly available where most disease occurs.
Despite large numbers of patients, and a high frequency of endpoints (mortality rate), 
there is already a move away from clinical endpoint trials in cryptococcal meningitis, 
perhaps because of cost and the pressure to publish [99, 137, 138, 186, 205]. Measuring 
the rates of fall of viable yeast counts in CSF seems to be a sensitive detector of the 
potency of antifungal efficacy, but surrogate markers can be misleading. Surrogate 
markers, such as early fungicidal activity, are unable to detect effects of treatment on 
mortality that are not related to the expected mode of action. Reliance on surrogate 
markers can thus hinder therapeutic advances. For example, one of the few HIV 
antiretroviral studies powered to clinical endpoints (the SMART trial of structured 
treatment interruptions) gave results that few would have predicted prior to the study,
and has led to new insights into the immunopathogenesis of cardiovascular disease 
[212].
Because cryptococcal meningitis in immunocompetent patients is rare, and the most 
studied disease in immunocompetent patients has been due to infection with C. gattii, 
the disease modifying effects of HIV are not as clearly defined as might be expected. In 
China, disease in the immunocompetent has been reported to be due to C. ne o f  or mans 
var grubii, the variety responsible for most HIV related disease worldwide. Comparing 
the clinical phenotypes between these 2 groups of patients would enable a determination 
of whether disease phenotype is primarily driven by the immune response or the 
pathogen itself, and is a question I will address in this thesis.
A large number of prognostic factors have been identified in patients with cryptococcal 
meningitis. This contrasts with tuberculous meningitis, where a robust grading system 
exists that correlates well with outcome in both HIV infected and uninfected patients. 
The infectious disease research community has a poor record in performing large 
adequately powered clinical trials. This is in marked contrast to the history of clinical 
research in cardiovascular diseases [213, 214]. A problem with smaller randomised 
controlled trials can be the unequal distribution, by chance, of patients with different 
severities of disease between treatment arms. This can be ameliorated by stratification 
according to disease severity. If robust prognostic factors can be identified in 
cryptococcal meningitis the practical uses would include stratification in clinical trials. 
In addition, the prognostic factors could be used to identify patients who may need more 
intensive treatment, or in whom more toxic but potentially more effective treatment 
could be justified. The already identified prognostic factors in cryptococcal meningitis
need to be evaluated in an independent dataset, and this will form part of the work of 
this thesis.
Cryptococcal meningitis in HIV uninfected patients is rare. When it occurs, the question 
arises as to whether it. is due to some undiagnosed immune deficit in the patient, or is 
due to contact with a rare strain of Cryptococcus that has increased virulence. I will 
address this question in the thesis through investigating the molecular epidemiology of 
strains in Viet Nam.
Finally, there are no data on the antifungal susceptibility of Cryptococcus spp from Viet 
Nam. While antifungal sensitivity testing has been shown to have some clinical utility in 
Candida infection, this has not been shown for cryptococcosis, although the studies are 
generally small. In this thesis I will describe the antifungal sensitivities of Vietnamese 
isolates and relate these to in vivo responses and clinical outcome.
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Chapter 2 
Materials and Methods.
2.1 Introduction
This chapter describes the research setting, region, hospital and study wards, and 
outlines the focus, aims and structure of the thesis. General clinical research and 
laboratory methods are described. Further relevant details are also described in 
subsequent chapters.
2.2 Setting
2.2.1 Geography
Viet Nam has a population of 86 million people, is the world’s 13th most populous 
country and fifty per cent o f the world’s population lives within 2000km of Ho Chi 
Minh City. The land mass occupies 329 500 square km and stretches over 1600km along 
the eastern coast of the Indo-Chinese peninsula, lying between latitudes 8° and 24° north 
of the equator (figure 2.1). Subsequently there are wide variations in climate along the 
length of the country, the tropical south having hot dry winter months followed by the 
monsoon season (May to November). In the north, the capital Ha Noi has a temperate 
climate. In recent years the country has seen rapid economic growth of 6.5 - 9% p.a. 
[215]. Gross national income per capita in 2008 was 890USD/year, but 21% of the 
population live on less than 1.25USD/day [216]. The country received 1.86 billion USD 
in overseas development aid in 2006, and 4% of government expenditure is spent on 
health [216].
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Figure 2.1 Map of Viet Nam (www.worldmapfinder.com)
2.2.2 Health Service
Health care is delivered by the private and state sectors. Most hospitals are state owned 
and run. WHO estimated there were 6 doctors per 10 000 of the population in 2002 
(more recent data are unavailable) and government spending on health per capita was 10 
USD in 2005, accounting for 6% of gross domestic product. Limited health insurance is 
provided by the state for all legally resident children up to the age of 6 years, but all 
other health costs must be borne by the patient, with the exception of chemotherapy for 
tuberculosis. State employees and employees of foreign-owned companies have health 
insurance, although the cover provided is limited. There are well developed and 
efficient referral patterns from commune health posts to district hospitals, onward to 
provincial hospitals and finally to tertiary referral centres such as the Hospital for 
Tropical Diseases. As a consequence, the Hospital for Tropical Diseases has a catchment 
population of 40 000 000 people. Life expectancy at birth is currently 74 years, the 
under-5 mortality rate is ranked 126 in the world at 15 per 1000 and HIV prevalence is 
estimated at 0.5% [215, 216].
2.2.3 The Hospital for Tropical Diseases, Ho Chi Minh City
The Hospital for Tropical Diseases (HTD) acts as a primary, secondary and tertiary 
referral centre for patients with infectious diseases from the whole of southern Viet 
Nam. It has approximately 500 beds and admits 35 000 patients per year. There are 
paediatric and adult intensive care wards. Important causes of admission include HIV, 
hepatitis, dengue fever, tetanus, pneumonia and septicaemia. The Viet Anh ward has 18 
beds with a dedicated 5 bed intensive care unit where ventilation and haemofiltration can
be performed. HTD has laboratories for haematology, biochemistry, microbiology, 
serology, parasitology and mycology. These facilities are housed in the clinical sciences 
building alongside the OUCRU. Hospital laboratories partake in an external quality 
assurance scheme organised through the South East Asia Infectious Diseases Network 
(www.seaicm.org).
2.2.4 Oxford University Clinical Research Unit
OUCRU was established in 1991, and historically has been primarily funded by the 
Wellcome Trust UK. Its purpose is to facilitate high quality clinical and laboratory- 
based scientific research and training in order to improve human and animal health. The 
research interests of the Unit are driven by the clinical needs of the local population, and 
initially work was focused on severe malaria[217-220]. Over the past 18 years the 
research interests have expanded to include central nervous system infections, dengue, 
respiratory infections, tetanus, enteric infections, helminthiases, tuberculosis and 
HIV[81, 129, 130, 221-241]. Research trials are run on multiple wards within the 
hospital, including the Viet Anh ward (formerly the Malaria Ward and now almost 
exclusively concerned with CNS infections), the adult intensive care unit, the paediatric 
intensive care ward and a general infectious diseases ward.
2.3 HIV in Viet Nam
There were an estimated 243 000 people infected with HIV in Viet Nam in 2009 and the 
prevalence doubled between 2000 and 2005 [242]. HIV cases have been reported from 
all 64 provinces/cities. The prevalence in 1 5 -4 9  year olds is estimated at 0.5% (95%
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confidence intervals 0.3% to 0.9%), which is similar to Spain, although the epidemics 
are at different stages [242]. The prevalence is rising in Viet Nam, expected to increase 
by 10% by 2012, with around 12 000 new infections per year [243]. The epidemic is 
currently concentrated among key populations at higher risk including intravenous drug 
users, sex workers and their partners, and men who have sex with men, but heterosexual 
transmission is becoming more significant [243]. Ho Chi Minh City has the highest 
number of reported cases of HIV (23 231 reported by July 2006) [242]. In 2007 28.4% 
of adults with advanced HIV infection were believed to be receiving anti-retro viral 
therapy (ARV), and only 13% of pregnant women received ARVs to prevent mother to 
child transmission[242].
At the Hospital for Tropical Diseases the number of patients admitted with HIV 
infection has risen dramatically since 1994. The total hospital mortality rate for all in 
patients was falling until the mid 1990s, but since then has risen, and this increase in 
death rate is entirely accounted for by HIV infection. 75% of all in-hospital deaths are 
now accounted for by HIV infected patients. In concert with this rise in HIV prevalence, 
Cryptococcus neoformans has become the commonest microbiological isolate from both 
cerebrospinal fluid and blood (Figures 2.2 and 2.3).
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2.4 Focus, Aims and Structure of the Thesis
This thesis examines cryptococcal meningitis in Viet Nam, and aims to address the 
following questions:
1. Is the clinical phenotype of cryptococcal meningitis influenced by HIV 
infection?
2. What are the prognostic factors in cryptococcal meningitis?
3. What is the molecular epidemiology of human isolates of Cryptococcus 
neoformans in Viet Nam, and is this influenced by HIV serostatus?
4. What is the utility of antifungal sensitivity testing in cryptococcal meningitis, has 
the antifungal susceptibility of C. neoformans changed over time, and do the 
susceptibility profiles of C. neoformans differ by infecting variety and immune 
status o f the host?
These questions are addressed in the following chapters.
2.5 Clinical Methods
2.5.1 Scientific and Ethical Approval
HTD Scientific and ethical committee approved all study protocols, and informed 
consent was obtained from each patient or accompanying relative. In addition to ethical 
approval from the Hospital for Tropical Diseases, the BMD study had ethical approval 
from the Oxford Tropical Ethics Committee and the BK study from Liverpool School of 
Tropical Medicine Research Ethics Committee.
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2.5.2 Study Site
All studies took place at the Hospital for Tropical Diseases, Ho Chi Minh City. All 
patients with suspected or definite central nervous system infections are referred to the 
Viet-Anh (Clinical Research Ward) where they are assessed and cared for by a dedicated 
Clinical Research team of doctors, nurses and allied professionals. All patients in this 
analysis were recruited to one of 2 studies -  the BMD study or the BK study (the study 
codes BMD and BK have no specific meaning but were codes allocated from an internal 
trial registry spreadsheet). HIV uninfected patients were recruited from the BMD study, 
and HIV infected patients from the BK study.
2.5.3 The BMD Study
This study is an on-going prospective descriptive study of HIV uninfected patients with 
central nervous system infections at the Hospital for Tropical Diseases. Informed 
consent is obtained from all patients. All HIV uninfected adults (> 15 years old) with a 
syndrome consistent with a central nervous system infection, or a recognized pathogen 
isolated from cerebrospinal fluid, are eligible for study entry. Other than HIV infection, 
there were no exclusion criteria. Thus the HIV negative cryptococcal meningitis patients 
form a subset o f patients from this study. All patients were recruited consecutively from 
between 1996 and 2007. The definition o f cryptococcal meningitis was any patient 
presenting with CNS symptoms (e.g. fever, headache, neck stiffness, confusion, coma, 
convulsions, focal neurology) and a positive cryptococcal antigen test, India ink or 
culture o f Cryptococcus species from either cerebrospinal fluid (CSF) or blood, or any 
patient with positive India ink, cryptococcal antigen titre or culture of Cryptococcus
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species from CSF in the absence of CNS symptoms. Evidence of any other central 
nervous system infection was an exclusion criterion. All patients had to have 2 negative 
HIV antibody/antigen and negative rapid tests (HIVAXSYM HIVl/2gO, Determine 
HIV 1/2, Abbott, Maidenhead, UK).
2.5.4 The BK study
The BK study is an ongoing 3 arm open label randomized controlled trial of antifungal 
treatment for cryptococcal meningitis in HIV infected adult patients. All patients for this 
analysis were taken from the control arm, in which patients receive treatment for 
cryptococcal meningitis according to Vietnamese guidelines. The definition of 
cryptococcal meningitis was a syndrome consistent with meningoencephalitis and 
isolation of Cryptococcus species (culture or positive cryptococcal antigen titre from 
blood or CSF or positive India ink from CSF), or isolation of Cryptococcus species from 
CSF in the absence of neurological symptoms. Study recruitment began in April 2004. 
The exclusion criteria were a previous diagnosis of cryptococcal meningitis, previous 
azole therapy, pregnancy or renal or liver failure, or active TB requiring treatment with 
rifampicin.
2.5.5 Clinical Assessment
All patients in both studies had a full clinical evaluation at study entry including detailed 
history and physical examination by the dedicated study team.
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2.5.6 Investigations
Routine haematological investigations and CSF examination using standard methods 
were performed on all patients at study entry including full blood count, urea and 
electrolytes, liver enzymes, blood glucose, CSF cell counts, protein and glucose. CSF 
samples were stained and cultured by standard methods for pyogenic bacteria, fungi, and 
mycobacteria. Opening CSF pressure was measured at each lumbar puncture. 
Cryptococcal antigen titres were determined using the Remel Cryptococcus Antigen 
Test Kit according to the manufacturer’s instructions (Lenexa, USA). All patients were 
tested for antibodies to HIV (Determine HIV 1/2; Abbott), and positive results were 
confirmed by Western blot analysis. For all HIV-infected adults, peripheral blood CD4 
and CD8 lymphocyte counts were measured as soon as possible after randomization by 
use of flow cytometry (FACSCalibur; Becton Dickinson, Franklin Lakes, USA).
2.5.7 Imaging
Chest X-rays and brain imaging (Computerised Tomography (CT, Toshiba XVIsion, 
Toshiba, Japan) or Magnetic Resonance Imaging (MRI, General Electric, UK, 1.5T)) 
were performed at the physician’s discretion.
2.5.8 Treatment
All HIV-infected patients received treatment with amphotericin B 1 mg/kg/day 
(Photericin B®, Cipla Ltd, Mumbai, India) for 4 weeks followed by fluconazole 
400mg/day (Flucoric®, Ranbaxy Laboratories Ltd, Gurgaon, India) for a further 6 
weeks. The fluconazole dose was then reduced to 200mg daily as long term secondary
prophylaxis. Antiretroviral therapy was prescribed at the attending physician’s 
discretion. All patients received Pneumocystis jirovecii primary prophylaxis with 960mg 
trimethoprim-sulfamethoxazole daily.
HIV negative patients were also treated with amphotericin B 1 mg/kg/day for at least 2 
weeks, prior to switching to fluconazole. The duration of therapy with amphotericin B 
beyond this point was at the attending physician’s discretion. Flucytosine 1 OOmg/kg/day, 
in 4 divided doses (Ancotil®, Valeant Pharmaceuticals International, CA, USA) could 
be given for the first 2 weeks at the physician’s discretion. Following amphotericin 
patients were switched to fluconazole 400mg/day.
2.5.9 Management of raised intracranial pressure
All patients had the opening CSF pressure measured using a spinal manometer. The 
upper limit of measurement was 40cm/CSF. Lumbar punctures were performed at least 
weekly in HIV-infected patients for the first 4 weeks and at 10 weeks, and more 
frequently if the pressure was raised or the patient had symptoms of raised intracranial 
pressure (headache, vomiting). Frequency of lumbar puncture in HIV uninfected patients 
was at the physician’s discretion guided by symptoms/signs suggestive of raised 
intracranial pressure.
2.5.10 Follow up
All patients were followed up for 6 months.
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2.6 Microbiological methods
2.6.1 Identification
Isolation and identification of Cryptococcus species was made using standard 
microbiological methods. Initially India ink stain o f CSF was used to demonstrate the 
presence of budding encapsulated yeasts on India ink stain of cerebrospinal fluid (CSF). 
The CSF pellet was cultured at 35°C on chocolate and blood agar, brain-heart infusion 
broth, and at 30°C and 35°C on Sabouraud’s agar (Oxoid, Basingstoke, UK). 
Identification was confirmed through demonstration of the growth of characteristic 
colonies on Sabouraud’s and bird seed agar, demonstration of urease production 
(Christensen’s agar) and API 32C sugar assimilation tests (BioMerieux SA, Marcy 
l'Etoile, France). Isolates were stored at -30°C on Microbank plastic beads (Pro-Lab 
Diagnostics, Neston, Cheshire, UK). Strains were revived for speciation on Sabouraud’s 
agar and incubated at 30C and 37C. C. gattii was identified by biotyping with 
Canavanine Glycine Bromothymol Blue (CGB) agar, and isolates were further divided 
into eight molecular groups using Polymerase Chain Reaction- Restriction Fragment 
Length Polymorphism (PCR-RFLP) analysis of the URA5 (orotidine monophosphate 
pyrophosphorylase) gene [35]. Control strains were provided by Dr Wieland Meyer, 
Westmead Millennium Institute for Medical Research, Sydney, Australia.
2.6.2 Cryptococcal Antigen Testing
Antigen testing was performed on patient serum (qualitative) and cerebrospinal fluid 
(quantitative) using the Cryptococcal Antigen Latex Test R30851501 (Remel, Lenexa,
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KS, USA) as per the manufacturer’s instructions. A positive result was determined 
using the internal low positive control, equating to a level o f antigen of 12ng/ml.
2.6.3 Determination of Cryptococcal Load in CSF
Cryptococcal fungal burden was estimated in 2 ways. All patients had Cryptococcus 
antigen titres measured in CSF at presentation. In addition, all HIV patients had an 
assessment of fungal burden through measurement of the number of colony forming 
units (CFUs) of Cryptococcus per ml of cerebrospinal fluid using a serial dilution 
technique. Briefly, lOOuL of fresh CSF was serially diluted 4 times in 0.9ml of sterile 
water. CSF and subsequent dilutions were vortexed for 5 seconds before removal and 
after addition of each lOOuL aliquot. After vortexing each dilution, lOOuL of neat CSF 
/diluent was inoculated in 4 -  5uL aliquots onto the surface of a Sabouraud’s plate, in 
duplicate. Plates were incubated at 30C for 1 week and CFUs were counted daily. The 
mean number of CFUs was calculated using the duplicate inoculations from the plates 
that had between 20 and 130 Colony Forming Units. All patient CSF samples were 
processed within 4 hours.
2.6.4 Antifungal Sensitivity Testing
I used the Sensititre® YeastOne® (Trek Diagnostic Systems, East Grinstead, UK) 
microbroth susceptibility testing plates to determine.the MICs of 8 antifungal drugs 
against all the Cryptococcus species in the OUCRU strain collection. The Sensititre® 
YeastOne® system is a broth microdilution method that uses a 96 well plate format. A 
colorimetric indicator, Alamar Blue, denotes the presence of growth within a well by
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changing from blue to pink (Figure 2.4). Alamar Blue is water soluble and non-toxic to 
cells. The colour change is a result o f reduction by a number of intracellular molecules 
including NADPH, NADH and cytochromes[244]. Plates are read with the naked eye 
under nonnal laboratory lighting using a reading mirror. The antifungals tested were: 
amphotericin B, flucytosine, fluconazole, ketoconazole, itraconazole, posaconazole, 
voriconazole and caspofungin. Cryptococcus species are inherently resistant to 
caspofungin.
■ ■ ■ ■
Figure 2.4 Sensititre YeastOne antifungal susceptibility plate. Growth results in colour change from 
blue to pink.
MICs were determined in accordance with the manufacturer’s instructions, with one
adaptation -  I adjusted the inoculum to 1.0 McFarland rather than 0.5 McFarland, since
this more consistently resulted in the recommended final organism density of 1.5 -  8X
103 colony forming units (CFUs) per ml. Briefly, inocula were made from a 24 hour old
growth of pure isolate added to sterile water. 20uL were transferred to 11ml YeastOne®
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culture medium (broth). Suspensions were vortexed for 15 seconds during adjustment 
and prior to addition to broth. The broth was transferred to a sterile seed trough and an 8 
channel pipette was used to inoculate the 96 well plate. lOul of suspension was removed 
from the positive control well and plated onto a Sabouraud’s agar plate to check purity 
and final pathogen density. A correct final pathogen density of 1.5 -  8x103 CFUs per ml 
would result in between 1 5 -8 0  CFUs on the purity plate. Plates were covered with an 
adhesive seal and incubated at 35C, stacked no more than 3 high as per the 
manufacturer’s instructions. Since the inoculum preparation step and the subsequent 
plate inoculation should take no more than 15 minutes each, no more than 4 isolates 
were processed at one time, the duration o f the process being measured with a 
stopwatch. The MICs were estimated at 48 and 72 hours following inoculation. MICs 
were not estimated unless there was colour change in the positive control well, and the 
organism density was in the correct range. The MICs were identified as the lowest drug 
concentration preventing the development of red or purple broth discolouration (growth) 
-  i.e. the first blue well. The ranges of drug concentration tested are detailed in table 2.1 
below. All isolates were obtained prior to the instigation of treatment.
Quality control was performed using Issatchenkia orientalis (formerly Candida krusei) 
ATCC 6258 and Candidaparapsilosis ATCC 22019, and was performed with every 7 
isolates for the first 49 isolates, and then every 47 isolates.
All results were entered onto a spreadsheet (Microsoft Excel 2003, Microsoft 
Corporation, Seattle, USA).
Table 2.1
Concentration ranges of the 8 antifungal drugs in the Sensititre® YeastOne® 
_____________________________________ test plate.____________________ _________
Antifungal Agent Dilution range (ug/ml)
Posaconazole 0.008 - 8
Amphotericin B 0.008 -  16
Fluconazole 0 .1 2 5 -2 5 6
Itraconazole 0 .0 0 8 - 16
Ketoconazole 0.008 -  16
5-Flucytosine 0.03 -  64
Voriconazole 0 .0 0 8 - 16
Caspofungin 0.008 - 16
2.6.5 Control strains
Control strains used for antifungal sensitivity testing were Issatchenkia orientalis ATCC 
6258 and Candida parapsilosis ATCC22019.
Control strains for typing were provided by Dr Wieland Meyer, Westmead Millennium 
Institute for Medical Research, Sydney, Australia (Table 2.2).
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Table 2.2
Cryptococcus control strains for molecular typing
Species Code URA5 RFLP Serotype
Group [35]
Cryptococcus ne o f  or mans var grubii WM148 VNI A
Cryptococcus neoformans var grubii WM626 VNII A
Cryptococcus neoformans hybrid WM628 VNIII AD
Cryptococcus neoformans var neoformans WM629 VNIV D
Cryptococcus neoformans var gattii WM179 VGI B
Cryptococcus neoformans var gattii WM178 VGII B
Cryptococcus neoformans var gattii WM175 VGIII B
Cryptococcus neoformans var gattii WM779 VGIV C
2.7 Molecular Methods
2.7.1 DNA Extraction
Whole genomic DNA was extracted according to the method of Wen et al[245]. Briefly, 
isolates stored at -30C (Microbank plastic beads, Pro-Lab Diagnostics, Neston,
Cheshire, UK) were revived on Sabouraud’s agar and incubated at 30C for 3 days.
Single colonies were spread for confluent growth on Sabouraud’s plates and incubated at 
30C for 24 hours. All cell growth on the plate (approximately 0.5g wet weight) was 
used for DNA extraction. Cells were resuspended in sodium citrate sorbitol buffer (SCS) 
containing 20mM sodium citrate and 1M D-sorbitol (Sigma-Aldrich), pH adjusted to 5.8 
and centrifuged at 13000g for 5 minutes. This process was repeated, and the pellet was
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then resuspended and incubated in freshly made protoplasting solution (10 mg lysing 
enzymes from Trichoderma harzianum, Sigma in 1 ml SCS solution) at 37C for 1 hour. 
The solution was centrifuged at 13000g for 5 minutes and the pellet resuspended in 1 ml 
of lysing solution (8% DTAB (Dodecyltrimethylammoniumbromide Sigma D-8638), 1.5 
M NaCl, 100 mM Tris (pH 8.6), 50 mM EDTA (pH 8)). The suspension was separated 
into 2 eppendorfs, gently shaken and incubated at 68C for 30-60 minutes. After cooling 
to room temperature 0.5ml of fridge-cold chloroform was added to each tube, mixed by 
inversion and centrifuged at 4C at 13000g for 10 minutes. The supernatant was added to 
0.5 x volume of 5% CTAB solution (cetyltrimethylammoniumbromide, Sigma Aldrich, 
with 0.4 M Nacl) and 2 x volume of ELGA water. After gentle mixing this was 
centrifuged (13000g for 2 minutes) at 4C. The supernatant was discarded and the DNA- 
CTAB pellet resuspended in 1.2M NaCl. 1 ml of ice cold 100% ethanol was added and 
mixed by inversion before re-centrifuging tube (12 000 rpm for 10 min at 4 C). The 
pellet was rinsed in 1ml of ice-cold 70% ethanol and re-centrifuged (12 000 rpm for 5 
min at 4C). The supernatant was discarded and the pellet dried, after which it was 
resuspended in lOOuL of TE buffer and left to dissolve overnight. One uL of lOOmg/ml 
RNAse was added, and the presence of DNA was confirmed through electrophoresis on 
a 1% agarose gel. DNA was quantified using a Nanodrop ND1000 spectrophotometer 
(Thermo Scientific, Wilmington, USA).
2.7.2 Restriction Fragment Length Polymorphism (RFLP) Analysis
RFLP o f the orotidine monophosphate pyrophosphorylase (URA5) gene was carried out
according to the methods of Meyer et al [35]. PCR of the URA5 gene was conducted in a
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final volume of 50uL. Each reaction contained 50 ng of DNA, IX PCR buffer (10 mM 
Tris-HCl, pH 8.3, 50 mM KC1, 1.5 mM MgC12; Applied Biosystems, Foster City, CA), 
0.2 mM each of dATP, dCTP, dGTP, and dTTP (Roche Diagnostics GmbH), 3 mM 
magnesium acetate, 1.5 U AmpliTaq DNA polymerase (Applied Biosystems, Foster 
City, CA), and 50 ng of each primer URA5 (5'ATGTCCTCCCAAGCCCTCGACTCCG 
3') and SJ01 (5' TTAAGACCTCTGAACACCGTACTC 3'). PCR was performed for 35 
cycles in a PerkinElmer 480 Thermal Cycler (PerkinElmer Inc, Massachusetts, USA) at 
94°C for 2-min initial denaturation, 45 s of denaturation at 94°C, 1 min annealing at 
61°C, and 2-min extension at 72°C, followed by a final extension cycle for 10 min at 
72°C. Successful amplification was confirmed through demonstration of a 779bp 
product on electrophoresis (lOuL of product, 1% agarose gel, 110V, 45 minutes).
20 pL of PCR products were double digested with 2uL Sau96I (10 U/uL) and 2uL Hhal 
(40 U/pl), with 5uL of NE buffer 4 and 0.5uL of bovine serum albumin, made up to a 
final volume o f 50uL with ELGA water. The reaction mix was incubated at 3 7C for 3 
hours at and 20ul of final product was separated by 3% agarose gel electrophoresis at 
100 V for 3 h. RFLP patterns were assigned visually by comparing them with the 
patterns obtained from the standard strains (VNI-VNIV and VGI-VGIV) provided by 
Associate Professor Wieland Meyer, University of Westmead, Sydney.
2.7.3 Amplified Fragment Length Polymorphism Analysis (AFLP)
AFLP was based upon the Carter lab protocol, a modification of the method described 
by Halliday et al [246].
81
2.7.3.1 Restriction digest
Each reaction mix contained 1.3uL of EcoRl (Helena Biosciences Europe, Gateshead, 
UK, lOU/uL) and 0.7uL Msel (Helena Biosciences Europe, Gateshead, UK, lOU/uL), 
20uL of genomic DNA (20 -  60ng), 4uL of One-phor-all buffer (Amersham 
Biosciences, GE Healthcare Life Sciences, Little Chalfont, UK) and ELGA water to a 
final reaction mix of 40uL. To check adequate digestion, lOuL of reaction mix was 
removed to a fresh tube and luL of lambda DNA (Promega UK Ltd, Southampton, UK, 
50ng/uL). Samples and digestion checks were incubated at 37C for at least 3 hours. The 
lambda digest was run on a 1% agarose gel to check there were no undigested 5kb 
lambda DNA fragments.
2.7.3.2 Adapter Ligation
Double stranded oligonucleotide adapters were prepared by boiling high concentrations 
(lOOuM) of complementary single stranded oligonucleotides (EA1 and EA2 or MAI and 
MA2) for 2 minutes. Adapter sequences are illustrated in table 2.3.
7.5uL of ligation mix (0.75pl lOx One-phor-all buffer, 0.75pl ATP (Invitrogen, lOmM),
0.1875pl T4 ligase (Helena Biosciences Europe, Gateshead, UK, 4 Weiss units/pl),
0.75pl EcoRl adapters (5pM), 0.75pl Msel adapters (50pM), and 4.3125pl ELGA 
water were added to each 30uL restriction digest mix. Ligation mix was incubated at 
room temperature (25C) overnight.
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2.7.3.3 PCR amplification
Preselective and selective amplification primers are detailed in Table 2.3. The AFLP 
preamplification and selective amplification reactions were performed in a final volume 
of 25 pi. The preamplification reaction mixture contained 1 X PCR buffer, 5 nM 
concentrations of each deoxyribonucleotide triphosphate, 2 pM concentrations of the 
appropriate EcoRl and Msel preamplification primer pairs or selective primers, 5 U of 
Taq DNA polymerase (Amersham Biosciences, GE Healthcare Life Sciences, Little 
Chalfont, UK), and 1 pi of digestion ligation product.. The selective amplification 
mixture contained 0.5pM final concentrations of each primer. The selective primer pairs 
used in this study were: EcoRI-GT-Msel-GT, and EcoRI-AC- Msel-G. The selective 
EcoRl primer was labelled at the 5’ end with 6-carboxyfluorescein (6 FAM). The 
preamplification reaction conditions were 94°C for 2 minutes followed by 20 cycles of 
94°C for 20 s, 56°C for 30s, and 72°C for 2 min. The selective amplification conditions 
were 94°C for 2 minutes followed by 10 cycles of 94°C for 20 s, 66°C for 30 s, 
decreasing 1°C every cycle, and 72°C for 120 s, followed by 20 cycles consisting of 
94°C for 20 s, 56°C for 30 s, and 72°C for 120 s. All amplification reactions were 
performed in a BioRad C l000 thermal cycler (BioRad Laboratories Ltd, Hemel 
Hempstead, UK).
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Table 2.3
__________________ Oligonucleotides -  Adapters and Primers
Adapter Oligo name Sequence
EcoRl EA1 5'-CTCGTAGACTGCGTACC-3'-
EA2 3'-CATCTGACGCATGGTTAA-5'-
M sel MAI 5'-TACTCAGGACTCAT-3'
MA2 3'-GAGTCCTGAGTAGCAG-5'
Preselective Primer Pairs
EcoRl-A 5'-GACTGCGTACCAATTCA-3'
M sel-G 5’-GATGAGTCCTGAGTAAG-3'
EcoRl-G 5'-GACTGCGTACCAATTCG-3'
M sel-G 5'-GATGAGTCCTGAGTAAG-3'
Selective Primer Pairs
EcoRl-AC 5'-FAM6-GACTGCGTACCAATTCAC-3'
M sel-G 5'-GATGAGTCCTGAGTAAG-3'
EcoRl-GT 5’-FAM6-GACTGCGTACCAATTCGT-3’
M sel-GT 5'-GATGAGTCCTGAGTAAGT-3’
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2.13 A  AFLP Fragment Detection
Fragment analysis was performed using an Applied Biosystems 3130X 16 capillary 
(50cm) sequencer with Genemapper version 4.0 software (Applied Biosystems Inc, CA, 
USA). Amplification product was diluted as necessary, mixed with LIZ 500 size 
standard and HiDi Formamide (AB Biosystems Inc, CA USA), vortexed, heated to 95C 
for 3 minutes and then snap-cooled on ice before loading and using the default AFLP 
electrophoresis settings as recommended by the manufacturer.
2.7.3.5 Analysis
Raw file data was imported into Bionumerics Version 5.1 (Applied Maths, Belgium) for 
analysis. 144 files were imported simultaneously and normalised. Further details are 
given in the relevant chapter.
2.8 Statistical Methods
Statistical analysis was performed with R version 2.9.0 (R Foundation for Statistical 
Computing, Vienna, Austria) [247]. Statistical methods will be described in each 
individual chapter.
85
Chapter 3 
The Clinical Phenotype of Cryptococcal Meningitis and the 
Impact of HIV.
3.1 Introduction
HIV undoubtedly increases the risk of developing cryptococcal meningitis - the HIV 
epidemic, with over 40 000 000 people currently affected worldwide, has produced an 
epidemic of cryptococcal meningitis in its wake. There are estimated to be up to 1.5 
million cases per year world wide, with up to 1 125 000 deaths; in sub-Saharan Africa 
cryptococcal meningitis now probably outstrips even tuberculosis as a cause of death 
[1]. HIV-associated disease justifiably dominates research efforts and subsequently 
guides developments in treatment. However, while HIV-associated disease represents 
the vast majority of cases, disease is not limited to this group. The first culture-proven 
case o f cryptococcal meningitis was described well before the HIV pandemic in 1912 by 
Rusk and Famell, and there has been speculation that a case o f chronic meningitis 
described in 1860 was due to Cryptococcus neoformans [248]. Thus disease in the HIV 
uninfected is well recognised. However, it remains rare, and the differences in clinical 
phenotype between HIV infected and uninfected patients are not clear. Differences in 
clinical phenotype, presumably a result o f differences in disease pathogenesis, may have 
implications for effective treatment, which might need to be tailored to the immune 
status of the patient. Since disease in the HIV uninfected often occurs in patients with 
other underlying immunosuppressive disease, or is due to infection with C. gattii, it is 
difficult to ascribe differences in clinical phenotype to HIV alone. At the Hospital for
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Tropical Diseases, cryptococcal meningitis in the HIV uninfected is infrequently 
accompanied by other underlying disease. Moreover, my work suggests that most 
infections are due to Cryptococcus neoformans var grubii, the same species responsible 
for disease in the HIV infected patients. This affords the opportunity to define the impact 
o f HIV on clinical phenotype in cryptococcal meningitis. In this chapter I review the 
literature regarding the clinical phenotype of cryptococcal meningitis and examine the 
effect of HIV on clinical phenotype at the Hospital for Tropical Disease. In addition, I 
assess the validity o f previously described prognostic factors in cryptococcal meningitis.
3.2 Aims
1. To compare the clinical phenotypes of cryptococcal meningitis in the published 
literature according to HIV serostatus.
2. To determine the impact of HIV infection on the presentation of cryptococcal 
meningitis in southern Viet Nam.
3. To assess the reliability o f previously defined prognostic factors in cryptococcal 
meningitis.
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3.3 Methods
3.3.1 Literature review of clinical phenotypes and prognostic factors
Publications describing the clinical phenotype of cryptococcal meningitis were identified 
from the PUBMED database using the following search terms:
1. <Cryptococcus neoformans> with the LIMITS <clinical trials> and <humans> 
and <English Language>.
2. Using the MeSH terms: "Meningitis, Cryptococcal"[Mesh] AND 
"Prognosis"[Mesh] AND ("Clinical Trial "[Publication Type] OR "Descriptive 
Studies" [Mesh]).
Studies that detailed presenting findings were tabulated and the numbers of patients 
reported with and without particular symptoms were extracted, according to HIV status. 
Findings from different studies were synthesized using standard meta-analytic 
techniques. In particular, I visualized effects using forest plots and assessed between- 
study heterogeneity using the I2 statistic [249, 250]. The Chi squared test was used to 
compare the proportions of patients with each symptom or sign by HIV serostatus. 
Analyses were done with the statistical programme R version 2.9.0 (R Foundation for 
Statistical Computing, Vienna, Austria) [247] and the contributed R-package meta 
version 1.1-5. Presence of the following symptoms/signs was analysed: fever, headache, 
malaise, neck stiffness, meningeal signs, nausea/vomiting, visual impairment, focal 
neurological signs, fits and confusion. If studies reported neck stiffness then this was 
analysed both separately and carried forward to the meningeal sign group.
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3.3.2 Prospective comparison of clinical phenotype of cryptococcal meningitis in 
Vietnamese patients according to HIV infection status.
3.3.2.1 Patients
All patients at the Hospital for Tropical Diseases, Ho Chi Minh City, with suspected or 
definite central nervous system infections are referred to the Viet-Anh (Clinical 
Research) Ward where they are assessed and cared for by a dedicated Clinical Research 
team of doctors, nurses and allied professionals. All patients in this analysis were 
recruited to one of 2 studies -  the BMD study (HIV uninfected patients) or the BK study 
(HIV infected patients), described in Chapter 2. Both studies were based solely in the 
Hospital for Tropical Diseases. The studies had ethical approval from the Hospital for 
Tropical Diseases and either the Oxford University Tropical Research Ethics Committee 
(BMD study) or Liverpool School of Tropical Medicine Research Ethics Committee 
(BK Study).
The clinical assessment, investigations, treatment and microbiological methods are 
detailed in Chapter 2.
3.3.2.2 Statistical Methods
Baseline variables were compared between HIV infected and uninfected patients using 
Fisher’s exact test for categorical data and the Wilcoxon rank sum test for continuous 
data. All analyses were performed with R version 2.9.0 (R Foundation for Statistical 
Computing, Vienna, Austria [247]).
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3.3.3 Assessment of Prognostic Factors
The effect of previously published predictors for survival in cryptococcal meningitis 
patients was determined in this cohort o f Vietnamese patients.
Previously published predictors were identified through a literature search of PUBMED 
('http://www.ncbi.nlm.nih.gov/sites/entrez) using the terms <Cryptococcus> 
<meningitis> <outcome> <prognostic factors> and using the limits <human> and 
<clinical trial>. The search was repeated using the MeSH terms "Meningitis, 
Cryptococcal"[Mesh] AND "Prognosis"[Mesh] AND ("Clinical Trial "[Publication 
Type] OR "Retrospective Studies" [Mesh]). Both survival within 10 weeks and survival 
within 6 months following presentation were studied. Patients who did not die in the 
respective time interval were censored at the end of the interval or at the time of loss to 
follow-up, respectively. The Cox proportional hazards regression model was used to 
study the association between covariates and outcome. In a first step, the univariate 
association between candidate predictors and outcome was studied. Continuous 
covariates with a severely right-skewed distribution were loglO-transformed prior to the 
analysis (after adding 1 to the original value to deal with zero measurements in the case 
they occurred). Cut-offs for continuous covariates were only studied if they had been 
previously published as in general dichotomizing may create rather than avoid problems, 
notably a considerable loss o f power and residual confounding. In addition, the use of a 
data-derived 'optimal' cutpoint can lead to serious bias [251, 252]. In a second step, I 
developed a multivariate Cox regression model as follows: All covariates which 
achieved a p-value of <0.20 in the univariate analysis and were missing in less than 20% 
o f patients were included as candidates in the multiple regression model. Backward
model selection was performed according to Akaike’s information criterion (AIC) to 
select a more parsimonious model. Finally, the stability of the backwards model 
selection was determined by investigating the variability of the model selection in 100 
bootstrap resamples of the original dataset [253]. Of note, this investigation may 
overestimate the true stability as it only validated the backwards selection but not the 
initial screening of the covariates for inclusion in the multivariate model.
No imputation of missing data was performed and effects were displayed as hazard 
ratios with the two-sided 95% confidence interval.
3.4 Results
3.4.1 Literature review of the clinical phenotype of cryptococcal meningitis
The literature search identified 140 studies. O f these, 24 studies were found where the 
clinical presentation of cryptococcal meningitis was described by HIV serostatus and the 
raw data including outcome were extractable [57, 61, 62, 76, 99-107, 127, 144, 157, 
254-261]. While some papers presented large or historically significant series, it was not 
always possible to extract the raw data for patients with meningoencephalitis (other 
cryptococcal disease was included) or to compare by HIV serostatus [70, 154, 156, 262]. 
In total, data were available for 2204 patients, 1541 HIV infected and 663 HIV 
uninfected. The raw numbers assessed and reporting each symptom and sign, 
prevalences, odds ratios and P values for differences by serostatus are shown in table 3.1 
below. While in theory it would have been possible to compare the results of laboratory 
investigations between studies using a t-test, in practice the mean values and standard 
deviations of laboratory parameters were rarely presented in the papers and thus
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concatenation and comparison of results was not possible. The Cryptococcus species 
causing disease is not determined in most patients; therefore, I have not attempted to 
distinguish clinical syndrome by infecting species.
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The range refers to the maximum and minimum percentages of patients reported to have 
the symptom or sign in individual studies. From this crude analysis, it appears that there 
are some significant differences in the clinical phenotypes of cryptococcal meningitis 
according to HIV serostatus. The prevalence of fever, headache, photophobia and 
respiratory symptoms were no different by HIV serostatus, but neck stiffness, confusion, 
focal neurological signs, fits, visual impairment and nausea or vomiting were all 
statistically significantly more common in the HIV uninfected group. There was no 
difference in prevalence of the collective symptom ‘meningeal signs’, although this was 
not always clearly defined in the reports. I tested the heterogeneity of the patient
9 • •populations presented in the publications using the I statistic. The I2 statistic describes 
the percentage of variation across studies that is due to heterogeneity rather than chance 
[249, 250]. It is based on the traditional measure of variance, the Cochran Q statistic 
[263]. Unlike Q it does not inherently depend upon the number o f studies considered.
•y
Substantial heterogeneity exists when I exceeds 50%. The analyses revealed that both 
the HIV infected and HIV uninfected patient populations were highly heterogeneous -  
i.e. there were large variations in the reported prevalence of a particular symptom or sign 
within a superficially similar group (Table 3.2). The heterogeneity between study 
populations is further illustrated by the Forest plots for the symptom/sign prevalence by 
HIV serostatus (Figures 3.1 -  3.7).
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Table 3.2
Heterogeneity testing of symptom/sign prevalences in cryptococcal meningitis in
published series by HIV serostatus
HIV infected HIV uninfected
Symptom I2 value 95% Cl I2 value 95% Cl
Fever 92.7 89.3 - 95 86.3 7 2 .4 -9 3 .2
Headache 96.2 94.9 -  97.2 86.1 74.6 -  92.4
Neck Stiffness 96.3 94 .4 -9 7 .5 0.0 0.0
Meningeal
Symptoms
97.3 9 6 .4 -9 8 .0 95.5 9 1 .3 -9 7 .6
Confusion 94.5 92.2 -  96.2 2.4 0 -6 5 .6
Focal deficit 93.9 8 8 .5 -9 6 .7 0 0 - 4 3
Fits 70.8 32.1 -8 7 .5 81.0 5 9 .3 -9 1 .2
Visual
Impairment
29.2 0 -9 2 .6 81.1 41.1 -94
Respiratory
Symptoms
76.6 43.2 -  90.4 NA* NA
* Only 1 study reported presence or absence of respiratory symptoms for HIV 
uninfected patients.
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3.4.2 Clinical Phenotype in southern Viet Nam
57 HIV uninfected patients and 67 HIV positive patients were recruited during the study 
period. O f the 57 HIV uninfected patients, eleven (19.3%) had potentially 
immunosuppressive pre-existing health problems. Two patients had cirrhosis, one had 
both cirrhosis and renal impairment and one had diabetes mellitus. Seven patients had 
taken more than three months of corticosteroid therapy (2 for nephrotic syndrome, 2 for 
Evan’s syndrome, 2 for chronic arthritides and 1 for systemic lupus erythematosus).
3.4.2.1 Demography and symptoms
Demographic findings and symptoms on presentation are presented in Table 3.3 below: 
HIV infected patients were younger (median age 26 years versus 37 years, p=0.002) and 
more likely to be male (88.1% versus 54.4%, PO.OOl). The median duration of 
symptoms at presentation was shorter in HIV infected patients (14 days versus 30 days, 
p<0.001). Headache was a more frequent symptom in HIV infected patients (97.0% 
versus 71.9%, p<0.001), and focal neurological symptoms were more common in HIV 
uninfected patients (40.35% versus 21.0%, p=0.028). There were no differences in the 
presence of the symptoms fever, neck stiffness, confusion, coma or fits between groups.
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Table 3.3
Demographic and Historical Findings on Admission HIV Uninfected versus HIV
Infected patients
HIV Uninfected HIV Infected Comparison
Findi"g Median (IQR) Median (IQR)
. N • N P-value
or N (%) or N (%)
Age (years) 57 37 (23,51) 67 26 (23.5,29.5) 0.002
Male Gender 57 31 (54.4%) 67 59 (88.1%) <0.001
Length of History 57 30 (10,38) 61 14(7,21) <0.001
(days)
Fever 57 • 44(77.2%) 66 53 (80.3%) 0.83
Headache 57 41 (71.9%) 66 64 (97.0%) <0.001
Neck Stiffness 57 49 (86.0%) 60 45 (75.0%) 0.17
Confusion 57 20 (35.1%) 67 26 (38,8%) 0.71
Coma 57 14 (24.6%) 67 9(13.4%) 0.16
Fits 57 7(12.3%) 64 9(14.1%) 0.80
Focal Neurological 
Symptoms
57 23 (40.4%) 62 13(21.0%) 0.03
3.4.2.2 Examination findings
Examination findings are shown below in table 3.4. There were differences detected in 
distribution o f both systolic and diastolic blood pressure between patient groups.
Table 3.4
Admission Findings on Examination HIV Uninfected versus HIV Infected
patients.
HIV Uninfected HIV Infected Test
Finding
N Median (IQR) or N N
Median (IQR) or N P-Value
(%) (%)
Weight (kilo) 26 45.5 (38.3, 52) 6 6 45.0 (40.3,50) 0.96
Temperature (C) 57 37.5 (37, 38) 6 6 37.6 (37,38.2) 0.62
Pulse (bpm) 57 90 (80, 100) 6 6 90 (80, 100) 0.56
Systolic Blood 
Pressure (raraHg)
57 120(106, 130) 6 6 ' ; - , 1 2 0 ) 0.005
Diastolic Blood 
Pressure (mmHg)
57 70(60,80) 6 6 70 (60, 80) 0.03
Glasgow Coma 
Score
57 15(14,15) 6 6 15 (13, 15) 0.80
Cranial Nerve 
lesion
57 24 (42.11) 67 22 (32.84) 0.35
Papilloedema 57 22 (38.6) 59 12(20.3) 0.04
Visual Impairment 53 23 (43.4) 55 19(34.6) 0.43
Photophobia - - 58 6(10.3) -
Neck Stiffness 57 49 (86.0) 6 6 49 (74.2) 0 . 1 2
Hemiplegia 57 3 (5.3) 67 1(1.5) 0.33
Paraplegia 57 2(3.5) 67 0 (0 ) 0 . 2 1
Urinary Retention - - 6 6 3 (4.6) -
Lymphadenopathy 57 0 (0 ) 67 6(9.0) 0.03
Respiratory
symptoms
57 2 (3.5) 64 4(6.3) 0 . 6 8
Splenomegaly 57 0 67 0 1 . 0
Hepatomegaly 57 0 67 5 (7.5) 0.06
Oral thrush - - 6 6 44 (66.7) -
Any Focal Sign 57 27 (47.4) 67 22 (32.8) 0 . 1 0
36
The median systolic blood pressure was 120 mmHg in HIV uninfected patients versus 
110 in HIV patients (p = 0.005). Papilloedema occurred in 38.6% of HIV uninfected 
patients versus 20.3% of HIV infected patients (p = 0.04). Visual impairment was 
determined using bedside tests -  presence of symptoms, the ability to read news print (if 
literate), finger counting, movement detection, light perception, and visual fields tests by 
confrontation. The rate of visual impairment was not different between groups (43.4% 
versus 34.6%, p=0.43). Lymphadenopathy was uncommon and more prevalent in HIV 
infected patients (0 versus 9.0%, p = 0.03). There were no statistically significant 
differences seen in the presence o f neck stiffness, any focal neurological signs, cranial 
nerve lesions, hemi or paraplegia, Glasgow coma score or respiratory symptoms.
3.4.2.3 Laboratory investigations
The results of haematological investigations are given in Table 3.5 below. Total white 
cell count, neutrophil count and lymphocyte count were all lower in HIV infected 
patients (p < 0.001). The median CD4 count in HIV infected patients was 14.5 cells/uL. 
Serum bilirubin was slightly higher in HIV uninfected patients (p = 0.043). CD4 count 
was measured in 20 of the HIV negative patients. The median CD4 count was 416.5/uL, 
and 7 patients had CD4 counts less than 200 /uL.
There were no differences in the rates o f positive cryptococcal antigen tests in blood 
between patients (100% versus 97.44%, p = 0.47).
The results o f cerebrospinal fluid examination are shown in Table 3.6 below. There were 
no differences in CSF opening pressure between patient groups. Cell counts in 
cerebrospinal fluid from HIV infected patients were significantly lower than in HIV 
uninfected patients.
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Table 3.5
Haematological Findings on Admission HIV Uninfected versus HIV Infected
________________________  patients______________________________
HIV Uninfected HIV Infected Test
Investigation
N
Median (IQR) 
or N (%)
N
Median (IQR) 
or N (%)
P Value
Haemoglobin (g/dl) 
White cell count 
(X103 cells/uL) 
Neutrophil count 
(X103 cells/uL) 
Lymphocyte count 
(X103 cells/uL) 
Platelets 
(X103 cells/uL) 
Sodium 
(mmol/L) 
Potassium 
(mmol/L)
Urea
(mmol/L)
Creatinine
(mmol/L)
AST
(U/L)
ALT
(U/L)
Bilirubin 
(mmol/L) 
Cryptococcal 
antigen (positive) 
CD4 (cells/uL)
57 12.4(11.2,13.9) 60
55 10.5(8.15,12.8) 62
52 8.39(6.4,10.6) 62
51 1.21 (0.7,1.6) 62
57 237 (140,335) 62
51 133 (128.5,137.5) 62
51
51
56
47
47
47
44
20
3.7(3.2,4.08)
4.32 (3.55,6.4)
85.6(68.1,87.8)
37 (23,49)
40 (27,68)
12 (8,16.5)
44(100%) 
416.5(53 -  494)
62
61
61
58
58
52
39
48
12.1 (10.15,13.45) 0.06
7.3 (4.67,8.44) <0.001
5.72(3.5,6.9) <0.001
0.6
< 0.001
(0.4,1.02)
200(149,267) 0.17
134.1 (129.62,137) 0.55
3.63 (3.2,4.2) 0.99
4.5 (3.9,6) 0.80
80 (64,95) 0.46
38 (28,54.25) 0.75
51.5 (34.5,74.8) 0.15
1 0 (8 , 1 2 ) 0.04
38 (97.4%) 0.47
14.5(8,28) <0.001
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Table 3.6
Cerebrospinal Fluid Findings HIV Uninfected versus HIV Infected patients
HIV Uninfected HIV Infected Comparison
Investigation
N
Median (IQR) 
or N (%)
N
Median (IQR) 
or N (%)
P value
Opening Pressure 
(cm/CSF)
Opening Pressure 
>20cmCSF
White cells (cells/mL) 
Neutrophils (cells/mL) 
Lymphocytes (cells/mL) 
Red cell count (cells/mL) 
Protein (g/L)
Lactate (mmol/L) 
Glucose (mmol/L)
Blood glucose (mmol/L) 
Blood:CSF glucose ratio 
Culture positive
Log2 Cryptococcus 
Antigen titre
Log 10 Cryptococcus 
colony forming units/ml
54 36.5
(18.2->40)
54 36 
(66.67)
57 147
(66,250)
53 40
(13, 144)
53 83
(40, 130)
55 20 
(0.5, 180)
57 1.2
(0.85, 1.55)
55 4.6
(3.3, 6.05)
57 1.4
( 1, 2)
57 5.8
(5.2, 7.1)
57 4.35
(3.23,7.14)
57 56
(98.3%)
52 8
(5,10)
11 5.22
(4.37,6.10)
53 27
(17 -> 4 0 )
53 36 
(67.92)
63 26 
(4.5, 67.5)
48 9.5 
(2, 38.75)
49 30 
(7, 67)
61 1
(0, 48)
64 0.7 
(0.5, 1.2)
54 2.65 
(1.83,3.5)
64 2.3
(1.58,3)
63 5.4
(4.7,6.29)
62 2.33
(1.86,3.15)
67 67(100%)
65 11 (9 - 1 3 )
48 6.02
(5.63, 6.61)
0.33
1.0
< 0.001
< 0.001
< 0.001
0.08
< 0.001
< 0.001
< 0.001
0.03
< 0.001
0.46
< 0.001
0.02
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In HIV infected patients CSF protein and lactate were significantly lower (median 0.7 
versusl.2 g/L, p<0.001 and 2.65 versus 4.6 mmol/L, p < 0.001), and the blood:CSF 
glucose ratio was smaller (p < 0.001). The fungal load was higher in HIV infected 
patients compared with HIV uninfected patients as measured by both the CSF 
cryptococcal antigen titre (1/2048 versus 1/256, p < 0.001) and the CSF viable 
cryptococcal count (1 050 000 CFU/ml versus 166 000 CFY/ml, p = 0.02). Log2 CSF 
cryptococcal antigen titre and quantitative fungal count were correlated for each group: 
Spearman’s rank correlation was 0.49, p<0.001 for HIV infected patients and 0.61, 
p=0.04 for HIV uninfected patients.
3.4.2.4 Radiological Findings
21.4% of HIV uninfected patients had abnormalities on chest X-ray compared with 
38.9% of HIV infected patients (p = 0.06). Infiltrative shadowing was the most 
frequently reported finding. One patient had bilateral pleural effusions; cavitation was 
not described. Overall only 39 patients had CT brain scans. 65.4% of HIV uninfected 
patients had abnormal scans, compared with 30.8% of HIV infected patients (p=0.09) 
(Table 3.7).
Table 3.7
_______Abnormal Radiological Findings HIV Uninfected versus HIV Infected
HIV Uninfected HIV Infected Comparison
Characteristic Summary Summary
N N P value
Statistic statistic
Chest
56 12 (21.43%) 54 21 (38.9%) 0.06
X-ray
CT brain scan 26 17(65.4%) 13 4 (30.8%) 0.09
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3.4.2.5 Microbiology
Isolates were available from 60 of the HIV infected patients and 37 of the HIV 
uninfected patients. All isolates from HIV infected patients were Cryptococcus 
neoformans var grubii ( URA5 RFLP molecular group VN1). 11 (29.7%) isolates from 
HIV uninfected patients were C. neoformans var gattii (9 URA5 RFLP group VG1 and 2 
URA5 RFLP group VG2); the rest (26, 70.3%) were Cryptococcus neoformans var 
grubii, all of molecular group VN1. This difference in species distribution was highly 
significant (p<0.001, Fishers’ exact test). Of the HIV uninfected patients, 2 of 11 (18%) 
with C. gattii infection had underlying disease, versus 9 of 26 (34%) patients with var 
grubii infection (p = 0.45, Fisher’s exact test). Representative RFLP profiles are shown 
in Figure 3.8.
Figure 3.8.Representative PCR-RFLP profiles for the URA5 gene of 20 isolates and 8 controls. A  =  
VN1, B = VN2, C = VN3, D = VN4, E = VG1, F = VG2, G = VG3, H = VG4. * identifies 
different molecular groups.
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3.4.2.6 Mortality
The survival curves are shown in Figure 3.9.
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Figure 3.9.Six month Kaplan -  Meier survival curve for HIV infected and uninfected patients with 
cryptococcal meningitis.
By 6 months 41 of 124 patients had died (33.1%). 2 HIV infected patients were lost to 
follow up, and 10 had withdrawn from the study. There was no loss to follow-up of HIV 
uninfected patients. The differential study withdrawal rate between the HIV serostatus
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groups likely represents their difficult social circumstances (including high rates of drug 
abuse). 31 deaths occurred in HIV infected patients (46.3%) and 10 in HIV uninfected 
patients (17.5%). HIV infection increased the hazard for death within 6 months by a 
factor o f 3.78 (95% confidence interval (Cl) 1.841 - 7.734, p<0.001). By 10 weeks there 
were 35 deaths in total (28.2%), 7 occurring in the HIV uninfected group (death rate 
12.3%) and 28 in the HIV infected group (death rate 41.8%). HIV infection increased 
the hazard for death by 10 weeks 4.5 fold (95% confidence interval 1.96 - 10.34, p = 
0.0004). One of 11 HIV uninfected patients with var gattii infection died versus 6 of 26 
with var grubii infection (Odds ratio 2.93, 95% Cl 0.29 -  151.46, p = 0.65, Fisher’s 
exact test).
3.4.3 Prognostic Factors
The literature search identified 25 papers which described prognostic factors in 
cryptococcal meningitis [53, 61, 62, 80, 99-104, 106, 108, 155-157, 204, 255-257, 259, 
260, 262, 264, 265]. Over 40 prognostic factors associated with death were identified, 
listed in Tables 3.8 a and b.
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Table 3.8
Table 3.8a. Previously reported prognostic factors in cryptococcal meningitis 
____________________(history and examination findings) ________________
Prognostic Factor Number of 
Studies Reporting 
Factor
Univariate
Significance
Multivariate
Significance
a
mo
CQ
c
E
*
W
ns
C
cs
o
CJ
U
Mini Mental Test Examination score< 25
Weight <55 kilo
Weight <40 kilo
Male gender
Age
Age > 30yrs 
Underlying Disease 
Haematological Malignancy 
Disseminated Infection 
Malignancy 
Diabetes Mellitus 
Hepatitis B Infection 
AIDS
Renal Failure
Systolic Blood Pressure >150 mmHg 
Abnormal Mental Status 
‘Cerebral Dysfunction’ (GCS< 15 or 
Seizures)
G CS< 13 
GCS <10 
Coma
Abnormal Neurology*
Convulsion 
Blurred vision 
Absence of Headache 
Hydrocephalus 
Organ Failure 
Mechanical Ventilation 
Previous ITU admission
Y 
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
* Abnormal neurology = any reported neurological deficit (eg hemiplegia, cranial nerve lesion etc)
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Table 3.8b. Previously reported prognostic factors in cryptococcal meningitis 
_______________________________(investigations)___________________________
Prognostic Factor Number of Univariate Multivariate
Studies Reporting Significance Significance
Factor
a
•  miW)
©
a
E©
C3
X
&D
*3C2
Fungaemia
Cryptococcal Antigen Titre > 1/512
Cryptococcal Antigen Titre
Low haematocrit
White Cell Count > 10 000/ml
Thrombocytopenia
Hyponatraemia
High Blood Urea Nitrogen
Low albumin
Y
Y
Y
Y
Y
Y
Y
Y
Y
High CSF Pressure 2 Y
Opening pressure > 60 cm CSF 1 Y
e
.O Opening Pressure > 30 cm CSF 1 Y Y
2  Positive India Ink 2 Ycs
£  Cryptococcal colony Forming Units/ml
^  2 Y Y
tt CSF
W
High CSF Cryptococcal antigen titre 1 Y
J2 Cryptococcal Antigen titre > 1/512 1 Y
_  Cryptococcal Antigen titre > 1/1024 2 Y Y
3^
.2  Low white cell count 1 Y
&
g  White Cell Count <0.02X109/L 3 Y Y
jS High CSF protein 1 Y
Protein<0.35g/L 1 Y Y
Low CSF Glucose 1 Y
CSF Glucose < 2mmol/L 1 Y
Imaging Abnormal Brain Imaging 3 Y
Abnormal Thoracic Imaging 1 Y
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3.4.3.1 Univariate Analysis
A Cox regression survival analysis was used to determine the validity o f these factors in 
our dataset, both for all patients combined and separated by HIV serostatus, over both 70 
days (the end of intensive treatment and the point at which patients are switched to long 
term suppressive therapy) and 6 months. The results of univariate analyses are 
summarised in Tables 3 .9 -3 .1 3 . The factors significantly associated with outcome are 
summarised in Table 3.14. For the combined group 6 factors (HIV infection, confusion, 
Glasgow Coma Score, cerebrospinal fluid cryptococcal antigen titre, cerebrospinal fluid 
colony forming unit quantitative count, and CSF white cell count) were associated with 
an increased hazard o f death by both 70 days and 6 months. In addition, an abnormal 
chest X-ray was associated with death at 6 months. A low CSF glucose was associated 
with a reduced hazard of death, contrary to the published literature, perhaps indicating a 
robust immune response. For HIV patients, male sex was associated with a reduced 
hazard of death by both 70 days and 6 months, and presence of focal neurological 
symptoms with death by 6 months. For HIV uninfected patients, age, hemiplegia and 
blood urea were associated with death by both 70 days and 6 months.
115
Table 3.9 Univariate Cox Regression of Demographic and Symptom Related
Prognostic factors
Variable 
(N: all, HIV+, 
HIV-)
70 day outcome 
Hazard Ratio 
[Lower 95% Cl - Upper 95% Cl] 
P value
6 month outcome 
Hazard Ratio 
[Lower 95% Cl - Upper 95% Cl] 
P value
All Patients HIV
infected
HIV
uninfected
All Patients HIV
infected
HIV
uninfected
Gender (male) 
(124 ,67 ,57)
0.947 
[0.46- 1.97] 
0.88
0.165 
[0.07 -0. 41] 
<0.0001
1.155 
[0.26 -5.16] 
0.85
1.056
[0.53-2.11]
0.88
0.165 
[0.06 - 0.41] 
<0.0001
1.31 
[0.37 -4.64] 
0.68
Age + 10 years 
(124 ,67 ,57)
1.0
[0.78 - 1.28] 
0.98
1.0
[0 .5 9 - 1.69] 
0.99
1.66
[1 .06-2 .60]
0.03
1.08 
[0.86 - 1.34] 
0.52
1.02 
[0.63 - 1.68] 
0.93
1.77
[1 .21-2 .58]
0.003
Length o f History 
(+ 1 day) 
(118,61, 57)
0.984 
[0.96 - 1.00] 
0.15
1.007 
[0.98 - 1.04] 
0.64
0.9823
[0 .94-1.02
0.39
0.991
[0.98-1.01]
0.30
1.009 
[0.98 - 1.04] 
0.55
0.997 
[0.98- 1.01] 
0.69
HIV status
(positive)
(124)
4.50 
[1.96 - 10.34] 
0.0004
3.773 
[1.84 -7.731 
0.0003
Headache 
(124, 67, 57)
6.364 
[0.87 -46.55] 
0.07
All have 
headache
2.165 
[0.26 - 17.98] 
0.47
2.487 
[0.77 - 8.08] 
0.129
All have 
headache
0.855 
[0.221 - 3.31] 
0.82
Confusion
(124 ,67 ,57))
1.962 
[1.01 - 3.81] 
0.05
1.166 
[0.55 - 2.47] 
0.69
12.72 
[1.53 -105.8] 
0.02
1.859 
[1.01 -3.44] 
0.05
1.017 
[0.49 - 1.89] 
0.96
9.312 
[1.97- 43.99] 
0.005
Convulsion 
(121,64, 57)
1.555 
[0.64 - 3.77] 
0.33
1.051 
[0.36 - 3.05] 
0.93
3.357 
[0.65 - 17.33] 
0.15
1.53 
[0.68 - 3.47] 
0.31
0.894 
[0.311 - 2.57] 
0.84
3.748
[0.97-14.52]
0.06
Focal Neurological 
Symptoms 
(119, 62, 57)
0.9041 
[0.42 - 1.96] 
0.80
2.067 
[0.86 - 4.98] 
0.11
0.556 
[0.11 - 2.86] 
0.47
1.252 
[0.64 - 2.46] 
0.52
2.31 
[1.01 - 5.31] 
0.049
1.399 
[0.41 - 4.84] 
0.60
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Table 3.10 Univariate Cox Regression of Physical Examination Predictors
Variable 
(N: all,
HIV +, HIV )
70 day outcome 
Hazard Ratio 
[Lower 95% Cl - Upper 95%  Cl] 
P value
6 month outcom e 
Hazard Ratio  
[Lower 95% Cl - Upper 95% Cl] 
P value
All Patients HIV-Positive HIV-negative All Patients HIV-Positive HIV-negative
Weight<40kg 
(92, 66, 26)
0.3432 
[0.08 - 1.44] 
0.14
0.374 
[0.05 - 2.76] 
0.33
0.793 
[0.08 - 7.63] 
0.84
0.0.29 
[0.07 - 1.22] 
0.09
0.334 
[0.05 - 2.45] 
0.28
0.582 
[0.07 - 5.211] 
0.63
Systolic 
BP>150mmHg 
(123 ,66 , 57)
1.332 
[0.18 - 9.75] 
0.78
1.428 
[0.19 - 
10.53] 
0.73
8.059e-07 
[0 - Inf] 
1.0
1.192 
[0.16 - 8.69] 
0.86
1.428 
[0.19 - 
10.53] 
0.73
8.05e-07 
[0 - Inf] 
1.0
GCS (+1) 
(123 ,66 , 57)
0.860  
[0.78 - 0.95] 
0.002
0.884 
[0.77 - 1.01] 
0.07
0.767  
[0.66 - 0.90] 
0.001
0.876 
[0.80 - 0.96] 
0.004
0.903 
[0.79 - 1.03] 
0.13
0.801 
[0.70 - 0.919] 
0.002
GCS<15 
(123 ,66 , 57)
2.237  
[1.15 - 4.34] 
0.02
1.524 
[0.72 - 3.22] 
0.27
12.72 
1.53 - 105.8] 
0.02
2.143 
1.16 - 3.96] 
0.02
1.37 
[0.66 - 2.83] 
0.40
9.312 
[1 .97 - 43.99] 
0.005
Cranial nerve
lesion
(124)
0.960  
[0.48 - 1.91] 
0.91
1.429 
[0.67 - 3.05] 
0.36
0.513 
[0.10 - 2.65] 
0.41
1.283 
[0.69 - 2.38] 
0.43
1.643 
[0.80 - 3.36] 
0.17
1.288 
[0.37 - 4.45] 
0.69
Blurred Vision 
(1 0 8 ,5 5 ,5 3 )
0.659  
[0.30 - 1.47] 
0.31
0.822 
[0.33 - 2.06] 
0.68
0.472 
[0.09 - 2.43 
0.37
0.556 
[0.27 - 1.17] 
0.12
0.795 
0.34 - 1.88] 
0.60
0.289 
[0.06 - 1.36] 
0.12
Hemiplegia
(124)
2.798  
[0.86 - 9.14] 
0.10
2.055 
[0.28 - 15.25] 
0.48
8.42 
[1.63 - 43.55] 
0.01
2.579 
[0.79 - 8.38] 
0.12
2.055 
[0.28 - 15.25] 
0.48
6.371 
[1 .33- 30.44] 
0.02
Any Focal
Sign
(124)
0.980  
[0.50 - 1.93] 
0.95
1.429 
[0.67 - 3.05] 
0.36
0.801 
[ 0 .1 8 -  3.58] 
0.77
1.277 
[0.69 - 2.36] 
0.44
1.643 
[0.80 - 3.36] 
0.17
1.613 
[0.46 - 5.72] 
0.46
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Table 3.11 Univariate Cox Regression of Blood Investigation Related Predictors
Variable 
(All, HIV+, 
HIV-)
70 Day Outcome 
Hazard Ratio 
[Lower 95% C l - Upper 95% Cl] 
P value
6 Month Outcome 
Hazard Ratio 
[Lower 95% Cl - Upper 95% Cl] 
P value
All Patients HIV-Positive HIV-negative All Patients HIV-Positive HIV-negative
WCC +loglO 
(103/uL )
(117, 62, 55)
0.48 
[0.14- 1.62] 
0.24
2.62 
[0.34 - 20.1] 
0.36
0.62 
[0.05 -8.41] 
0.72
0.63 
[0 .20- 1.05] 
0.46
3.22 
[0.46 -22.7] 
0.24
1.34 
[0.08 - 22.3] 
0.84
WCC >10 
*103/uL
(117, 62,55)
0.43 
[0.18 - 1.03] 
0.06
1.17 
[0.35 - 3.89] 
0.80
0.61 
[0.14 - 2.74] 
0.52
0.56 
[0.26 - 1.17] 
0.12
1.48 
[0.52 -4.26] 
0.47
0.81 
[0.23 - 2.78] 
0.73
Sodium 
(by+1 mmol/L)
1.01 
[0 .9 6 - 1.07] 
0.65
1.03
[0 .96 -1 .10 ]
0.42
0.98 
[0 .8 8 - 1.09] 
0.76
1.02
[0 .97 -1 .07 ]
0.48
1.03
[0 .97 -1 .10 ]
0.34
1.0
[0.91 -  1.09] 
0.95
Sodium <130
mmol/L
(113,62,51)
1.32 
[0.64 - 2.71] 
0.45
1.23 
[0.54 - 2.81] 
0.63
1.96 
[0.44 - 8.76] 
0.38
1.10 
[0.55 - 2.20] 
0.80
1.11 
[0.49 - 2.49] 
0.81
1.30 
[0.33 - 5.19] 
0.71
Urea ( +logl0
mmol/L)
(117,61,56)
2.37 
[0.34 - 16:68] 
0.39
0.78 
[0.08 -7.27] 
0.83
90.65 
[1.99- 41361 
0.02
2.09 
[0.34 - 12.92] 
0.43
0.74 
[0.09 - 6.20] 
0,78
41.7 
[1.32 - 1319] 
0.034
Urea >6.7 
mmol/L
1.11 
[0.46 - 2.69] 
0.82
1.03 
[0.35 - 2.99] 
0.96
1.78 
[0.35 - 9.18] 
0.49
1.13 
[0.50 - 2.56] 
0.78
0.92 
[0.32 - 2.64] 
0.88
2.20 
[0.55 - 8.78] 
0.27
Cr (by+loglO
mmol/L)
(117,61,56)
3.04 
[0.15 - 62.6] 
0.47
1.20 
[0.05 - 30.93] 
0.91
246.8 
[0.26-2* 10A5] 
0.12
1.72 
[0.10 - 28.43] 
0.71
0.73 
[0.03 - 16.36] 
0.84
39.96 
[0.12- 12944] 
0.21
Positive Blood 
culture 
(28, 28, 0)
1.84 
[0.23 - 14.53] 
0.56
2.154 
[0.28- 16.72] 
0.46
HBsAg 
positive 
(40, 40, 0)
1.56 
[0.44 - 5.47] 
0.49
1.28 
[0.37 - 4.40] 
0.70
CD4 count 
(by+ log 10 
cells/uL) (48)
0.57 
[0.17 - 1.85] 
0.34
0.57 
[0.30- 1.07] 
0.08
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Table 3.12 Univariate Cox Regression of Cerebrospinal Fluid Associated Predictors
Variable 
(N: all,
H IV + , HIV-)
70 day outcome 
Hazard Ratio 
(Lower 95% C l - Upper 95% Cl] 
P value
6 month outcome 
Hazard Ratio 
[Lower 95% Cl - Upper 95% Cl] 
P value
All Patients HIV-Positive HIV-negative All Patients HIV-Positive HIV-negative
CSF Opening 
Pressure >40 cm 
CSF
(107, 53,54)
0.79 
[0.38 - 1.64] 
0.52
1.04 
[0.44 - 2.43] 
0.94
0.81 
[0.18 - 3.63] 
P0.79
0.77 
[0.38 - 1.56] 
0.47
0.97 
[0.42 - 2.25] 
0.94
0.87 
[0.23 - 3.25] 
0.84
CSF OP>30 cm 
CSF
(107 ,53 ,54)
0.83 
[0.41 - 1.67] 
0.59
1.14 
[0.51 - 2.56] 
0.74
0.82 
[0.18 - 3.68] 
0.80
0.87 
[0.45 - 1.71] 
0.69
1.06 
[0.48 - 2.33] 
0.89
1.25 
[0.31 - 4.98] 
0.76
CSF OP>20 
cmCSF 
(107, 53 ,54)
0.97 
[0.46 - 2.06] 
0.93
0.93 
[0.40 - 2.17] 
0.87
1.14 
[0.22 - 5.86] 
0.88
1.11 
[0.53 - 2.32] 
0.79
0.98 
[0.42 - 2.28] 
0.97
1.61 
[0.33 - 7.73 
0.56
Log2CSF CrAg 
(117,65,52)
1.20 
[1.08 - 1.34] 
0.001
1.07 
[0.94 - 1.23] 
0.30
1.29 
[1.03 - 1.63] 
0.03
1.22 
[1.10 - 1.35] 
<0.001
1.08 
[0.95 - 1.24] 
0.24
1.31 
[1.08 - 1.59] 
0.007
Log 10 QC CSF 
(CFU/ml)
(58, 47,11)
2.31 
[1.24 - 4.30] 
0.008
1.97 
[0.96 - 4.03] 
0.07
4.16 
[0.76 - 22.7] 
0.10
2.04 
[1.16 - 3.57J 
0.013
1.64 
[0.85 - 3.14] 
0.14
4.16 
[0.76- 22.65] 
0.10
Log 10 QC>4.7 
(58,47, 11)
3.70 
[0.50 -27.58] 
0.20
0.91 
[0.12 - 6.89] 
0.93
1X10A8 
[0 - Inf] 
0.99
4.49 
[0.61 - 33.32] 
0.14
1.07 
[0.14 - 7.80] 
0.95
11236498 
[0 - Inf] 
0.99
Log10 CSF 
WCC/ml 
(120, 63 ,57)
0.54 
[0.36 -0.82] 
0.004
0.72 
[0.43 - 1.20] 
0.21
1.36 
[0.29 - 6.48] 
0.70
0.55 
[0.37 - 0.81] 
0.003
0.70 
[0.43 - 1.14] 
0.15
1.31 
[0.35 - 4.86] 
0.69
Protein CSF/0.1 
g/L (121, 64, 57)
0.98 
[0.92 - 1.04] 
0.41
1.00 
[0.93 - 1.06] 
0.91
1.03 
[0.92 - 1.16] 
0.59
0.97 
[0.92 - 1.03] 
0.34
0.99 
[0.93 - 1.05] 
0.70
1.04 
[0.94 - 1.14] 
0.47
Protein <0.35g/L 
(121 ,64 ,57 )
1.27 
[0.31 - 5.31] 
0.74
0.71 
[0.167 - 2.99] 
0.64
All values 
greater than 
0.35g/L
1.8
[0.26 - 4.47] 
0.92
0.61 
[0.15 -2.58] 
0.51
All values 
greater than 
0.35g/L
LoglO Glucose 
CSF mmol/L 
(121,64, 57)
7.06 
[1.75 - 28.44] 
0.006
1.96
[0 .3 3 -1 1 .8 ]
0.46
134.2
[1 .11-16211]
0.05
6.51 
[1.70 - 25.0] 
0.006
2.14
[0 .39 -11 .7 ]
0.38
21.0 
[0 .3 7 - 1285] 
0.14
Glucose<2.0
mmol/L
(121 ,64 ,57 )
0.50 
]0.25 - 0.99] 
0.05
0.95 
[0.44 -2.08] 
0.90
0.32 
[0.07 - 1.41] 
0.13
0.59 
[0.31 - 1.10] 
0.10
0.96 
[0.45 - 2.01] 
0.91
0.62 
[0.17 - 2.19] 
0.46
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Table 3.13 Univariate Cox Regression of Imaging Findings and Outcome
Variable 
(N all, N 
HIV+, N 
H IV )
70 day outcome 
Hazard Ratio 
[Lower 95% C l - Upper 95% CI[ 
P value
6 month outcome 
Hazard Ratio 
[Lower 95% C l - Upper 95% Cl] 
P value
All Patients HIV-Positive HIV-negative All Patients HIV-Positive HIV-negative
Normal Chest 
X-ray :
(110, 54, 56) ;
0.59 
[0.28 - 1.23] 
0.16
0.76 
[0.33 - 1.74] 
0.52
0.67 
[0.13 - 3.47] 
0.64
0.47 
[0.25 - 0.92] 
0.03
0.67 
[0.31 - 1.45] 
0.31
0.40 
[0.11 - 1.40] 
0.15
Normal CT 
Brain Scan 
(39 ,13 ,26)
1.43 
[0.32 -3.38] 
0.64
0.75 * 
[0.14 - 4.11] 
0.74
1.399e-07 
[0 - Inf] 
0.99
1.38 
[0.37 - 5.15] 
0.63
0.75 
[0.14 - 4.11] 
0.74
0.78 
[0.07 - 8.57] 
0.84
Table 3.14 Summary of variables found to be associated with outcome by univariate
analysis.
Variable 70 Day Survival 6 Month Survival
N
Hazard
Ratio
95%
Confidence
Interval
P
value
Hazard
Ratio
95%
Confidence
Interval
P value
Confusion 124 1.96 1.01-3.81 0.046 1.86 1.01 -3.44 0.048
Glasgow Coma 
Score (+1)
123 0.86
0.78 - 0.95 0.0019 0.88 0.80 - 0.96 0.004
Logio CSF WCC/ml 120 0.54 0 .3 5 -0 .8 2 0.004 0.55 0 .37-0 .81 0.003
HIV Infected 124 4.50 1 .96-10 .34 0.0004 3.77 1.84-7 .73 0.0003
Log2 CSF CrAg titre 117 1.20 1.0- 1.34 0.001 1.22 1 .10-1 .35 0.0002
Logio CSF Yeast 58 2.31 1.24-4.295 0.008 2.04 1 .16 -3 .57 0.013
Count
Logio CSF Glucose 121 7.06 1.75 - 28.44 0.006 6.51 1.70- 24.98 0.006
mmol/L
Normal Chest X-ray 110 NA 0.47 0.25 0.92 0.026
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3.4.3.1 Multivariate analysis
To be included in the multivariate analysis variables, the p-value of the univariate 
analysis had to be <0.2. In addition, in order not to decrease sample size too 
dramatically, data on the variable had to exist for at least 80% of the subjects. Because 
of limitations imposed by the sample size and the number of events, the multivariate 
model was only fitted to the 6 month time point for the whole group of patients. Table 
3.15 summarises the variables where 0.05<P<0.2 over 6 months for the whole patient 
group.
Table 3.15
Summary of variables associated with death with 
P values 0.05 < P < 0.2 (all patients).
Variable 6 Month Survival
N Hazard Ratio 95% Cl P value
(Wald)
Weight <40 kilo 92 . 0.29 0 .0 7 -1 .217 0.091
Hemiplegia 124 2.579 0.794 - 8.375 0.115
Blurred Vision 108 0.556 0.265 - 1.17 0.122
Headache 124 2.487 0.766 - 8.076 0.129
Blood WCC>10 117 0.555 0.263 - 1.169 0.121
*103 cells/uL
WCC = white cell count
121
CSF yeast quantitative counts and weight data were only available for 58 (47%) and 92 
(74%) patients. Thus eleven variables met the inclusion criteria for the final model -  
HIV serostatus, headache, confusion, blurred vision, hemiplegia, Glasgow coma score, 
CSF glucose, CSF cryptococcal antigen titre, CSF white cell count, blood white cell 
count and abnormalities on chest X-ray and the dataset with complete data on all these 
variables included 99 patients. After backward selection, 5 covariates remained in the 
model for prediction of death at 6 months (Table 3.16).
Table 3.16
________________ Multivariate Analysis - Final Model (99 patients)
Variable Hazard Ratio Lower 95 Cl Upper 95 Cl P value
Log2 CrAg CSF (+1 Iog2) 1.249 1.10 1.42 <0.001
GCS (+1) 0.839 0.74 0.96 0.007
Hemiplegia 3.76 0.80 17.61 0.093
Abnormal Chest X-ray 1.83 0.89 3.74 0.098
CSF WCC 0.53 0.33 0.85 0.008
(+ lLogiocells/ml)
CrAg = cryptococcal antigen titre, GCS = Glasgow Coma Score, WCC = white cell count
Glasgow coma score, cryptococcal antigen titre in CSF and CSF white cell count were 
highly significantly associated with an increased hazard of death. Refitting the variables 
identified by the model on all subjects with complete data increased the model size to
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104 patients. The same variables remained significantly associated with death (Table
3.17).
Table 3.17
Effect of refitting the multivariate model on all patients with observations on the 
_______________________ selected covariates (104 patients)_______________________
Variable Hazard Ratio Lower 95 Cl Upper 95 Cl P value
Log2 CrAg CSF (+1 log2) 1.23 1.09 1.38 <0.001
GCS (+1) 0.81 0.73 0.92 <0.001
Hemiplegia 3.27 0.72 14.94 0.126
Abnormal Chest X-ray 1.82 0.92 3.61 0.087
CSF WCC 0.47 0.31 0.73 <0.001
(+ lLogiocells/ml)
CrAg = cryptococcal antigen titre, GCS = Glasgow Coma Score, WCC = white cell count
Because of the differences in mortality rate between HIV infected and uninfected 
patients, the backward selection was repeated but forcing HIV status into the model. 
Glasgow coma score and CSF cryptococcal antigen titre remained significantly 
associated with death (Tables 3.18 and 3.19).
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Table 3.18
Multivariate analysis - final model, HIV status forced into model 
_________________________________ (99 patients)________________________
Variable Hazard Ratio Lower 95 Cl Upper 95 Cl P value
Log2CrAg CSF 1.226 1.07 1.40 0.003
Glasgow Coma Score 0.842 0.74 0.96 0.009
Hemiplegia 3.99 0.85 18.83 0.080
Abnormal Chest X-ray 1.89 0.92 3.90 0.083
LoglO CSF WCC 0.60 0.34 1.04 0.068
HIV infected
WCC = white cell count
1.46 0.54 3.91 0.45
Table 3.19
Refitting the model on all patients with observations, + HIV status (104 patients)
Variable Hazard Ratio Lower 95 Cl Upper 95 Cl P value
Log2CrAg CSF 1.20 1.06 1.37 0.004
Glasgow Coma Score 0.82 0.73 0.93 0.001
Hemiplegia 3.52 0.77 16.15 0.106
Abnormal Chest X-ray 1.88 0.0.95 3.76 0.072
LoglO CSF WCC 0.54 0.32 0.90 0.019
HIV infected 1.54 0.58 4.04 0.385
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In a 100 iteration boot strap analysis all 5 variables initially chosen by the model 
reselected at least 50% of the time (Table 3.20).
Table 3.20
_______________ Bootstrap Analysis of Final Model_____________
Variable Probability of the selected 
variable being included in 
the final model
Log2 Cryptococcal Antigen in CSF 
Glasgow Coma Score 
Log 10 white cell count CSF 
Hemiplegia 
Abnormal Chest X-ray 
Visual Impairment 
Log 10 blood white cell count 
HIV status
CSF Glucose< 2 mmol/L 
Headache 
Confusion
0,92
0.77
0.76
0.66
0.54
0.49
0.41
0.41
0.40
0.31
0.27
3.5 Discussion
3.5.1 Published Clinical Phenotypes
There was heterogeneity in the groups of patients from whom descriptions of the clinical 
phenotype of cryptococcal meningitis have been published. This might have been 
expected for HIV uninfected patients, since their medical backgrounds are diverse, 
ranging from the solid organ recipient to the immunocompetent. More surprisingly the 
heterogeneity was at least as marked within the HIV infected population. This may have 
implications for the extrapolation of study findings from one patient group to another.
O f note, van der Horst’s study, which has been the key study underlying the 
development o f treatment guidelines for cryptococcal meningitis, was remarkable for the 
relatively low proportion o f patients suffering headache in contrast to other series[107,
110]. Since headache can be a symptom of raised intra-cranial pressure, this may signify 
that patients in the study were less severely ill than the general population of patients 
with cryptococcal meningitis -  ie they were not a representative sample. There were 
marked differences in the prevalence of neck stiffness and meningeal signs between 
studies. The absence of meningeal signs could conceivably be a marker of both mild and 
severe disease -  absent in severe cases because o f the inability o f the patient to report it, 
or because of profoundly suppressed immunity and subsequent minimal inflammatory 
response. The differences in presence of symptoms at baseline may also represent health 
seeking behaviour that occurs at different disease stages because of differences in wealth 
or access -  French describes patients from Uganda, whereas van der Horst reports 
patients from the USA. O f course, intervention studies are biased in their presentation of 
clinical symptoms and signs by their inclusion criteria, and purely descriptive studies,
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with less stringent entry criteria, are more likely to give an accurate clinical phenotype. 
However, a clinical trial where the study population does not accurately reflect the 
general population is of limited value.
The intra-group (HIV infected or not) heterogeneity that I have demonstrated suggests 
that my data concatenation must be interpreted with a deal of caution. My concatenation 
suggests that there are significant differences in clinical phenotype between HIV 
infected and uninfected patients, regarding the presence of confusion/impaired conscious 
level, focal neurological signs, fits, visual impairment and nausea and vomiting. How 
this compares with the experience in Viet Nam is discussed below.
3.5.2 Clinical Phenotype in Viet Nam
3.5.2.1 History and Examination
I found statistically significant differences in historical findings but few differences in 
examination findings in patients with cryptococcal meningitis according to HIV 
serostatus. HIV infected patients were more likely to be male (88.1% versus 54.4%) and 
the median age at presentation was lower (26 years versus 37 years). The age and gender 
distribution in HIV infected patients mirrors the demographics of the HIV epidemic in 
Viet Nam. There was no gender preponderance in HIV uninfected patients (31 of 57 
patients were male, 54.4%). The duration of illness prior to presentation in HIV infected 
patients was shorter than in HIV uninfected patients (14 versus 30 days). It might have 
been expected to be longer given that a high proportion of the HIV infected patients are 
intravenous drug users (67.75%) -  a group that is generally considered to be in a socially 
disadvantaged position with impaired contact with health services. The shorter illness
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duration presumably represents more rapid disease progression because of 
immunosuppression. Consistent with this, the markers of fungal burden (CSF 
cryptococcal antigen titres and yeast colony forming units) were significantly higher in 
HIV infected patients at presentation. However, despite the shorter disease duration and 
higher fungal burdens, physical examination findings, including Glasgow Coma Score, 
were similar in each group.
Headache, a symptom associated with raised intra-cranial pressure, was frequent in both 
groups but more commonly reported in HIV infected patients (97% versus 72%, 
p<0.001). However, papilloedema was marginally more common in HIV uninfected 
patients (38.6% versus 20.34%, p = 0.04). The different rates of papilloedema, which 
takes time to develop, perhaps represent the differences in symptom duration in each 
group -  longer in the HIV uninfected. The median systolic and diastolic blood pressures 
were the same between groups, but the spread was different, with more HIV uninfected 
patients having higher values (p = 0.005). Other indicators of raised intracranial 
pressure, such as the presence of coma, pulse rate and the opening CSF pressure were no 
different between groups.
Lymphadenopathy was not reported in the HIV uninfected patients but was present in 
9% of HIV infected patients, and is likely to be a manifestation of HIV rather than 
cryptococcosis per se.
While in these patients the prevalence o f particular symptom/signs by HIV status were 
broadly similar to that shown in the data concatenation, I did not find the same 
statistically significant differences. This may be a function of study size. Of note, visual 
impairment was much higher in our HIV infected patients compared with the published
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literature. Perhaps other factors were important, such as malnutrition or toxins related to 
intravenous drug use, which is prevalent in these patients. Unlike the concatenation, I 
found headache to be more common in HIV infected patients (97% vs. 72%, p<0.001).
3.5.2.2 Haematological Findings
As might be expected, HIV infected patients had markedly lower blood lymphocyte 
counts than HIV uninfected patients (p<0.001). The median neutrophil count was also 
significantly lower (5.72 X 103/uL, p<0.001) although still within the normal range. The 
median CD4 count was 14 cells/uL in HIV patients. Only 20 HIV uninfected patients 
had CD4 counts measured on admission and the median count was 416 cells/uL. 9 
patients had CD4 counts less than 400 cells/uL and 7 patients had CD4 counts less than 
200 cells/uL. While CD4 lymphopenia is a recognised risk factor for cryptococcosis, 
transient CD4 lymphopenia is a well recognised feature of some infections including 
cryptococcosis and tuberculosis. Which of these possibilities is the case in our patients is 
not clear, since the CD4 count was not measured serially, although one can be confident 
that it is not due to HIV infection. I could not demonstrate any increased hazard for 
death at 70 days or 6 months of a low CD4 count in HIV uninfected patients.
Differences in total bilirubin (median 10 mmol/L versus 12 mmol/L, p=0.043) were 
clinically unimportant, and due to the number of comparisons (discussed in more detail 
below) also statistically insignificant.
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3.5.2.3 CSF Examination Findings
There were significant differences in CSF examination findings consistent with an 
attenuated immune response in the HIV infected patients. Total white cell count, 
neutrophil count and lymphocyte count were all lower in HIV infected patients (p<0.001 
for all variables). Other CSF markers of inflammation including protein and lactate were 
significantly higher in HIV uninfected patients, and CSF glucose was lower in HIV 
uninfected patients, consistent with other reports from the literature [104, 156, 266]. The 
median CSF:blood glucose ratio was 0.23 in HIV uninfected patients versus 0.43 in HIV 
patients (p = 0.001). A similar impact of HIV on CSF parameters has been described in 
tuberculous meningitis [267]. O f note, in HIV negative patients there was no correlation 
between blood CD4 count and CSF lymphocyte count (Spearman’s coefficient -0.01, p = 
0.97).
There have been few studies of the effect of HIV on the presentation of cryptococcal 
meningitis. Rozenbaum and Goncalves retrospectively compared 130 patients with 
cryptococcal meningitis from Brazil according to underlying immune status (HIV 
infected, underlying potentially immunosuppressive disease excluding HIV, and not 
immunosuppressed)[259]. In keeping with my findings, they found that papilloedema 
was significantly more common in HIV uninfected patients. They also found impaired 
consciousness, neck stiffness, and cranial nerve lesions to be statistically significantly 
more common in HIV uninfected patients compared with HIV infected patients (Table
3.17). Similarly, I found increased rates of neck stiffness and cranial nerve lesions in 
these HIV uninfected patients, although the differences did not reach statistical 
significance.
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Lui et al reported 31 patients from Taiwan with cryptococcal meningitis of whom 7 had 
HIV and 8 had other potentially immunosuppressive co-morbidities[104]. Consistent 
with this experience they found that immunocompetent patients had more indolent 
disease (p=0.02), higher CSF white cell counts (p=0.03) and better clinical outcomes 
(p=0.04). Moosa and Coovadia reported 44 HIV infected patients and 21 HIV uninfected 
patients with cryptococcal meningitis from Durban, South Africa[257]. They also found 
HIV infected patients were more likely to have headache (p = 0.04), were younger 
(p=0.02), had higher CSF cryptococcal antigen titres and lower CSF white cell counts 
than HIV uninfected patients. The in-hospital mortality rate was 7 fold higher for HIV 
infected patients (64% versus 9%, p=0.0007). Moosa et al reported that HIV infected 
patients were more likely to be female (p=0.01), (consistent with the demographic 
differences in the HIV epidemic in South Africa compared with Viet Nam), and that 
HIV infected patients were more likely to have neck stiffness (p = 0.02). Focal 
neurological signs were present in 50% of their HIV infected patients and 29% of their 
HIV uninfected patients (p = 0.1), compared with 32.8% and 47.4% respectively in our 
patients (p = 0.1). 7% of their HIV infected patients had normal CSF examination 
compared with none of the HIV uninfected patients (p = 0.05).
Dromer et al reported 53 HIV uninfected patients and 177 HIV infected patients from 
France[156]. 187 patients had cryptococcal meningitis, and no difference was found in 
clinical presentation by HIV status. Of 53 HIV uninfected patients, co-existent morbidity 
was common -  solid organ transplantation in 11, malignancies in 21, other potentially 
immunosuppressive conditions (diabetes, cirrhosis, sarcoidosis, corticosteroid use, 
idiopathic CD4 lymphopenia and hypogammaglobulinaemia) in 12 and no identified risk
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factor in 9 (of whom 5 had disease limited to the skin). This contrasts with our HIV 
uninfected patients (all with meningitis), the majority of whom have no identified 
potentially immunosuppressive co-morbidities. Speed and Dunt reported 133 patients 
from Victoria, Australia, of which 96 had meningitis and 25 had HIV infection, but did 
not compare clinical phenotype by HIV infection status[76].
Conclusions drawn from studies directly comparing cryptococcal meningitis clinical 
phenotype by HIV serostatus are limited by the small sizes of the studies. Further data 
regarding clinical phenotype can be derived from other study types, focusing on either 
patient group, such as randomised controlled trials. I identified baseline clinical data 
published on 2204 patients from the medical literature [57, 61, 62, 99-107, 144, 154, 
157, 254-261]. However, these data must be interpreted with caution. For example, the 
largest RCT on cryptococcal meningitis (381 patients) was the Mycoses Study Group 
and ACTG trial (Van der Horst et a l ) published in 1997[107]. This study on HIV 
infected patients had stringent exclusion criteria which served to exclude patients 
considered to be more severely ill. Patients who were comatose, unable to take oral 
medication, unable to provide consent or who had moderate or severe haematological, 
renal or hepatic dysfunction were excluded from the study. Thus any conclusions about 
clinical phenotype must be considered within this context of presumably milder disease. 
Of course, all patient sub-populations are potentially biased, not least those seen in our 
hospital, which serves a large geographical area. The distances some patients need to 
travel could act as a barrier preventing the most unwell patients from reaching our 
hospital, although the death rates in our patients are similar to those reported from 
elsewhere in Asia. While it is tempting to collate the data from the studies noted above,
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and it is possible to describe differences by HIV serostatus (Table 3.18), tests for 
heterogeneity reveal that the patient populations from which the data are drawn (even 
amongst HIV patients) are indeed highly heterogeneous and that this data collation is 
therefore likely to be misleading. This is illustrated in Table 3.19 and the Forest plots in 
Figures 3 .3 -3 .1 0 .
The other confounder that should be considered is that of multiple testing. I compared 55 
baseline variables -  probably not dissimilar to most descriptive studies, and thus might 
have expected to find at least 3 variables different between groups at a statistical 
significance level o f p = 0.05. A Bonferroni correction (which is conservative) would 
suggest that the null hypothesis should be rejected for a comparison only where the P 
values is (approximately) 0.001 [268]. We found 14 variables with a P value <0.001 
(which should thus be considered significant at the P=0.05 level). 13 were laboratory 
measurements where the differences are plausible given that they might be expected to 
be lower in immunosuppressed patients, and the other was the rate of presence of 
headache, which was more frequent in HIV infected patients. Possible explanations for 
the differential presence of headache are more rapid disease progression in HIV infected 
patients, with subsequently more rapid changes in CSF pressure (CSF pressure 
measurement was essentially ‘clipped’ at 40cm CSF because of the measuring limit of 
the manometers used, so we cannot be certain that there were no differences by 
measurement), a higher fungal burden resulting in higher CSF pressures, again 
undetected for the reasons just described, or reduced pain tolerance in HIV patients 
because of opiate withdrawal due to disability amongst IV drug users.
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3.5.2.4 Microbiology
All HIV infected patients were infected with Cryptococcus neoformans var grubii and 
this is in line with expectations for HIV patients outside of Europe. O f the 37 viable 
strains from HIV uninfected patients, 11 were Cryptococcus neoformans var gattii, 9 
belonging to URA5 RFLP molecular group VG1 and 2 belonging to molecular group 
VG2. In this tropical location, it might have been expected that more cases in HIV 
uninfected patients would have been due to infection with Cryptococcus gattii [64, 76, 
269]. The ratio of war grubii to var gattii isolates was 3:1. Var grubii infection, the 
commonest cause of cryptococcal meningitis worldwide since the HIV epidemic, most 
frequently occurs in patients with an underlying immunosuppressive conditional, 62, 
270, 271]. Most of the HIV uninfected patients (81%) had no concomitant disease 
associated with immunosuppression, although I did detect CD4 lymphopenia at 
presentation in 9 patients, 3 of whom did not have other underlying conditions. I found 
no difference in the rate of underlying disease according to infecting isolate, although 
this could be explained by the relatively small numbers in this study.
Historically, the disease phenotypes due to infection with var grubii and C. gattii are 
considered to be different. Henderson first proposed the hypothesis that inherent 
differences in pathobiology according to variety could result in different clinical 
phenotypes [272]. Subsequently both Speed and Mitchell found that C. gattii tends to 
cause disease in the immunocompetent and that infections are frequently complicated by 
focal parenchymal brain lesions which are associated with hydrocephalus, cranial nerve 
palsies and seizures [61, 76]. In addition, the history is prolonged in C. gattii infection, 
frank pulmonary involvement is more common, and the outcome is better. However,
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these differences in phenotype might be explained by the host immune response rather 
than the pathogen.
The small number of C. gattii infections I identified means my study lacks power to 
detect differences by infecting species, and, as might be expected, I found no differences 
in clinical phenotype between the 2 infections. However, the number of C. gattii 
infections was small, yet the pattern of disease seen in the HIV uninfected cases 
mimicked that seen in case series of C. gattii infection published from Papua New 
Guinea, suggesting that host immune status is indeed important in determining clinical 
phenotype [62, 80]. Male gender has been identified as a risk factor for Cryptococcus 
gattii infection in Australian patients (most of whom are HIV uninfected). Of the 11 C. 
gattii infections in our HIV uninfected patients, 4 were in women.
The remaining 26 isolates from HIV uninfected patients, like all the isolates from the 
HIV infected patients, were all C. grubii of URA5 PCR-RFLP molecular group VN1. An 
alternative explanation to the host immune status as the prime determinant o f clinical 
phenotype hypothesis, and that would explain why our C. grubii predominantly infected 
HIV negative patients have clinical phenotypes similar to that in patients with C. gattii 
infection, is that disease in these patients is due to a distinct sub-group of C. grubii that 
shares pathogenic features more usually associated with C. gattii. A study from China 
has recently reported that Cryptococcus strains causing cryptococcal meningitis in HIV 
uninfected patients there are most frequently C. grubii VN1, and that there is remarkable 
genetic homogeneity between the isolates, perhaps suggesting the existence o f a strain in 
Asia with particular propensity for infecting the immunocompetent[273]. In fact, the 
authors of the study suggest that in China most cases of cryptococcal meningitis seem to
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be occurring in the immunocompetent. This is not so in Viet Nam, where the major 
burden of disease is in HIV positive patients, with more than 200 cases diagnosed per 
year in the Hospital for Tropical Diseases (unpublished data).The molecular 
epidemiology of the infecting strains in Vietnamese isolates will be discussed in more 
detail in Chapter 4. The results of antifungal sensitivity testing of the strains will be 
discussed in more detail in Chapter 5. Ultimately, it seems most plausible that disease 
phenotype is determined by both the specific pathogen’s properties and the host’s 
immune status.
3.5.2.5 Mortality
The 6 month death rate in these HIV infected patients was 46.3% (95% Cl 34.9 -  
58.1%), which is in line with death rates reported from other low income countries. In 
Africa mortality rates for patients on fluconazole treatment are as high as 100% at 6 
months, with a median time to death of 19 days [258]. Mayanja-Kizzi reported 6 month 
death rates of 78% (95%CI 64.6% - 87.4%) in patients randomised to receive either 
fluconazole or fluconazole combined with flucytosine [144]. Longley reported a 10 
week death rate of 54% (95%CI 41.6 -  66.6%) in patients receiving high dose 
fluconazole in south-western Uganda [274]. In Thailand, the in-hospital mortality rate in 
patients receiving ‘high dose’ amphotericin is 28% (median hospital stay 28 days, range 
1 -  91); the death rate at 6 months is not clear, but the cumulative mortality rate at 12 
months in this study was 76% [106]. Rozenbaum’s study from Brazil found the 
mortality rate to be 65.7% (95%CI 53.7 -  75.9%) in patients with cryptococcal 
meningoencephalitis [259]. In Durban, the in hospital death rate for HIV infected 
patients was 64% (95%CI 48.8 -  76.3%) [257].
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In high income countries, the death rate is probably lower. The largest clinical trial is the 
ACTG randomised controlled trial of amphotericin B in combination with flucytosine in 
cryptococcal meningitis. In this multicentre USA-based study, which excluded severely 
ill patients, patients were initially randomised to amphotericin B with or without 
additional flucytosine. If the patients improved on this regime, they were then re­
randomised into the second part of the trial, either to treatment with itraconazole or 
fluconazole. It is difficult to estimate an overall 10 week death rate in this study because 
there were patients who were initially randomised but subsequently left the study 
because they did not meet the criteria for the second randomisation step. Of the 381 
patients enrolled, 21 died within the first 2 weeks. However, only 306 were considered 
eligible to be randomised to the second stage of the study. Of the 54 patients who did not 
enter the second stage at least 27 had deteriorated or had drug toxicities and 21 withdrew 
or were lost to follow up. Counting just the deaths in patients who remained in the trial 
and the deaths in the first 2 weeks, the 10 week death rate was 10.1% (33/327), 95% Cl
7.2 -  13.9%. There was no follow-up after 10 weeks. This low death rate contrasts with 
Larsen et al, a small study of 20 patients from the USA, where the death rate was 40% at 
10 weeks (95% Cl 21.8 -  61.4%) [142].
The 6 month death rate in the HIV uninfected patients in our study was 17.5% (95%CI
9.6 -  29.6%). Comparing death rates between studies in HIV uninfected patients with 
cryptococcal meningitis is complicated by the heterogeneity of the underlying patient 
groups, in particular the presence of underlying disease that itself has significant 
mortality. Most series include patients receiving non-steroid immunosuppressive drugs, 
and malignancies, most usually haematological [53, 64, 103, 104, 156, 259, 262, 264,
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275]. However, since most studies are small, the 95% confidence intervals are wide, 
and overlap between series. In immunocompetent patients with C. gattii infection, 
Seaton reports a death rate of 34.1% (95%CI 25 -  44.5%) in Papua New Guinea [62].
C. gattii infection in immunocompetent patients in Australia is associated with a 
mortality rate of 15% (95%CI 5.5 -  34.2%)[61]. Rozenbaum found the death rate in 
Brazil to be 38.6% (95%CI 25.7 -  53.4%) in patients with no apparent underlying 
disease and 36.8% (95%CI 19.1 -  59.1%) in patients with underlying disease excluding 
HIV. The proportions of disease due to C. gattii or C. grubii were not described in this 
paper[259]. Lui reports death rates of 18.8% (95%CI 5.8 -  43.8%), 62.5% (95%CI 30.4 
-  86.5%)and 28.6% (95%CI 7.6 -  64.8%) for immunocompetent patients, patients with 
underlying disease excluding HIV, and HIV infected patients respectively, although the 
numbers in each group were small [104]. Shih found an overall death rate of 19.2%
(95% Cl 12.4 to 28.3 %) in 94 HIV uninfected patients with meningitis, of whom 42 had 
underlying disease [256]. Moosa and Coovadia reported an in hospital death rate for 
HIV negative patients of 9% (95%CI 7.1 -  40.6%) [257]. To my knowledge, none of 
the HIV negative patients in our series had underlying malignancies or were taking 
immunosuppressive drugs (other than corticosteroids). The death rate in our patients, at 
the lower end o f the spectrum compared with the literature, probably reflects this fact.
3.5.3 Prognostic indicators
Over 40 prognostic indicators have been identified in cryptococcal meningitis. This high 
number may be a consequence of study methodology, where multiple testing of baseline 
variables results in associations which are the consequence of chance rather than
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genuine. In an attempt to be more rigorous, I elected to test previously defined 
prognostic indicators on the dataset, rather than to identify prognostic variables from 
within that dataset. O f all the previously identified prognostic factors, I found that 7 
(HIV infection, confusion, Glasgow Coma Score, cerebrospinal fluid cryptococcal 
antigen titre, cerebrospinal fluid viable yeast count, CSF white cell count and CSF 
glucose) were associated with death at both 70 days and 6 months, and in addition an 
abnormal chest X-ray was associated with death at 6 months. When prognostic factors 
were examined by HIV serostatus, there were some differences, but these must be 
considered in the context of the reduced sample size. For HIV patients, male gender 
alone was associated with a reduced hazard for death at both 70 days and 6 months, and 
focal neurological symptoms were associated with an increased hazard for death at 6 
months. Why male gender was protective against death is not clear, but may represent 
culturally different opportunities for health seeking behaviour in families with limited 
resources. For example, it is traditional in Viet Nam for married couples to live with the 
groom’s parents, and finances are often controlled by the groom’s family, such that 
wives do not have any financial independence. Since most health care must be paid for, 
this can impair women’s access to care. An alternative explanation is that physiological 
differences between the sexes somehow affect pathogenesis. However, human sex 
hormones that have been shown to regulate growth of other fungi in vitro (for example 
17-beta-oestradiol and progesterone stimulate growth of Coccidiodes immitis) have not 
been found to have the same effect for C. neoformans [276, 277].
In HIV uninfected patients, age, confusion, lower Glasgow Coma Score, hemiplegia, 
blood urea and CSF cryptococcal antigen titre were associated with an increased hazard
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of death. The effect of HIV infection presumably obscures the effects of these other 
factors in the HIV infected group.
The multivariate analysis was carried out only on the 6 month end point and for the 
group of patients as a whole. This is because there is a danger of ‘over-fitting’ a model 
where the model size is small, and where the number of events is relatively low [278]. 
Since there were more deaths at 6 months compared with 10 weeks, using the 6 month 
endpoint allowed us to enter more variables into the model, which may contribute 
important data. Eleven variables met the inclusion criteria for the model which initially 
included 99 patients. Five variables remained in the final model. Three factors were 
associated with an increased hazard of death with a significance level of P<0.05 -  higher 
log2 CSF cryptococcal antigen titres, lower CSF white cell count and lower Glasgow 
Coma Score. The other 2 variables left in the model were abnormal chest x-ray (P= 
0.098) and hemiplegia (P = 0.093). There were 104 patients where data for all 5 
variables were available, and when the model was refitted on these cases log2 
cryptococcal antigen count, Glasgow coma score and log 10 CSF white cell count 
remained significantly associated with survival (P 0 .001 for all variables). A bootstrap 
analysis showed that the model selection of these 5 variables was reasonably robust: all 
selected variables were included in the final model in at least 50% of bootstrap 
resamples of the data and the variables log2 CSF cryptococcal antigen titre, Glasgow 
Coma Score and CSF white cell count were selected at least 75% of the time. 
Interestingly, HIV status was not independently associated with an increased hazard for 
death in the multivariate model. This is because it is associated with low CSF 
lymphocyte counts. When HIV status was forced into the model, the same 3 variables
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were independently associated with increased hazard for death. It should be noted that 
the p-values generated by the model should be interpreted with caution -  they are biased 
low since they do not account for the fact that the model is the result of a selection 
process [279].
If the study size were large enough, and there were enough deaths, all the identified risk 
factors could have been included in the final model. Given that the number of events 
(deaths) should be at least 10 times the number of variables tested, this model would 
have required at least 1300 patients [278],
Of the factors identified by multivariate analysis, the Glasgow Coma Score and log2 
cryptococcal antigen titre were also associated with an increased hazard of death by 
univariate analysis, both for the cohort as a whole and for HIV uninfected patients at 70 
days and 6 months. For HIV patients, there was a suggestion that Glasgow Coma Score 
at presentation may have prognostic value for 10 week survival, but the values did not 
reach conventional levels of statistical significance (p = 0.07). I may have failed to show 
an association for cryptococcal antigen titre and outcome for HIV infected patients alone 
because the fungal burden in general was so high in the HIV cohort -  median antigen 
titre was 8-fold higher than in HIV uninfected patients.
The factors identified by the final model as having prognostic significance are 
biologically plausible, and each was previously identified as a prognostic factor by more 
than one study (table 3.8).
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3.6 Conclusions
Published reports on cryptococcal meningitis are from highly heterogeneous 
populations, both HIV infected and uninfected, rendering the effect of HIV on the 
clinical phenotype difficult to determine. Underlying disease is rare in HIV uninfected 
patients with cryptococcal meningitis in Viet Nam, allowing a clearer understanding of 
the impact of HIV on disease. I found Vietnamese patients to have differences in age 
and gender by HIV serostatus -  differences that are explained by the demographics of 
the HIV epidemic in Viet Nam. Of note, I found the duration of illness in HIV infected 
patients to be shorter than in HIV uninfected patients, and headaches to be a more 
prominent symptom. The rate of visual impairment is similar between groups and high 
at over 30%. Differences by HIV serostatus are more marked on clinical investigation, 
with little evidence o f inflammation in HIV infected patients. The fungal burden in HIV 
patients is considerably higher, as is the risk of death. Most disease in Viet Nam is due 
to infection with C. grubii, irrespective of HIV serostatus, and underlying potentially 
predisposing disease is found in only 20% of HIV uninfected patients. CSF cryptococcal 
antigen titre, CSF white cell count, and Glasgow Coma Score are independently 
correlated with an increased hazard of death at 6 months.
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Chapter 4
The Molecular Epidemiology of Human Isolates of 
Cryptococcus Species in Viet Nam.
4.1 Introduction
The aim of the work described in this chapter of the thesis was to determine the 
molecular epidemiological relationship between strains of Cryptococcus neoformans 
causing meningitis in HIV infected and uninfected patients, the underlying hypothesis 
being that the strains infecting HIV negative patients had relatively increased virulence, 
and formed a distinct population. To achieve this I first used Polymerase Chain Reaction 
-  Restriction Fragment Length Polymorphism analysis (PCR-RFLP) of the URA5 
(orotidine monophosphate pyrophosphorylase) gene to determine the infecting species 
and molecular group [35]. To further define the strain relationships I used a high 
resolution whole genome-based molecular typing method -  Amplified Fragment Length 
Polymorphism analysis (AFLP) [34, 280, 281].
4.2 Population structure of Cryptococcus neoformans
Three different varieties of the encapsulated basidiomycetous yeast Cryptococcus
neoformans exist [36, 248]. Cryptococcus neoformans var grubii occurs world-wide, is 
found associated with pigeon guano in the environment and predominantly causes 
disease in the immunocompromised [282, 283]. Cryptococcus neoformans var 
neoformans occurs mainly in Western Europe, and again tends to affect 
immunosuppressed patients [270]. While infection in almost all body tissues has been
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described, the most common site of disease is the central nervous system. Cryptococcus 
neoformans var gattii {Cryptococcus gattii) occurs mainly in the tropics and sub-tropics, 
although since 1999 disease has been reported from British Columbia, Canada and there 
is now good evidence of autocthonous spread [63, 69, 284, 285]. Most cases of C. gattii 
are reported from Papua New Guinea and Australia where it is associated in the 
environment with eucalyptus trees [48, 60, 269, 286, 287], C. gattii usually affects 
immunocompetent patients and the commonest disease presentations are lung disease or 
meningoencephalitis [76, 269, 288-293]. Separate species status has been proposed for 
C. gattii [21], It can be distinguished from Cryptococcus neoformans var grubii and 
Cryptococcus neoformans var neoformans using Canavanine-Glycine bromothymol blue 
agar (CGB agar). C. gattii is inherently resistant to the antifungal L-canavanine 
contained in the medium [294]. The agar also contains a colour indicator - bromothymol 
blue. Yeast growth causes a change in pH with a resultant change in agar colour from 
yellow to blue. There is a single report in the literature of a canavanine resistant C. 
neoformans var grubii strain[295].
The 3 varieties are also serologically distinguishable. Evans and Kessel showed in the 
1940s that rabbit sera could be used to define 3 serotypes A, B and C[16-18]. 
Subsequently a 4th serotype D was identified, and a hybrid AD strain discovered in the 
1980s[l 9, 20]. In general, Cryptococcus neoformans var grubii types as serotype A, 
Cryptococcus gattii as serotype B or C, and Cryptococcus neoformans var neoformans 
as serotype D, although there are occasional inconsistencies reported in the literature. 
Worldwide, the vast majority of cases o f cryptococcal meningitis occurs in HIV infected 
patients and are due to infection with C. neoformans var grubii. In Europe, C.
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neoformans var neoformans accounts for about 25% of cases o f cryptococcal meningitis 
in HIV patients; the rest are due to infection with C. neoformans vox grubii [156], In 
Australia and New Zealand Chen at al report that C. gattii accounts for less than 0.8% of 
cases of disease in HIV infected patients, and that 56% of all cryptococcal disease in 
immunocompetent patients is caused by either var grubii or var neoformans, although 
the clinical phenotypes (i.e. whether this is meningitis, pulmonary or other disease) are 
not described [64]. Overall, 20% of C. neoformans var neoformans disease was reported 
to occur in immunocompetent patients.
Few data exist from India, but the dominant isolate is C. neoformans var grubii, 
although C. neoformans var neoformans has been reported [296]. A 3 year surveillance 
of cryptococcosis from South Africa (1912 isolates) found no serotype D or AD isolates, 
and that C. neoformans var grubii accounted for 98% of infections in HIV infected 
patients, var gattii accounting for the remainder. C. gattii accounted for 25% of infection 
in HIV uninfected patients, but there were only 4 such cases[70].
Meyer reported that of 340 environmental, human and animal isolates of C. neoformans 
from 8 South American countries and Spain, 20.4% were C. gattii, 73.8% were C. 
neoformans var grub ii, 0.3% were C. neoformans var neoformans and 3.8% were AD 
hybrids[35]. Using URA5 PR-RFLP, they found that of the C. neoformans var grubii 
strains, 92.4% were molecular group VNI, and 7.7% were VNII. O f cerebrospinal fluid 
derived isolates from HIV positive patients, 87.1% were C. neoformans vex grubii and 
3.6% were C. gattii. Of CSF-derived isolates from patients who were HIV negative or 
HIV status unknown, 53.5% were C. gattii and 46.5% were C. neoformans var grubii. In 
34 patients with CNS disease in whom there was no underlying disease 61.8% of
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infections were due to C. gattii and 38.2% due to C. neoformans var grubii [35]. Of 
note, there appears to be markedly more intra-species diversity in isolates from North 
America compared with Brazil[282].
Chen et al determined the genotype of 129 human isolates of Cryptococcus neoformans 
from 16 provinces in China collected over the period 1980 to 2006 [273]. Surprisingly, 
they report that most cryptococcal meningitis in China seems to occur in patients 
without underlying disease, HIV being associated with only 8.5% of patients and other 
underlying disease in 20.5% of patients. 120 of the isolates were Cryptococcus grubii. 
Microsatellite and multi locus sequence typing found that the isolates were highly 
homogeneous and belonged to a cluster that has diverged phylogenetically from the 
URA5 VNI reference strain. There are no data on the molecular epidemiology of 
Cryptococcus neoformans from Viet Nam.
4.3 Molecular typing techniques in cryptococcal research
Numerous molecular typing techniques have been used to investigate the diversity of C.
neoformans, including karyotyping, RAPD, PCR-RFLP, mini and microsatellite and 
AFLP typing[34, 35, 246, 282, 283, 297-304]. More recently the consensus loci and 
primers for multi locus sequence typing (MLST) have been published[305]. PCR-RFLP 
of the URA5 gene is a well established and frequently used methodology that divides the 
C. neoformans complex into 8 reproducible molecular groups that correspond with 
serotyping (see table 4.1) [35].
Amplified fragment length polymorphism analysis is a typing tool that has been used to 
investigate the genetic diversity of C. neoformans both globally, within defined
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geographic areas and within micro-biospheres such as single trees [34, 246, 306, 307]. 
Originally developed as a typing tool for plants, AFLP is popular because it has high 
resolution, is whole genome based, and is compatible with automated sequencers[280]. 
Table 4.1
Relationship between species, serotype and URA5 PCR-RFLP derived
molecular group
Species/Variety Serotype Molecular Group
Cryptococcus neoformans var grubii A VNI
VNII
Cryptococcus neoformans Hybrid AD VNIII
Cryptococcus neoformans var neoformans D VNIV
Cryptococcus gattii B VGI
VGII
VGIII
C VGIV
The process involves extraction of high quality DNA, complete digestion with a frequent 
and a moderately rarely cutting restriction enzyme, ligation of adapters of known 
sequence and subsequent rounds of amplification using primers complimentary to the 
adaptor sequences, which can be made more selective through the addition of further 3 ’ 
nucleotides to the primer sequence (Figure 4.1). Disadvantages are that it is relatively 
labour intense, requires high quality (although only small amounts) of genomic DNA, 
and the multiple reaction stages complicate the optimization process. The first use of
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AFLP to type Cryptococcus spp was published by Boekhout in 2001 [34]. He described 6 
major molecular types defined by AFLP. He used primers complimentary for the adapter 
sequence and made further specific by adding 5’- AC-3’ to the EcoRl primer and 5’-G- 
3’ to the Msel adapter. Other groups have used multiple primer sets with greater 
selectivity[34, 246, 307]. Unfortunately most researchers make no mention of how 
reproducible their results are when a single isolate is repeatedly typed, so the amount of 
difference between strains that is due to experimental error rather than genuine variation 
is not clear. However, most groups define clades at the level of 85% similarity [34, 307].
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Figure 4.1 Schematic representation of AFLP. Adapted from Mueller and Wolfenbarger [308].
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4.4 Methods
4.4.1 Strains
Strains from HIV uninfected patients were sequentially collected isolates from patients 
enrolled into the BMD study (see the methods section) collected between 1996 and April 
2009. Strains from HIV positive patients were selected randomly from sequentially 
collected isolates from patients enrolled into the BK study (described in the methods 
section) between April 2004 and April 2009. All strains were confirmed as 
Cryptococcus species using classical mycological methods as described in chapter 2, 
including colony morphology, microscopy, characteristic growth on bird seed agar 
plates, urease production, sugar assimilation tests and biotyping with canavanine-glycine 
bromothymol blue agar. Control strains used for AFLP and RFLP were the 8 URA5 
PCR-RFLP defined molecular types provided by Associate Professor Wieland Meyer, 
Westmead Millennium Institute for Medical Research, Sydney, Australia.
4.4.2 DNA extraction
Single colonies of each isolate were spread for confluent growth on Sabouraud’s agar 
and incubated at 30C. After 24 hours incubation plates were scraped for DNA extraction 
using the modified Wen protocol as detailed in Chapter 2.
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4.4.3 RFLP
The URA5 gene was amplified and digested according to the method of Meyer et al, as 
detailed in Chapter 2 [35]. Product was run on a 3% agarose gel at 100V for 3 hours, the 
products stained with ethidium bromide and the banding patterns visually inspected and 
compared with the 8 control strains to determine the URA5 PCR-RFLP molecular type.
4.4.4 AFLP
The final protocol was derived from the protocol of Associate Professor Dee Carter’s 
laboratory, Department of Microbiology, University of Sydney, and has been described 
in the Chapter 2 [246]. The optimization process is described in the following results 
section. Two primer sets were used to generate the genotypes, one set with slightly 
greater selectivity than the other. The primers sets are detailed in the methods chapter 
(Table 2.3). Fragment analysis was performed on an AB systems 3130X sequencer (AB 
Biosystems Inc, Foster City, CA) with 50cm capillaries according to the manufacturer’s 
instructions. A LIZ500 internal standard (3 5 -5 0 0  base pairs) was included with each 
experiment. Trace files were generated using the AFLP protocol of the Genemapper 
version 4.0 (AB Biosystems Inc, Foster City, CA) software package. Raw file data were 
imported directly into Bionumerics version 5.1 (Applied Maths, Sint-Martens-Latem, 
Belgium) for analysis.
AFLP data for individual experiments were compared in two ways. First, the 
densitometric curves for each isolate were compared using the Pearson correlation. Only 
the curves within the range of the internal size standard (35 -  500 base pairs) were used 
in the analysis. I tested AFLP consistency through duplicate experiments on single
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control isolates. For this analysis, trees were constructed using the Unweighted Pair 
Group Method with Arithmetic mean (UPGMA). This algorithm uses the highest 
average similarity between two entries or clusters to determine which ones to merge, and 
provides an easy measure of the per cent similarity between 2 isolates. However, 
UPGMA does not perform as well where distances between isolates are longer, and 
assumes a constant rate of evolution [309]. Therefore, for the definitive analyses, where 
the actual relationship between isolates was not known, I used the Neighbour Joining 
Tree method (NJT) [310], The NJT method has been shown to be statistically consistent 
under many models of evolution, and performs favourably compared with other tree 
construction methods[311, 312]. The algorithm uses the lowest sum of all branch lengths 
as it merges entries and clusters, starting with a "star tree" of equal branch lengths and 
ending with an unrooted dendrogram. It differs from other algorithms in that it does not 
assume that the rate o f evolution remains constant throughout the dendrogram. The 
statistical significance of the clusters was tested by cophenetic correlation. The 
advantage of using densitometric curves for analysis is that all the information between 
defined gel distances (band sizes) is used, protecting the procedure from operator bias 
and loss of potentially informative bands. However, it is not possible to perform a 
bootstrap analysis.
Secondly, I performed a band-based analysis. I used the automated band assigning 
algorithm within Bionumerics 5.1 to define polymorphic band classes across the AFLP 
dataset, and these were used to generate NJTs for each primer set. Only band classes that 
were intense, polymorphic and that occurred within the range defined by the internal 
size standard were used in the analysis. The Dice method was used to create the trees,
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and the statistical significance of the clusters was tested by cophenetic correlation and 
bootstrap analysis. The disadvantages of using a band-based approach for analysis are 
that it is open to investigator bias, and potentially informative information is lost through 
the choice of rules to define bands. However, bootstrap analysis can be performed. 
Experiments, from DNA extraction to final amplification, were performed on batches of 
24 strains. The strains for each batch were randomly selected using a random number 
sequence generated in an Excel spreadsheet (Microsoft Office 2003, Microsoft, Seattle, 
USA). In the VN1 strain analysis 192 experiments, representing each HIV negative 
strain in duplicate, 2 C. neoformans var grubii and 2 C. neoformans control strains in 
duplicate, and 96 HIV associated strains were fragment analysed in a single run and 
uploaded simultaneously to Bionumerics v5.1 (Applied Maths NV, Sint-Martens- 
Latem, Belgium) for normalisation and analysis. Fishers’ exact test was used to compare 
the proportions of strains in identified clades by the HIV infection status of the isolate 
source.
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4.5 Experiment optimization
The experimental optimisation process will be described first, followed by the 
experimental results.
4.5.1 DNA Extraction
Whole genomic DNA was obtained using the modified Wen protocol [245]. All extracts 
were treated with RNAse. The median concentration of extracted DNA was 1143.58 
ng/uL (range 105.81 ng/uL to 4992.4 ng/uL).
4.5.2 RFLP Optimization
URA5 PCR and restriction digestion worked without protocol modification. All 8 control 
strains were easily distinguishable (see figure 4.2).
Figure 4.2 Representative PCR-RFLP profiles of the URA5 gene of 45 Cryptococcus isolates. Typical 
patterns: Lane 1 = VN1, Lane 6 = VG1, Lane 16 = VG2.
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4.5.3 AFLP Optimization
Optimization was initially performed using each primer set according to the unmodified 
Carter protocol. Using 200 to 600ng of genomic DNA and the unmodified protocol 
resulted in poor quality bands, despite digestion appearing to have been complete. A 
systematic approach was adopted in order to problem solve the technique and optimise 
conditions. All optimization experiments were performed on genomic DNA from the 
same 4 isolates, using the Carter lab pre-amplification and selective amplification PCR 
settings, and the Boekhout lab pre-amplification and selective amplification PCR 
settings[34, 246]. Electrophoresis of product on agarose gels and visual inspection for 
bands was used to determine the impact of protocol changes. DNA digestion and 
ligation were carried out in 0.2ml PCR tubes. Digestion was carried out at 37C in a 
water bath. Ligation was performed at 22C in a PCR machine (BioRad Tetrad2 DNA 
Engine, BioRad Laboratories Ltd, Hemel Hempstead, UK). Polymerase chain reaction 
amplification was performed using a BioRad Tetrad2 DNA Engine (BioRad 
Laboratories Ltd, Hemel Hempstead, UK).
4.5.3.1 Optimization Experiment 1:
Hypothesis: Restriction digestion is incomplete
A digestion check control is built into the protocol using lambda DNA. However, failure 
of one enzyme to cut efficiently would not be detected. Failure of one enzyme to cut 
would result in failure of ligation and subsequent amplification. In order to confirm that 
both enzymes EcoRl and Msel were digesting efficiently each was incubated separately 
with lambda DNA and the standard reaction conditions.
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Results: Cleavage occurred with each restriction enzyme (Figure 4.3). EcoRl digestion 
produced the expected 6 bands [313]. The more frequently cutting Msel produced the 
expected restriction smear.
Kk 22d BJ: 222BJ: 220 .BJ: 222
M sel (T
Figure 4.3 Separate restriction 
digest of lambda DNA with EcoRl 
and M sel.
Conclusion: Both enzymes cut efficiently in the protocol digestion buffer.
4.S.3.2 Optimization experiment 2:
Hypothesis: amplification is inefficient due to inadequate Magnesium Chloride or 
Taq DNA polymerase concentrations.
I tested the effects of adding additional MgCb and altering the amount of Taq 
polymerase in the reaction mixes. These 2 effects were tested in a factorial design (see 
table 4.2).
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Table 4.2
Optimisation experiment 2 design
Total reaction volume 0.075 uL Magnesium 0.75 uL Magnesium
25uL Chloride 50mM Chloride 50mM
0.5 uL Taq DNA
Polymerase 5U/uL
A B
1 uL Taq DNA
Polymerase 5U/uL
C D
Results: Bands were generated only with the higher concentration of magnesium 
chloride, and were better quality with the higher Taq polymerase concentration (figure 
4.4).
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Figure 4.4. Effects of varying magnesium and Taq concentrations on band amplification.
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Conclusion: Amplification was more efficient with 0.75uL o f 50mM magnesium 
chloride and 5U (0.5 uL) o f Taq polymerase per reaction. However, overall the quality 
of the bands was poor.
4.5.3.3 Optimization Experiment 3
Hypothesis: Either the pre-selective or selective primers were failing to generate 
product
In order to determine whether there was a problem with either the pre-selective or 
selective primer set, the protocol was run using
i) only the pre-selective primers in both the selective and pre-selective
amplification steps,
ii) only the selective primers in the pre-selective and selective
amplification steps, and
iii) using the selective PCR primers on the product from experiment i).
In addition, the normal protocol was run as a control. All reactions used 0.75uL of 
MgCl2 50mM and 5U Taq polymerase.
Results: Amplification occurred with each individual primer set, but bands remained 
faint (figure 4.5).
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Standard PCR New PCR setting 
Preselective + Selective Amplification (Control)
Preselect Select Preoelect Select
PCR standard New PCR setting
Figure 4.5 The effect on amplification of using preselective primers for both rounds of amplification 
(upper gel, labelled ‘preselective’), selective primers for both rounds of amplification (right gel, 
labelled ‘selective’), and the standard protocol (left gel).
Conclusion: Amplification is possible with each primer set.
4.5.3.4 Optimization experiment 4
Hypothesis: There was too much substrate (DNA) for effective 
ligation/amplification
Efficient and reproducible AFLP depends upon there being reagent in excess, to ensure 
that there is complete digestion, ligation and amplification. The DNA concentration used 
in the Carter protocol is 20 fold higher than in the Boekhout protocol (200ng versus 10 
ng), although the primers used by each group differed in their selectivity. I considered 
that the poor band production may have been related to too many annealing sites for too 
low a concentration of primer, or insufficient other reagents at any of the particular 
stages (digestion, ligation or amplification). Thus I next experimented with the DNA 
concentration (Table 4.3).
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Table 4.3
Optimization experiment 4 design
Experiment DNA added (ng)
1 200 -  600
2 40-120
3 20-60
4 2-6
Results:
Figure 4.6.The effect o f  
altering the quantity o f DNA 
on band generation.
The clearest bands were produced with 40ng of DNA, and reasonable bands were 
produced with 2 -  6 ng (Figure 4.6).
Conclusion: 40ng of DNA seemed to result in most efficient amplification.
4.5.3.5 Optimization Experiment 5
Hypothesis: poor band amplification was due to inadequate primer concentrations
The stock primer solution concentration was 25uM. I experimented with primer 
concentration in the reaction mix: Initially the concentration of pre-selective primer was 
varied -  1, 2 or 4 uL were added to the final reaction mix of total volume 25uL. In each
Bk
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reaction product 3 different concentrations of selective primer were used: 0.5, 1.0 or 2 
uL of primer solution were added.
Results:
H I  f i  IJP1F issi 'fpl
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(1;0.5) ( l i l )  (1;2) <2;0.5) (2;1) (2;2) <4;0;S> <4;1) <4;2)
Strains: Bk 221, 222 Standard PCR
Figure 4.7 The effect o f altering primer concentration in preselective (1, 2 or 4 uL per reaction) and 
selective (0.5, 1 and 2 uL per reaction) reactions on band amplification.
Using 2uL of pre-selective primer and 0.5uL o f selective primer gave the cleanest and 
best intensity bands (figure 4.7). However, this experiment was not reproducible. The 
primer stock was old - the experiment was repeated with new primer sets.
4.5.3.6 Optimization Experiment 6
Hypothesis: Variability in amplification efficacy was due to old primers.
DNA was re-extracted from the test strains, digestion and ligation performed according 
to the optimized protocol using 20 to 60ng of DNA. New primer stocks were used. 2uL 
of pre-selective primer was used and product was amplified with 0.5, 1 or 2uL of 
selective primer.
161
Results: Good bands were achieved with the GT primers and 0.5uL of selective primer, 
but the AC bands were faint - there appeared to be some bands present following pre­
selective amplification, but after selective amplification bands were present but very 
sparse. It was considered that a trial of a different PCR machine might be helpful.
4.5.3.7 Optimization Experiment 7:
Hypothesis: Inconsistent band amplification was due to PCR machine variability
The experiment was repeated with 2uL of pre-selective primer and 0.5 uL of selective 
primer and using the BioRad C l000 thermal cycler (BioRad, Hemel Hempstead, UK) in 
place of the BioRad Tetrad2 DNA Engine.
Results: Figure 4.8 shows products generated with 2 different PCR machines. Band 
quality was improved (Figure 4.8)
8. TJ BtTI. Skill Skill
P i im e is : E coR lG T / M se lC T
Primers: BmRlGT/MselCT EcoRlAC/MselG
Primers: EcoRlAC/ MselG
Biorad C l000
Figure 4.8.Comparison of the BioRad Tetrad 2 PCR engine (centre gel) with the BioRad C1000 
thermal cycler (left and right gels) on AFLP amplification efficiency. 110V, 90mins.
Conclusion: sharper more intense bands were generated with the BioRad C l000 thermal 
cycler.
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4.5.3.8 O ptim ization Experim ent 8
Aim: determ ination o f optim al product dilution for fragm ent analysis
An AB Biosystems 3130x Selective amplification product was diluted 5 fold, 10 fold, 50 
fold, 100 fold and 500 fold and run on the sequencer according to the manufacturer’s 
instructions.
Results: The 1:10 dilution gave good quality peaks without clipping (Figures 4.9a and 
4.9b)
Figure 4.9.GT primer set AFLP trace file -  a) C. neoformans var grubii VN1. b) C. gattii VG1 
control strains (Genemapper version 4.0). Blue peaks represent isolate fragments, gold peaks the 
LIZ 500 internal size standard.
Fig 4.9a)
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4.5.3.9 Optim ization Experim ent 9
Aim: AFLP of all 8 control strains and patient isolates with GT prim er pair
AFLP was carried out with the above modifications.
Results: Excellent band patterns on agarose gel (figure 4.10).
Figure 4.10 A FLP band pattern 
with GT/GT prim ers for the 8 
control strains. 110V, 90mins.
VN VN VN VN VG VG VG VG 
1 2 3 4 |  2 3 4
Printers. EcoRl GT/ M se l GT
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The GT primer set was thus optimized. The following optimization experiments relate 
only to the AC/G primer set.
4.5.3.10 Optimization Experiment 10
AC/G primer pairs would be expected to produce approximately four times as many 
bands as -GT/-GT primer pairs. I considered whether this explained the decreased 
intensity of bands seen on the AC/G gels.
Hypothesis: The faint and poorly defined bands seen with -AC/-G primer 
amplification compared with -GT/-GT amplification are consistent with the 
increased number of bands generated. Amplification with similarly selective AC- 
GT primer pairs will produce band patterns similar to the -GT/-GT primer pairs.
I performed selective amplification with -AC/-GT primer pairs to see if this resulted in 
fewer more intense bands, and a gel pattern similar to that obtained with -GT/-GT 
primer pairs.
Results: Amplification was successful but the bands produced were still less intense than 
those produced by the -GT/-GT primer pair.
•\
4.5.3.11 Optimization experiment 11
Hypothesis: there was too much substrate for -AC/-G primer binding to enable 
efficient amplification.
The pre-selective A/G primer product was diluted prior to AC/G amplification. 5ng of 
pre-selective amplification product was used for each reaction.
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Results: Good bands seen on agarose gel. Good traces obtained on fragment analysis 
without the need for product dilution.
4.5.3.12 Optimization Experiment 12: Reassessment of magnesium 
concentration for -AC/-G primers.
5ng of preselecive product was used. The MgCh (50mM) volume added to the pre­
selective reaction mix was 0.25, 0.5 or 0.75uL. Pre-selective product was diluted 1 in 25 
or 1 in 10 for each selective amplification round. Each selective amplification round 
took place with 0.25, 0.5 or 0.75uL of MgC^.
Figure 4.11 The effect of different 
MgCh concentrations on band 
generation (AC/G primer set). 
110V, 90mins.
The best bands were produced when the pre-selective PCR product was diluted 1 in 10 
and combined with 0.5uL of MgC^ (Figure 4.11).
4.5.3.13 Optimization Experiment 13: Increased dNTP concentration
Given that the optimization experiments for the -AC/-G primers suggested that I did not 
have sufficient reagent in excess (i.e. amplification efficacy improved as the DNA
Results:
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substrate concentration were reduced) I considered whether increasing dNTP 
concentrations would improve amplification.
Hypothesis: dNTPs were not present in excess
The concentration o f each individual dNTP in the PCR reaction mixes were increased to 
20mM from 5 mM and compared with 5mM.
Results: There was no clear difference in band generation by dNTP concentration.
4.5.3.14 Optimization experiment 14
Fragment analysis o f AC and GT primer products on the AB 3130x sequencer.
Product was analysed with the AFLP protocol according to the manufacturer’s 
instructions. A LIZ 500 base-pair internal size standard was used.
Results: Satisfactory fragment traces were produced with undiluted amplification 
product.
This completed the -AC/-G primer set optimization process.
Figure 4.12 shows the typical band patterns generated with the AC/G and GT/GT primer 
sets after protocol optimization.
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AFLP EcoRl AC/MselG
Figure 4.12 Typical band patterns obtained with AC/G primers (top gel) and GT/GT 
(bottom gel), 110V, 100 minutes.
primers
4.5.4 Determination of the reproducibility of AFLP typing
In order to understand the consistency of the typing method, I performed multiple 
duplicate experiments on the control strains. In my optimized protocol, there were 
separate digestion and ligation steps. However, since the ligation of adapters does not 
reproduce the EcoRl or Msel cut sites, it is possible to perform these steps in duplicate. 
While the optimal temperature for each reaction is different (37C for digestion, 22C for 
ligation), this is an approach that has been used by some groups [34]. I compared
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digestion followed by ligation with simultaneous digestion and ligation overnight at 
room temperature, and simultaneous digestion and ligation for 2 hours. Each digestion 
ligation reaction was performed in duplicate, and each digestion ligation product 
underwent duplicate pre-selective and selective amplification. Each selective 
amplification product underwent duplicate fragment analysis. Thus a single digestion 
ligation product resulted in 8 fragment analysis experiments, and for each control strain 
24 experiments were performed. Analysis was performed in Bionumerics v5.1. UPGMA 
trees were generated using the Pearson coefficient to compare the fragment trace files. 
The percentage similarity between each identical strain was compared according to 
experiment type. The experimental design is shown in Figure 4.13, and the resulting 
dendrograms for control strains VN1 (C. neoformans var grubii), VN4 (Cryptococcus 
neoformans var neoformans), VG1 and VG 2 (Cryptococcus gattii) are shown in figures
4.14 and 4.15 below.
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Figure 4.13 AFLP Consistency experimental design.
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overnight
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overnight
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37C, 2 hours
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Figure 4.14 AFLP UPGMA dendrogram for Cryptococcus grubii (VN1) and Cryptococcus
neoformans (VN4) control strains.
Pearson correlation [18.1 %-79,6%)
aflp 40
. . . .  ft . . . .  V . . .
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40 VN4 DL37-1.2.2 
40 VN4 DL37-2.2.2 
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40 VN4 DLOvn-2.1.1 
40 VN4 DLOvn-2.2.1 
40 VN4 DL37-1.1.1 
40 VN4 DL37-1.2.1 
40 VN4 DL37-2.2.1 
40 VN4 DL37-2.1.1 
40 VN4 D-L-2.1.1 
40 VN4 D-L-2.2.1 
40V N 4 D-L-1.1.1 
40 VN4 D-L-1.2.1 
40 VN4 D-L-1.2.2 
40 VN4 D-L-2.1.2 
40 VN4 D-L-2.2.2 
40V N 4 D-L-1.1.2 
40VN1 D-L-1.1.1 
40VN1 D-L-2.1.1 
40VN1 D-L-1.2.1 
40VN1 D-L-2.2.1 
40 VN1 D-L-1.2.2 
40VN1 D-L-2.2.2 
40VN1 D-L-1.1.2 
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40VN1 DL37-1.2.2 
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40 VN1 DLOvn-1.2.1 
40VN1 DL37-2.1.1
Nomenclature: VN1/VN4 = control strain; D-L = digestion followed by ligation, DLOvn -  
simultaneous digestion and ligation overnight at room temperature, DL37 = simultaneous digestion 
and ligation at 37C for 2 hours ; the first number of the suffix refers to the first or second of the 
duplicate digestion/ligation experiments, the second number to the first or second round of selective 
or preselective amplification, and the final number refers to the group (1 or 2) the experiment was in 
for the fragment analysis run.
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Figure 4.15 AFLP UPGMA dendrogram for Cryptococcus gattii (VG1) and Cryptococcus gattii
(VG2) control strains.
Pearson  correlation (18.1%-79.6%)
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Nomenclature: VG1/VG2 = control strain D-L = digestion followed by ligation, DLOvn -  
simultaneous digestion-ligation overnight at room temperature, DL37 = simultaneous digestion- 
ligation at 37C for 2 hours; the first number o f the suffix refers to the first or second o f the duplicate 
digestion/ligation experiments, the second to the first or second round of selective or preselective 
amplification, and the final to the group (1 or 2) the experiment was in for the fragment analysis run.
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The dendrograms illustrate that the isolates cluster initially by RFLP molecular type -  
i.e. the AFLP clearly distinguishes the species and the individual isolates. The 
experiments also cluster by the method used to generate the ligation product, suggesting 
that this influences the AFLP banding pattern, presumably by generating differing 
proportions or intensities of substrate DNA fragments. A striking feature of the trees is 
that clustering occurs by fragment analysis run, and this accounts for the largest 
variability between experiments for individual isolates. This could be explained by 
voltage fluctuations during electrophoresis, but could also be explained by 
contamination during sequencer set-up, or ageing gel or capillaries. Within fragment 
analysis mns, the reproducibility varied according to the digestion/ligation methodology. 
The mean similarities between identical isolates according to digestion/ligation 
methodology are shown in table 4.4 below.
Table 4.4
Per cent similarity values for repeated AFLP experiments on the same 4 control
strains according to digestion/ligation method.
Digestion/Ligation
Method
Mean
similarity
Standard
deviation
95% Cl IQR N
Digestion followed 
by ligation
94.5 3.05. 9 3 .7 -9 5 .4 94.2 -  96.7 48
Simultaneous 
digestion/ligation, 
37C for 2 hours
89.9 9.62 8 7 .2 -9 2 .6 8 6 .5 -9 6 .4 48
Simultaneous 
digestion overnight
93.2 2.88 9 2 .4 -9 4 .0 90 .8 -9 5 .3 48
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Digestion followed by ligation resulted in the highest similarities for repeated analysis 
of a single isolate at 94.5%, compared with 93.2% for simultaneous overnight 
digestion/ligation and 89.9% for simultaneous digestion/ligation at 37°C for 2 hours. 
Thus the protocol was left unmodified with separate digestion and ligation steps. The 
variability seen between fragment analysis runs was unexpected, and may have been 
explained by different gel ages, old capillaries and voltage fluctuations. In order to 
minimize these effects, the capillaries and gel were replaced, and for the definitive 
experiments and analysis I decided to fragment analyze the maximum possible number 
of isolates in a single setting (two 96 well plates, 192 experiments), with the control and 
HIV negative isolate strains done in duplicate (each represented once on each plate) such 
that the degree of sequencer introduced error could be estimated.
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4.6 Results
4.6.1 Strain characterisation
All strains in the experiment were urease positive. All C. gattii strains grew on CGB 
agar; no C. neoformans var grubii strains were L-canavanine resistant. Strain BMD 761 
(clade 1) was amelanotic, producing cream colonies on birdseed agar. All strains were 
confirmed as Cryptococcus neoformans complex on sugar assimilation testing 
(Biomerieux API32C, Biomerieux, Craponne, France).
4.6.2 URA5 PCR-RFLP
53 isolates from HIV uninfected patients enrolled into the BMD study between 1996 and 
June 2009 were available for analysis. O f these, 39 were Cryptococcus grubii URA5 
PCR-RFLP molecular group VN1, and 14 were Cryptococcus gattii (12 C. gattii 
molecular group VG1 and 2 C. gattii molecular group VG2. 211 isolates were available 
from 238 HIV infected patients consecutively enrolled into the BK study. All were C. 
neoformans var grubii molecular type V N 1. Representative strains and the characteristic 
banding patterns are shown in Figure 4.2.
4.6.3 AFLP
AFLP using either primer set successfully distinguished Cryptococcus isolates by 
species. Neighbour joining trees for the HIV negative isolates created using the Pearson
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product moment correlation comparing densitometric curves are illustrated in figures
4.15 and 4.16 below for both primer sets.
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Figure 4.16 Neighbour joining tree showing speciation of Vietnamese C. neoformans \a r  grubii and
C. gattii human isolates using AFLP with AC/G primers.
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Figure 4.16. Neighbour joining tree 
showing speciation of Vietnamese C. 
neoformans var grubii and C. gattii human 
isolates using AFLP with AC/G primers.
C. gattii control strains are identified by a 
diamond. C. neofonnans var grubii with a 
star.
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Figure 4.17 Neighbour joining tree showing speciation of Vietnamese C. neoformans var grubii and
C. gattii human isolates using AFLP with GT/GT primers
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showing speciation of Vietnamese C. 
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Both primer sets distinguished Cryptococcus gattii strains from Cryptococcus 
neoformans. The red dotted line divides C. gattii (above) from C. neoformans var grubii 
strains (below). The nodes at the points of divergence o f the species were well supported 
with cophenetic correlation values of 99 for each primer set (green circles). In the AC/G 
experiment, one isolate, BMD 875, did not cluster with the other C. gattii strains, but 
appeared more closely related to the VN4 and VN2 control strains. BMD 875 is CGB 
agar positive, URA5 PCR-RFLP group VG1, and clusters with the C. gattii strains using 
the GT/GT primer set. Therefore it is almost certainly a C. gattii strain. I included this 
strain in the subsequent experiments investigating the relationships of the C. neoformans 
var grubii strains. It consistently clustered with the C. gattii out-group with both primer 
sets (see below). Therefore the failure to cluster with the C. gattii in this experiment 
represents experimental error -  most likely in labelling or in fragment analysis. 
Thirty-eight isolates from HIV uninfected patients were C. neoformans var grubii VN1. 
To determine the relationship of these strains with Vietnamese strains from HIV infected 
patients, an experiment set was created consisting of these 38, the 2 C. neoformans var 
grubii control strains (molecular groups VN1 and VN2), 2 Cryptococcus neoformans 
control strains (VN3 and VN4), and 99 HIV associated strains. In addition, the 
experiment set contained 3 Cryptococcus gattii strains from HIV uninfected patients as 
an ‘out’ group. The HIV associated strains were selected randomly from the 238 BK 
strains using random numbers generated in a Microsoft Excel spreadsheet. The 144 
isolates were randomly divided into 6 batches using random numbers generated in 
Microsoft Excel. AFLP, from DNA extraction up to the final round of amplification was 
performed by batch. 192 fragment analyses were performed in one run (the maximum
number possible). Fragment analysis was done in duplicate for all HIV negative and 
control strains - each of the two 96 well plates contained an aliquot from each HIV 
negative strain and each control. The remainder of the wells were filled with aliquots 
from the 99 HIV associated strain experiments.
The consistency of the fragment analysis is illustrated in Figures 4.17 and 4.18 which 
are UPGMA trees generated by comparing densitometric curves using the Pearson 
correlation for all the duplicate analyses. Table 4.5 shows the mean, standard deviation 
and percentile similarities between identical isolates for each primer set.
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Figure 4.18 AFLP derived UPGMA tree for HIV negative, control and out-group isolate duplicate
analyses using the AC/G prim er set.
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Figure 4.18 AFLP derived UPGMA tree for 
HIV negative, control and out-group isolate 
duplicate analyses using the AC/G primer 
set. Green line = VN1 Control 
Blue Line = VN2. 3 and 4 controls 
Red line = C. gattii out-group.
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Figure 4.19 AFLP derived UPGMA tree for HIV negative, control and out-group isolate duplicate
analyses using the GT/GT prim er set.
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Figure 4.19 AFLP derived UPGMA tree 
for HIV negative, control and out-group 
isolate duplicate analyses using the GT/GT 
primer set.
Green line = VN1 Control 
Blue Line = VN2, 3 and 4 controls 
Red line = C. gattii out-group.
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Table 4.5
Per cent similarity values between identical isolates for duplicate fragment 
analysis of HIV negative and control strains according to primer set used.
Primer Mean 95% Standard Median 10th
set Similarity Confidence Deviation centile
Intervals
AC/G 95.2 94.1 -9 6 .3  3.85 96.5 89.0
GT/GT 98.0 97 .5 -9 8 .5  1.63 98.6 96.5
The variability introduced by fragment analysis was improved after gel and capillary 
replacement, now accounting for a median variability of 1.4 % between identical 
experiments for the GT/GT primer set, and 3.5% for the AC/G primer set. This 
artefactual variability introduced by the fragment analysis process is greater for the 
AC/G primer set compared with the GT/GT primer set. Given the information from the 
previous consistency experiment, AFLP is unlikely to be able to distinguish isolates with 
greater than 90 -  95% homology. This performance is similar to that reported in the 
literature [246, 307].
Having demonstrated reasonable performance of the typing system, I next analysed the 
whole dataset -  controls, out-group, and strains from HIV infected and uninfected 
patients. The resulting trees are shown in figures 4.19 and 4.20.
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Figure 4.20 N JT for 144 C. neoformans var grubii VN1 hum an isolates, AC/G prim er 
set.
Figure 4.20 AFLP AC/G primers. 
Neighbour joining tree generated from 
densitometric curves for 144 C. 
neoformans var grubii VN1 human 
isolates. Red squares denote control 
strains, green squares denote isolates from 
HIV uninfected patients.
The green arrow identifies the 3 C. gattii 
strains.
All nodes on the main spine (blue arrows) 
are well supported with cophenetic 
correlation values of greater than 90.
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Figure 4.21 NJT for 144 C. neoformans var grubii VN1 hum an isolates, G T/G T
prim er set.
Figure 4.21 AFLP GT/GT 
primers. Neighbour joining tree 
generated from deiisitometric 
curves for 144 C. neoformans var 
grubii V N 1 human isolates. Red 
squares denote control strains, 
green squares denote isolates from 
HIV uninfected patients. The green 
arrow identifies the 3 C. gattii 
strains. All nodes marked by blue 
airows are well supported with 
cophenetic correlation values o f  at 
least 87.
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Amplification with the AC/G primer set reliably separated the C. gattii out-group, and 
the Vietnamese isolates clustered with the VN1 control. All the major nodes along the 
tree were well supported with cophenetic correlation values of greater than 90. 30 of 39 
isolates from HIV uninfected patients occurred in a monophyletic cluster marked by the 
blue line in the tree. The cophenetic correlation value of the node defining this cluster 
was 93.
Amplification with the GT/GT primer set also reliably defined the out-group and 
clustered the Vietnamese isolates with the VN1 control strain. Subsequently the 
population divided into two well supported main clades. The population of clade 1 
consisted of 68 isolates, o f which 30 were from HIV uninfected patients. Clade 2 
consisted of 69 isolates of which 8 were from HIV uninfected patients. The distribution 
Of isolates from HIV uninfected patients is shown in table 4.6 below.
Table 4.6
Distribution of isolates between clades by HIV status of source 
(GT primer set) (controls excluded).
Clade HIV infected HIV Total
uninfected
38 30 68
61 8 69
99 38 137
78.9% of isolates from HIV uninfected patients were from clade 1 (odds ratio 5.93, 95% 
confidence interval 2.4 -  16.6, p<0.0001). The HIV uninfected strains in clade 1 were
Clade 1 
Clade 2 
Total
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the same strains as those in the monophyletic cluster identified by the AC/G primer set. 
Five strains from HIV infected patients identified in clade 2 by the GT primer set were 
not preserved in the monophyletic clade using the AC/G primer set, and 3 HIV 
associated strains that the AC/G primer set identified within the monophyletic clade 
were assigned to clade 1 by the GT primer set.
I used the automated band assignment algorithm in Bionumerics 5.1 to assign band 
classes for the experiments with each primer set. Dendrograms created using band 
classes can be tested with bootstrap analysis. The band assignment algorithm contains a 
tolerance setting -  this defines the amount of gel distance that a band can have ‘drifted’ 
from a defined band class and still be classified as belonging to that class. This drift is 
described as a percentage of the total gel length. Since the automated sequencer can 
theoretically detect a difference in fragment length o f a single base pair, and I knew the 
percentage of the gel which the size standard (consisting of 466 base pairs from 35 to 
500) spanned, I was able to calculate that a single base pair change in length would 
account for approximately 0.14% of the gel length. I therefore set the tolerance value to 
be 0.07% (approximately +/- 0.5bp), which would enable the algorithm to assign bands 
to the nearest whole base pair length. The approach in assigning band classes used by 
other researchers is to define bands as having to be intense and polymorphic[246, 307]. 
The reason for using polymorphic bands is self-evident; however, how an intense band 
is defined is subjective, particularly if manual visual scoring is used. Bionumerics 5.1 
overcame this problem to some extent by performing automated scoring once parameters 
have been defined, and thus removed the potential for bias in determining whether a 
band meets the intensity criteria or not (although bands can still be manually added or
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removed by the operator after the automated step). However, the investigator still has to 
make a subjective decision regarding the range of intensity of bands that will be 
considered for scoring. Intensity is defined as a particular percentage of the most intense 
band on the gel. The level that defines intensity is chosen by the operator. I set the band 
defining algorithm to include all bands with at least 70% intensity of the maximum 
intensity for the GT primer set, and 20% for the AC primer set. The level was set lower 
for the AC primer set because there were few bands with 70% intensity. I then selected 
only the bands that were polymorphic. Using these parameters, 54 bands were generated 
for the AC/G primer set, and 63 bands for the GT primer set. I wanted to generate a 
large number of bands, because I suspected that my isolates were all closely related. The 
most diverse cryptococcal populations are African [307, 314]. Other investigators have 
found that using AFLP with 2 primer sets generating approximately 35 band classes 
each is sufficient to define genotypes in diverse populations [34, 315]. Since my strains 
were likely closely related, of a single molecular type and from a single geographic 
location, I thought that 35 bands might not be sufficient to distinguish the sub­
populations present. I chose an intensity parameter that generated approximately twice 
the number of bands used by those investigating diverse populations. Choosing 
parameters that generated fewer fragments resulted in less ordered trees, but little extra 
was gained by increasing the number of bands.
Once band classes are created, the programme creates a matrix for each primer set where 
each isolate is scored for the presence or absence of the defined band classes. The Dice 
coefficient is used to generate neighbour joining trees from the binary matrices created. 
Figures 4.21 and 4.22 show the NJTs for the AC/G and the GT primer sets respectively.
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Figure 4.22 NJT derived using the Dice coefficient with 54 bands defined from the
AC/G primer set.
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Bootstrap analysis (100 iterations) was used to determine the statistical significance of 
the clusters generated. In the AC-derived tree, 2 main clusters were defined. The HIV 
negative isolates were more evenly spread between the two main clusters, accounting for 
14 of 45 strains in the upper clade and 25 of 96 strains in the lower division (odds ratio 
1.38, 95% confidence intervals 0.59 -  3.19, p=0.42, Fisher’s exact test). Furthermore, 
the previous clustering of HIV negative strains was disrupted, with HIV negative strains 
transferring from cluster to cluster. Of particular note, one C. gattii strain (confirmed 
through URA5 PCR-RFLP and biotyping) was now clustered with the C. neoformans var 
grubii strains, suggesting there had been significant information loss during the band 
matching process. As might be expected, the bootstrap values to support the divisions in 
the tree were weak, the node at the division of the V N 1 clusters being generated in only 
16% of iterations. No cluster was well supported other than for the node dividing the 
out-group (bootstrap value 100%).
With the GT band-based tree, 2 major clusters were created. The tree more closely 
resembles that generated by the comparison of the densitometric curves. The same HIV 
negative isolates are preserved within the same clusters (9 of 38 occurring in clade 2 
compared with 29 of 38 in clade 1 (odds ratio 5.19, 95% Cl 2.11 -  13.89, p<0.0001, 
Fisher’s exact test). However, the bootstrap value at this node was low at 45%. All C. 
gattii strains were correctly sorted, although one might have expected the bootstrap 
value to be higher than the calculated 80%.
Band classes were identifiable that appeared to be highly discriminatory for either clade 
1 or clade 2 HIV negative isolates, occurring almost exclusively in one or other clade. 
There were 4 such bands for each primer set. If used in isolation, as expected they
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produced robust dendrograms. However, this approach is hardly scientifically valid, and 
illustrates the bias that can be introduced by manually assigning/scoring bands. If 
combined with other bands that had similar intensities in the whole population, the 
resulting dendrograms were no more robust than those presented in 4.19 and 4.20 (which 
indeed include the 8 discriminatory band classes).
4.6.4 Clinical Correlates
The HIV patients from whom strains were derived from this work are receiving different 
therapies as part of a randomised controlled trial which is not yet completed and thus 
cannot be analysed. Treatment, along with markers o f disease severity at presentation, 
would need to be adjusted for in any analysis on the impact of clade. However, some of 
the isolates are from the patients described in Chapter 3. The infecting clade and fungal 
burden at baseline was known for 19 of the HIV infected patients in the dataset 
described in chapter 3. An exploratory analysis of the HIV infected patients reveals that 
there was no difference in the mean yeast colony forming count in the CSF of patients in 
clade 1 compared with those in clade 2 (5.8 loglO versus 6.1 loglO, p = 0.5, 95% 
Confidence Interval for difference between the means -1.3 to 0.63, Welch 2 sample t- 
test). 11 of 19 HIV patients with clade 2 infections died compared with 4 of 10 with 
clade 1 infections (p = 0.45, Fisher’s exact test).
O f the HIV negative patients, the clinical dataset is complete for only 22, of whom 19 
were infected with clade 1 isolates. There was 1 death due to a clade 2 infection and 4 
due to a clade 1 infection (p = 1.0, Fisher’s exact test). Interestingly, only 4 of 19 
patients with clade 1 infection had underlying disease compared with 3 of 3 patients
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with clade 2 infection (p = 0.02, Fisher’s exact test), supporting the hypothesis outlined 
in the introduction that there are some strains with increased virulence. The CSF 
cryptococcal antigen was higher for clade 2 strains compared with clade 1, but this 
difference was not statistically significant (clade 1 log 10 CrAg titre = 2.2, clade 2 = 3.1, 
95% Cl for difference between means -3.96 to 2.14, p=0.37, n = 22).
4.7 Discussion
I have shown in Chapter 3 of the thesis that most HIV uninfected patients with 
cryptococcal meningitis in Viet Nam have no underlying immune deficit and that most 
disease is due to C. neoformans var grubii. The aim of this chapter was to determine the 
molecular epidemiological relationship between strains of Cryptococcus neoformans 
causing meningitis in HIV infected and uninfected patients, the underlying hypothesis 
being that the strains infecting HIV negative patients have relatively increased virulence, 
and would form a distinct population.
Until now there has been no detailed study of the molecular epidemiology of 
Cryptococcus spp from Viet Nam. I found that the vast majority o f infections in our 
patients, irrespective of HIV serostatus, are caused by C. neoformans var grubii URA5 
PCR-RFLP group VN1. At the time of AFLP typing, RFLP typing had been completed 
on 53 isolates from HIV uninfected patients, and 211 isolates from HIV infected 
patients. 14 of these were Cryptococcus gattii. Subsequently I have completed RFLP 
typing of a total of 366 Cryptococcus spp, and have identified just 2 further C. gattii 
isolates, and one C. neoformans var grubii molecular group VN2. The HIV status of the 
sources of these 2 further C. gattii isolates is not known. I have not found any cases of
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C. gattii in HIV positive patients. C. gattii thus accounts for less than 4% of cases of 
cryptococcal meningitis in our hospital.
I wanted to determine the relationship between strains infecting HIV uninfected patients 
in relation to strains infecting HIV infected patients using a typing method with high 
resolution. Having identified that the majority of strains in HIV uninfected patients were 
also C. grubii VN1,1 used AFLP with 2 primer sets to investigate the relationship 
between these VN1 strains. Using the AC/G primer set, which would be expected to 
generate approximately 4 times as many fragments as the GT/GT primer set, I showed 
that most strains from HIV uninfected patients appeared to be more closely related to 
each other clustering in one part of the dendrogram. All nodes on the dendrogram were 
well supported with high cophenetic correlation values, showing that the tree closely 
represented the true similarities calculated between isolates. I used the neighbour joining 
tree method, which is considered to be consistent under many evolutionary models, and 
more reliable than other models such as UPGMA. Most HIV negative isolates formed a 
monophyletic clade, being derived from a common ancestor. As would be expected, this 
clade also included strains from HIV infected individuals (HIV infected patients would 
not be expected to be protected from infection with this clade).
The GT primer set, which appeared to be slightly more consistent than the AC/G primer 
set in repeated experiments on identical isolates, revealed 2 clades of C. neoformans var 
grubii VN1. O f the 137 Vietnamese strains, 30 of 38 strains from HIV uninfected 
patients (78.9%) were in clade 1 (odds ratio 5.93, 95% confidence interval 2.4 -  16.6, 
p<0.0001). A possible explanation for the different distribution in HIV negative strains
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between clades is that strains in clade 1 are more virulent, and more able to cause 
disease in HIV uninfected patients.
Of note, in our dataset (99 HIV associated strains and 38 non-HIV associated strains) 
both clades 1 and 2 contain approximately the same total number of isolates -  thus there 
are more HIV associated strains in clade 2 than in clade 1. If clade 1 strains really are 
more virulent, and the rate of exposure to each clade is equal, then one would expect 
clade 1 to also be the dominant strain in HIV infected patients The fact that it isn’t (in 
fact, it is outnumbered approximately 2:1) suggests that exposure to clade 2 strains is 
more common than exposure to clade 1 strains. This is a pattern seen already with C. 
gattii. In Viet Nam, where the HIV seroprevalence rate in adults aged 15 -  60 is 0.5%, 
we have had had no definite cases of C. gattii infection in HIV infected patients even 
though we see disease in the immunocompetent, and a similar experience is reported 
from Africa, where the HIV prevalence is much higher [63, 70, 85, 87-89, 316, 317]. C. 
neoformans var grubii has been seen to replace C. gattii as the dominant human isolate 
as the HIV epidemic has spread [89]. For rare pathogens, where the ability to cause 
disease is not related to HIV status, one would expect to see more disease in the HIV 
uninfected patients where the HIV prevalence is low, since there is a greater chance of 
this group being exposed. Different exposures to the different clades is biologically 
plausible - Cryptococcus gattii occupies a different ecological niche to C. 
neoformans/grubii, and is well recognised to be much less prevalent in the environment 
[35, 48, 286, 318-321]. Since Cryptococcus species are not primary pathogens (unlike, 
for example, Salmonella enterica serovar Typhi or Plasmodium falciparum ), differences 
in pathogenicity likely represent different adaptations to particular environmental niches,
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rather than adaptations primarily to facilitate human disease. The prevalence and site of 
that niche in the environment will determine the risk of a potentially infectious contact 
between the pathogen and susceptible hosts (for example, as might be expected, Koala 
bears are prone to infection with C. gattii). Our data suggests that amongst HIV infected 
patients exposure to clade 2 strains is at least twice as common as exposure to clade 1 
strains, and could be higher still if  clade 2 is also less able to cause disease in HIV 
infected patients.
Alternatively, the higher number of clade 2 infections in HIV patients might be the 
consequence o f a particular exposure that is more common in HIV patients. For 
example, a large number (62.8%) of our patients with HIV associated cryptococcal 
meningitis are intravenous drug users. However, I found no difference in intravenous 
drug use rates amongst HIV positive patients by clade (21 of 37 versus 33 of 52, p =
0.84). The mode of acquisition of cryptococcal disease is not known, although it is 
thought inhalation o f desiccated yeast cells or basidiospores is the most likely 
explanation [4]. Whether disease represents primary infection or is the result of 
recrudescence of latent infection is also a matter of debate (both are described), although 
clearly the incubation period can be prolonged [73, 74].
A further possible explanation, and one that has been postulated for C. gattii in the past, 
is that Clade 1 organisms exploit some other ‘gap’ in the immune system that is not 
currently recognised. [322].
It could be that the clades created are artefactual, and a consequence of error somewhere 
in the experimental process. AFLP is a multi-stage procedure, and while reportedly 
reproducible, error could enter at any stage, for example through different efficiencies of
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digestion, ligation, PCR amplification or fragment detection [280, 281, 323]. I 
performed multiple experiments on single strains, as described, to determine which 
methods of digestion and ligation were the most consistent. In order to further reduce the 
effect of experimental error, I randomised the selection of strains for experimentation. 
The strains were randomly assigned to batches of 24, and experiments were done by 
batch from DNA extraction through to the final round of selective amplification.
Because during the optimisation process I identified that the sequencer fragment analysis 
was a potential source of experimental error, with variation in fragment detection by 
sequencer run, all samples were run at the same time, with fresh gel and capillaries, and 
the controls and HIV negative strain experiments were run in duplicate (1 copy on each 
96 well plate), to enable us to detect any significant sequencer variability by plate in the 
final experiment. All fragment files were updated at the same time to Bionumerics 5.1 
for normalisation. I am confident I have taken as many steps as possible to ensure 
experimental consistency. While the tree structure is slightly different for each primer 
set, the location of strains within the trees is similar, suggesting that the clustering of 
HIV negative isolates that I have found is genuine. Furthermore, the description of a 
homogeneous population of C. neoformans var grubii VN1 recently reported from China 
supports the validity of my findings [273].
The low values in the bootstrap analysis are in contrast to the high cophenetic 
correlation values seen at the nodes in the trees generated from the densitometric curve 
analyses. The cophenetic correlation values measure how accurately the derived 
similarity values of the dendrogram reflect the true similarity values. The bootstrapping 
process is an attempt to measure the influence different band classes have on the shape .
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of the dendrogram. This is achieved by randomly sampling band classes from the 
defined band set. Sampling is with replacement -  i.e. a single band class can be 
repeatedly added to the bootstrap experiment. Bands are sampled until the number of 
bands sampled in the iteration equals the number of bands defined in the dataset. The 
dendrogram is repeatedly constructed using the Dice coefficient [309]. At least 100 
iterations are performed, and the number o f times that a particular node is reconstructed 
is expressed as a percentage of the total number of iterations. The low bootstrap values 
in my dataset were disappointing, but may reflect the fact that the isolates are closely 
related, and that differences within clusters are due to numerous polymorphic bands that 
occur with low frequency in the dataset. Within a cluster, each strain may differ by only 
4 or 5 bands, but the bands that differ are unique for each strain (i.e. are present rarely in 
more than one strain). In other words, while the total number of band class differences 
between strains in a cluster is low, these differences can be spread over a large number 
of band classes. For example, in a comparison of strains that had >92% similarity to a 
randomly chosen "reference" strain, I found 107 band classes of which 47 were 
polymorphic - meaning that the average difference of about 5 bands between any given 
combination o f two patterns was spread over these 47 classes. Thus each bootstrap 
iteration is unlikely to result in the same cluster pattern for closely related strains. 
However, very different strains, such as the out-group, which were C. gattii, are robustly 
clustered. Where the strains are closely related, the band class defining process is 
associated, as might be expected, with a significant loss o f information. It is akin to 
artificially dichotomizing continuous data, and furthermore is subject to the bias of the 
investigator, particularly where bands are scored manually. However, the densitometric
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curve comparison process is free of operator interference. Information is also potentially 
lost in the band matching analysis since the presence/absence of bands is digitally 
scored, when in fact it is plausible that the difference in intensity of different bands has 
scientific meaning, because of homoplasy. The densitometric curve analysis takes into 
account differences in intensities between peaks within a profile and between isolates. 
While AFLP has the advantage of being a whole genome based typing system, the 
information drawn from fragment patterns is limited because the exact cause of different 
banding patterns is not known. Bands of different sizes may contain more than one 
sequence (homoplasy) that the technique cannot distinguish. It is not possible to infer 
exactly how an alteration in a cut site will alter the banding pattern. It is not possible to 
draw the same inferences about evolution that can be drawn with sequence data, and it is 
more difficult to confirm consistency.
Host and geographical factors have been shown to influence the species of Cryptococcus 
which cause meningitis in particular groups. However, a sub-group of C. neoformans var 
grubii that is associated with HIV uninfected individuals, such as I have shown, has 
been described only once before, despite extensive study [64, 80, 287, 324]. Boekhout 
used AFLP to genotype 207 isolates from all continents (except Antarctica) including 
human, animal and environmental isolates, and described 3 AFLP genotypes within the 
C. gattii and C. neoformans ( including C. neoformans var grubii) species [34]. All 
isolates had unique AFLP banding patterns. He found no association by AFLP genotype 
with HIV serostatus, but the genotypes were defined at the varietal level (var 
neoformans, var grubii and a hybrid clade). Of note he found no geographical 
substructure to C. neoformans var grubii strains, but he had only 4 strains from Thailand
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in his collection, and none from elsewhere in east and Southeast Asia. There were no 
differences in the genotypes of strains from HIV infected and uninfected patients. 
Litvintseva used AFLP to characterise environmental and clinical isolates of C. 
neoformans in North Carolina, and described 2 genotypes of C. neoformans var grubii 
[315]. No differences in genotype distribution were found by HIV serostatus of the 
isolate source. Meyer used minisatellite typing to determine the relationship of Ibero- 
American isolates of Cryptococcus [35]. Of 266 clinical isolates, 139 were C. 
neoformans var grubii V N 1 from HIV infected patients, and 21 were uninfected 
patients. No particular C. neoformans var grubii genotype was described as being 
associated with HIV uninfected strains. However, in 1995 Varma had described using a 
genomic probe UT-4p to create DNA fingerprints of Cryptococcus neoformans 
including 25 isolates from patients with HIV and 23 from patients without HIV [324]. 
Nine fingerprints were described for serotype A strains, and isolates from HIV 
uninfected patients were more likely to be genotype 2 than other genotypes. No 
particular association with genotype was found for isolates from HIV patients. More 
recently, it has been reported that in 91 apparently immunocompetent patients with 
cryptococcal meningitis in China, disease is due to infection with a highly homogeneous 
group o f C. neoformans var grubii VN 1. The strains were collected from 16 provinces 
over a 26 year period until 2006. All strains were found to be of a single (8 locus) MLST 
genotype. However, no comparison of genotype was made with strains from HIV 
infected patients. In a mouse infection model, 4 of these Chinese strains were found to 
have variable virulence -  one was similarly virulent to the hypervirulent H-99 strain, one 
had similar virulence to the VN 1 reference strain, and 2 had intermediate virulence,
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suggesting that there may be wide variation in the virulence of this particular strain [273, 
325]. Alternatively, there may be subpopulations of increased virulence that the MLST 
scheme used could not resolve. However, the validity of the mouse model in relation to 
human disease has not been determined [273].
In our patients, other than having an increased ability to infect HIV uninfected patients, 
it is currently difficult to determine whether clade 1 strains cause more severe disease 
because clinical data is not complete or is embargoed. The HIV patients from whom 
strains were derived from this work are receiving different therapies as part of a 
randomised controlled trial which is not yet completed and thus cannot be analysed. 
Treatment, along with markers of disease severity at presentation, would need to be 
adjusted for in any analysis on the impact of clade. However, an exploratory analysis 
using the clinical data presented in chapter 3 suggests that fungal load in HIV patients is 
independent o f infecting clade, and that there is no difference in the 10 week outcome. 
For HIV uninfected patients, underlying disease was more common in patients with 
clade 1, supporting the hypothesis that this is better able to cause disease in the 
immunocompetent, although differences in fungal burden, estimated by cryptococcal 
antigen titre, were not statistically significantly different.
4.8 Conclusion
Classical teaching would have suggested that, in our tropical location, more cases in 
HIV uninfected patients would have been due to infection with Cryptococcus gattii [76, 
269]. C. neoformans vex grubii infection, the commonest cause of cryptococcal 
meningitis worldwide since the HIV epidemic, most frequently occurs in patients with
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an underlying immunosuppressive conditional, 62, 270, 271]. I may have identified a 
clade of C. neoformans var grubii that has increased ability to infect immunocompetent 
patients. This clade is not the predominant cause of cryptococcal meningitis in HIV 
infected patients in Viet Nam, suggesting exposure is less frequent than to clade 2. At 
the time of writing, the available clinical dataset is not sufficient to describe differences 
in clinical phenotype to clade, but I will be able to answer this question in the future. 
Additional evidence of increased virulence would need to be obtained from animal 
studies. However, the result of AFLP typing is not conclusive -  the use of a sequence 
based typing method, such as MLST, may confirm the result, would allow more robust 
statistical analysis and would allow comparison with genotypes from other geographical 
areas. Next generation whole genome sequencing of multiple strains would provide the 
definitive answer. Current DNA based genotyping methods for typing Cryptococcus 
species offer a limited and varying degree of subspecies, clade and strain level 
discriminatory power. Whole genome sequencing is the most accurate and reliable 
method to identify, type and determine phylogenetic relationships among strains of a 
species. Additionally, whole genome sequence based SNP information gained from a 
representative population of strains may be used to perform evolutionary comparisons of 
strains, or selection of unique strains for whole genome sequencing projects. As the cost 
of sequencing falls with newer technologies, the approach is becoming feasible, as has 
been demonstrated already for some pathogens [326-328]. The same approach should 
be developed for Cryptococcus species.
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Chapter 5
Antifungal susceptibility testing and Cryptococcus neoformans.
The aims of this chapter of the thesis are as follows:
1. To describe the antifungal susceptibilities o f Vietnamese Cryptococcus clinical 
isolates to 7 antifungal agents, and to determine whether the susceptibilities have 
changed over time, vary by host HIV serostatus or by species.
2. To describe the correlation between susceptibility to different azoles.
3. To determine whether differences in amphotericin B susceptibility correlate with 
the rate of fungal clearance from cerebrospinal fluid.
4. To determine whether the results of antifungal sensitivity testing are associated 
with clinical outcome in patients with cryptococcal meningitis.
5.1 Introduction
The ideal testing system for determining the susceptibility of a microbe to a given 
antimicrobial drug would provide information that predicts the clinical outcome (or at 
least the sterilising or antimicrobial effect in the patient) when that particular drug is 
used. In addition, the test would be cheap, reliable, have high inter-user and inter­
laboratory consistency, and be simple to perform and interpret, generating results 
quickly enough to allow meaningful management interventions. The increasing 
prevalence o f invasive fungal infections together with the discovery of new antifungal 
agents has seen the development of numerous methods for determining the antifungal
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susceptibility of fungal pathogens [113, 159, 160, 162-164, 166, 167, 329-346]. The 
gold standard for yeasts, against which most other testing systems are measured, is the 
Clinical and Laboratory Standards Institute (CLSI, Wayne, PA) protocol M27A-A2 
[169]. This protocol is a liquid medium-based microbroth methodology using 96 well 
plates. Plates are not commercially available, but must be made up in house using pure 
drug, and prepared plates need to be stored at -80C. Growth in each drug dilution is 
estimated by using a spectrometer to measure the turbidity in each well. The MIC of 
drug for a particular isolate is that at which the turbidity is 20% of the positive control. 
The disadvantages of the method include the following: plate preparation is time 
consuming, there can be inter-laboratory variation in the quality of plates produced, 
plates have to be stored at -80°C and measurement of the MIC requires a 
spectrophotometer. However, the major limitation of the methodology is that it has not 
been demonstrated that it reliably predicts clinical outcome in cryptococcosis [178].
The Sensititre® YeastOne® (Trek Diagnostics, East Grinstead, UK) susceptibility 
testing system is a commercially available microbroth method that enables measurement 
of MICs of 8 licensed antifungal drugs. It uses a 96 well plate format, and an indicator 
(alamar blue) demonstrates the presence or absence of growth, enabling assessment of 
the MIC by the naked eye and without the need of a spectrophotometer. Centralised 
manufacturing ensures plate consistency, plates are robust and can be stored at room 
temperature, and reading the result is simple with the naked eye. This ensures 
consistency of measurement between laboratories [347]. MICs measured for azole 
drugs have good correlation with the results obtained by the CLSI M27A methodology, 
but correlation with amphotericin B MICs, particularly for Cryptococcus, is poorer[167].
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Given that amphotericin B MICs determined by the CLSI method have not been shown 
to be clinically relevant, this may not be a disadvantage. The failure to show a 
relationship between MICs and outcome in cryptococcal meningitis may be because the 
in vitro methodologies are poor models of the in vivo reality, or may be a reflection of 
the quality of the studies investigating this relationship. Most studies investigating this 
relationship have been small (25 -  96 patients), from case series or do not account for 
differences in disease severity at baseline [161, 182, 183, 348, 349]. The ideal data to 
investigate the relationship between MIC and outcome would come from randomized 
controlled trials, since it removes bias in treatment allocation. Additionally, baseline 
indicators of severity, such as those identified in Chapter 3, would need to be accounted 
for in the analysis. However, even in the absence of data correlating with clinical 
outcome, in vitro susceptibility testing may have a role in surveillance and in detecting 
differences in susceptibility between strains and species that may provide insight into 
mechanisms of drug action and the development of resistance. In this chapter of the 
thesis I use Sensititre® YeastOne® antifungal susceptibility test plates to describe the 
susceptibilities of Vietnamese clinical isolates of Cryptococcus, and relate this to HIV, 
time, species, clade, rate of clearance of yeast from the CSF and clinical outcome.
5.2 Methods
5.2.1 Determination of Minimum Inhibitory Concentrations
I used the Sensititre® YeastOne® (Trek Diagnostic Systems, East Grinstead, UK) 
microbroth susceptibility testing plates, as described in Chapter 2, to determine the
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MICs of 8 antifungal drugs against all the Cryptococcus species in the OUCRU strain 
collection.
5.2.2 Isolates
The isolates tested were derived from 3 sources: the BMD study (a prospective 
descriptive study o f CNS infection in HIV uninfected patients); the BK study (a 
prospective randomized controlled trial of combination antifungal therapies in 
cryptococcal meningitis in HIV infected patients); and a collection of arcHIVed (‘A- 
strain’) cryptococcal isolates dating from 1996 until the start o f the BK study in 2004. 
The BMD isolates dated from 1996 to 2009 (n = 60), the BK isolates from 2004 to 2009 
(n = 214), and the A-strain isolates were collected between 1996 and 2003 (n = 128). 
There were no clinical data for this last group of isolates, but they are almost certainly 
all isolates from HIV infected patients - since 1996 all HIV uninfected patients with 
cryptococcal meningitis at the Hospital for Tropical Diseases were cared for on the CNS 
infections ward (formerly the Malaria Research Ward), and were recruited to the BMD 
study. Patient names were available for the A-strain patients, and cross referencing with 
the BMD database revealed that there was no strain duplication.
5.3 Analysis
5.3.1 Antifungal Susceptibility
The isolates were assigned to groups by source in relation to HIV serostatus - HIV 
uninfected (the BMD study strains), HIV infected (the BK study strains) and unknown 
HIV status (the A-strain). A group of strains where HIV infection was highly likely was
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defined by combining all the strains from the BK study and the A-strain group. Strains 
were also assigned to groups according to the year of isolation.
All MICs were log2 transformed prior to analysis. Antifungal susceptibilities were 
described in 3 ways -  as the Minimum Inhibitory Concentration 50 (MIC50) -  the 
concentration of drug which inhibited growth of 50% of the isolates; as the Minimum 
Inhibitory Concentration 90 (MIC90) -  the concentration of drug which inhibited growth 
of 90% of isolates; and as the geometric mean of the minimum inhibitory 
concentrations. The MICs were compared by year and groups using a linear model. If 
the plot of MIC by year suggested that the relationship was unlikely to be linear then the 
relationship was instead modelled with a natural cubic spline with 5 degrees of freedom 
and a global F test was used to assess whether the year affected the MIC. Natural cubic 
splines allow flexible modelling and test for very general (linear or nonlinear) 
associations [279]. However, as spline functions are relatively complex objects, the 
estimated association cannot easily be quantified by simple effect measures.
5.3.2 Correlation Between Azole MICs
Pearson’s rank correlation was used to describe the relationship between the MICs of 
different azoles and fluconazole. Linear regression was used to determine the proportion 
of occasions on which the fluconazole 72 hour MIC exactly or closely (+/-1 dilution) 
predicted the MIC of the other azole drugs tested. Fluconazole was chosen as the 
reference azole, since it is the recommended and most frequently prescribed treatment 
for cryptococcal meningitis.
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5.3.3 Relationship between Amphotericin B MIC and rate of clearance of yeast.
Quantitative counts were determined as described in Chapter 2. We used a nonlinear 
mixed effects model to model the decline of quantitative counts over time in the HIV 
patients described in chapter 3, who all received 4 weeks of treatment with amphotericin 
B lmg/kg/day. We assumed that for each patient, the quantitative counts decline 
exponentially after treatment initiation, i.e. that the count for patient i on study day t is 
given by the relation Countj(t)~exp(aj+bj-t) where the coefficient exp(aj) refers to the 
‘true’ quantitative count (i.e. the quantitative count without measurement error) at 
therapy initiation (day 0) and exp(bj) refers to the relative count decline per day of 
treatment. The quantitative counts (after addition of 1 to cope with counts of zero) were 
log-transformed to normalize their distribution. Thus, the non-linear patient-specific 
"model assumed that loge(Countj(t)+l)~loge(exp(aj+bj-t)+l). In addition to this basic 
model we fitted an extended model where the patient-specific slope was allowed to 
change from day 14 onwards, i.e. we modelled the decline (on the logarithmic scale) 
with a linear spline function with one knot at 14 days.
The patient-specific intercepts and slopes (aj,bj) were modelled according to a bivariate 
normal distribution with average (population) intercept a and slope b plus normally 
distributed patient-specific deviations from these average values to describe between- 
patient variation. In the extended model, we additionally used a fixed (population) effect 
for the change in slope after day 14.
In order to assess whether the initial count or the rate of decline depended on the MIC’s 
o f amphotericin B or fluconazole (measured at 48 or 72 hours), respectively, we tested
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whether the population slope a and intercept b (plus the change in slope after day 14 for 
the extended model) depended linearly on the log2-transformed MIC-values.
Finally, we tested whether the initial count or the rate of decline predicted the patients’ 
6-month survival. This was done with a joint model where the counts were modelled as 
described above and the survival endpoint was modelled with a Weibull proportional 
hazards regression model where the hazard was allowed to depend on both the patient- 
specific intercept and slope aj and bj [350]. A joint model where the counts followed the 
extended model could not be fitted due to numerical problems, i.e. the algorithm did not 
converge. We used a Weibull model instead of the more commonly used Cox 
proportional hazards model as the two often give comparable results and a joint model 
was easier to implement with a parametric survival model.
5.3.4 Relationship to clinical outcome
To determine the relationship between drug susceptibility and clinical outcome, I used 
the clinical dataset and isolates from the patients described in chapter 3. The Cox 
proportional hazards regression model, described in chapter 3, was used to study the 
association between MIC and survival. Initially a univariate logistic regression was 
performed to investigate the relationship between MIC and survival. I then performed a 
multivariate analysis including in the model the MIC of the antifungal drug of interest 
and the 3 variables identified in chapter 3 as being independently associated with an 
altered hazard for death (log2 CSF cryptococcal antigen titre, Glasgow Coma Score and 
CSF white cell count), since these might otherwise have obscured an association with 
outcome. All patients were initially treated with at least 2 weeks of amphotericin B
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(lmg/kg/day) followed by fluconazole 400mg/day to complete 10 weeks treatment.
Long term suppression was continued with fluconazole 200mg/day.
5.3.5 Statistical software
Statistical analyses were performed using R version 2.9.0 (R Foundation for Statistical 
Computing, Vienna, Austria)[247]. The rate of clearance of yeast was modelled using 
the recommended R package nlme [247, 351]. The joint model of yeast clearance and 
survival was programmed with proc nlmixed of the statistical software SAS 9.2 (SAS 
Institute Inc., Cary, North Carolina, USA).
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5.4 Results
5.4.1 Antifungal Susceptibilities
402 clinical isolates were available for antifungal testing during period 1996 -  2009. The 
isolates are described in Table 5.2.
Table 5.1
Summary of number of samples tested by year and source HIV status
Year HIV 
Uninfected 
(BMD Strains)
HIV Infected 
(BK Strains)
HIV status 
Unknown 
(A-Strains)
Row Total
1996 0 0 7 7
1997 1 0 8 9
1999 1 0 2 3
2000 4 0 22 26
2001 3 0 39 42
2002 3 0 50 53
2003 4 0 0 4
2004 1 34 0 35
2005 9 63 0 72
2006 8 52 0 60
2007 12 35 0 47
2008 8 26 0 34
2009 6 4 0 10
Column
Total 60 214 128 402
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The spread o f MICs measured are described by the histograms in Figure 5.1 below.
Figure 5.1 Histograms depicting the distributions of MICs measured for the 8 
antifungal drugs after 48 and 72 hours of incubation.
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Figure 5.1 Legend: P = Posaconazole, AmB = Amphotericin B, F = 
Fluconazole, I = Itraconazole, K = Ketoconazole, FC = Flucytosine, V = 
Voriconazole, C = Caspofungin.
48 = 48 hours, 72 = 72 hours
The distributions of the log2 antifungal MICs are approximately symmetric with the 
exceptions o f amphotericin B and caspofungin. The percentages of isolates susceptible
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to each individual drug concentration at 48 and 72 hours are shown in Tables 5.3 and 5.4 
below. Fewer results are available at 48 hours because of the slow growing nature of 
Cryptococcus spp. resulting in insufficient growth from a number of isolates to enable 
MIC estimation (despite an adequate inoculation density). As a point o f reference, the 
CLSI M27A suggested interpretative breakpoints for Candida species are included in the 
table (shaded regions: green - sensitive; yellow - intermediate sensitivity; orange - 
sensitive dose dependent; red - resistant). Breakpoints for Cryptococcus are not 
established, but some investigators have used these in their analyses o f Cryptococcus 
sensitivities [352].
The range of MICs detected for amphotericin B was narrow, with 92.6% of strains 
susceptible to concentrations of 0.256 or 0.512 ug/ml after 72 hours incubation. As 
expected for Cryptococcus, all strains tested were resistant to caspofungin (data shown 
in histograms only). Growth occurred across the whole range of flucytosine and 
fluconazole drug concentrations suggesting the presence o f drug resistance. The strains 
for which MICs of fluconazole or flucytosine were in the defined resistance range for 
Candida species were all isolates from HIV positive patients from 2005 onwards (5 with 
fluconazole MICs>64mg/L, 2 with flucytosine MICs>32mg/L). The MICs of 
itraconazole for 2 isolates were 1 and 2 mg/L respectively (concentrations considered to 
denote resistance for Candida). One of these was a definitely HIV associated isolate 
from 2005, the other was a probably HIV associated isolate from 2000. Some strains 
from all groups of isolates had MICs that would be considered to represent intermediate 
resistance or a dose-dependent clinical response in Candida. The distribution did not 
appear to be different between groups.
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5.4.2 MICso, MIC90 and Geometric Mean MICs
The numbers tested, M I C 5 0 S, M I C 9 0 S and geometric means after 72 hours incubation are 
shown in table 5.4, according to HIV serostatus of the isolate source.
Multiple linear regression was used to test the effect of HIV serostatus on geometric 
mean MIC for each antifungal drug. Results for isolates from HIV infected patients were 
compared with 2 groups - HIV uninfected and patients with unknown HIV status. The 
coefficients in table 5.5 below give the estimated differences in geometric means of each 
group compared to HIV infected patients:
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Table 5.4 Antifungal MICs by HIV status of source (ug/mL)
Patient Status
Antifungal
H IV infected 
(BK) 
(214)
HIV uninfected 
(BMD)
(60)
Unknown Status 
(128)
Amphotericin B MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
0.512 
1.024 
0.064 -  2.048 
0.690 
0.650 -  0.732 
214
0.512 
1.024 
0 .2 5 6 -  1.024 
0.60 
0.544 -  0.666 
60
0.512 
1.024 
0 .1 2 8 -  1.024 
0.512 
0.476 -  0.551 
128
Flucytosine MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
8
16
0.48 - 128 
6.99 
6 .4 8 -7 .5 4
211
8
8
0.96 - 16 
4.91 
4 .0 8 -5 .9 2
60
4
8
0 .9 6 -1 6  
4.26 
3.87 -  4.69
128
Fluconazole 72 MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
8.0
16
0 .1 2 5 -5 1 2  
7.90 
7.08 -  8.82
212
8.0
16
1.-32
6.35
5 .1 9 -7 .7 7
60
8.0
16
0.0625 -32  
6.41 
5.64 -  7.28
128
Itraconazole MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
0.128 
0.256 
0 .0 0 4 -  1.024 
0.082 
0 .0 7 3-0 .093  
211
0.128
0.256
0 .0 3 2 -0 .256
0.099
0 .083-0 .116
60
0.064
0.128
0 .0 0 4 -2
0.064
0.055-0 .075
128
Ketoconazole MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
0.064 
0.128 
0 .0 0 4 -  1.024 
0.061 
0.055 -  0.068 
212
0.064 
0.256 
0 .016-0 .256  
0.065 
0.054 -  0.079 
60
0.032 
0.064 
0 .0 0 4-0 .256  
0.033 
0.029 -  0.038 
128
Posaconazole MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
0.128
0.256
0 .0 0 8 -0 .5 1 2
0.113
0 .1 0 3-0 .125
213
0.128
0.256
0 .064-0 .512
0.119
0 .100-0 .142
59
0.128
0.256
0 .008-0 .512
0.110
0 .097-0 .125
128
Voriconazole MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
0.064 
0.128 
0 .0 0 4-0 .512  
0.054 
0.049 -  0.060 
211
0.064
0.128
0 .016-0 .256
0.063
0 .052 -0 .076
60
0.064
0.128
0 .00 4 -0 .2 5 6
0.046
0 .0 4 0-0 .052
129
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Table 5.5 Effect of HIV status on geometric mean MIC
Drug
Amphotericin B
Flucytosine
Fluconazole
Itraconazole
Ketoconazole
Posaconazole
Voriconazole
Status Coefficient P Value
HIV Infected 1.0 -
HIV Uninfected 0.87 0.028
Unknown 0.74 <0.0001
HIV Infected 1.0 -
HIV Uninfected 0.70 <0.0001
Unknown 0.61 <0.0001
HIV Infected 1.0 -
HIV Uninfected 0.80 0.06
Unknown 0.81 0.0178
HIV Infected 1.0 -
HIV Uninfected 1.19 0.16
Unknown 0.78 0.01
HIV Infected 1.0 -
HIV Uninfected 1.075 0.52
Unknown 0.55 <0.0001
HIV Infected 1.0 -
HIV Uninfected 1.05 0.64
Unknown 0.97 0.70
HIV Infected 1.0 -
HIV Uninfected 1.17 0.15
Unknown 0.85 0.052
There were statistically significant differences between groups in geometric mean MICs 
when compared to isolates from known HIV infected sources. Clinical isolates from 
known HIV infected patients were less susceptible to antifungal agents than isolates 
from HIV uninfected patients or from patients of unknown HIV infection status. This 
was independent of drug class, holding true for amphotericin B and flucytosine for both 
the HIV uninfected and unknown status groups, and in addition for fluconazole, 
itraconazole and ketoconazole for isolates of unknown HIV serostatus source. In 
addition, the difference in fluconazole MICs between HIV infected and HIV uninfected 
patients was close to statistical significance (p = 0.057), but must be interpreted in the 
light of multiple tests having been performed.
5.4.3 Effect of year
I determined the effect of year on 72 hour MIC over the 13 year period on the whole 
group, and then by HIV status. Figures 5.2 to 5.4 are scatter plots illustrating the time 
trend in log2 MICs for amphotericin B, flucytosine, fluconazole, itraconazole, 
ketoconazole, posaconazole and voriconazole respectively for the whole group of 
strains. The blue lines represent the linear regression lines and the red lines are lowess 
(locally weighted scatter plot smoother) lines.
219
>g
2(
l72
)M
IC
 
 
 
lo
g2
(A
m
B7
2)
M
IC
Amphotericin B Flucytosine Fluconazole
1996 2000 2004 2008
Figure 5.2 Trends in amphotericin B, flucytosine and fluconazole MICs over the 13 year 
study period. Red line = lowess line, blue line = regression line.
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Figure 5.3 Trends in itraconazole, ketoconazole and posaconazole MICs over the 13 year 
study period. Red line = lowess line, blue line = regression line.
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Figure 5.4 Trends in voriconazole MIC over the 13 
year study period. Red line =lowess line, blue line - 
regression line.
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Linear regression was used to investigate the relationship between time (years) and 
MICs. The coefficients describing changes in MICs for the antifungals are shown in 
table 5.6 below.
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Table 5.6
Change in MIC of 7 antifungal drugs over time 
Coefficient of Coefficient of change P value
yearly change in in MIC 1996 -  2009
MIC
Antifungal Value Value 95% Cl
Amphotericin B 1.03 1.46 1 .21-1 .76 <0.001
Flucytosine 1.06 2.20 1 .70-2 .85 <0.001
Fluconazole 1.04 1.63 1 .16-2 .28 <0.001
Itraconazole 1.04 1.61 1 .11-2 .33 0.013
Ketoconazole 1.08 2.74 ; 1 .94 -3 .86 <0.001
Posaconazole 1.02 1.31 0 .9 6 -1 .7 9 0.08
Voriconazole 1.04 : 1.57 1.13-2 .17 0.007
With the exception of posaconazole the MICs for all the drugs tested increased over the 
13 year period. The greatest changes were seen for flucytosine and ketoconazole, where 
there was a doubling of MIC over the time period. The posaconazole MIC appeared to 
increase but did not reach conventional levels o f statistical significance. The linear 
model assumes that the change in log2 MICs can be described with a straight line. 
However, for amphotericin B, flucytosine, ketoconazole and posaconazole the scatter 
plots suggest that the relationship may not be linear, since lowess lines do not closely 
follow the regression lines (figures 5.2 and 5.3). Thus I also modelled the relationship 
using a natural cubic spline with 5 degrees of freedom and used a global F-test to assess 
whether there was an effect of year on MIC levels. Changes in MIC by year remained 
statistically significant for amphotericin B (p<0.001), flucytosine (pO.OOl),
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ketoconazole (p<0.001) and were also significant for posaconazole (p<0.013). As 
explained before, the estimated association cannot easily be quantified.
5.4.4 Effect of HIV serostatus
I then examined the effect of HIV serostatus on the change in MIC over time. The HIV 
infected group contained isolates from the years 2004 -  2009, the HIV uninfected 
isolates from 1996 to 2009, and the unknown HIV serostatus (A-strain) group from 1996 
-  2002.1 assumed all of the unknown HIV serostatus isolates were in fact HIV positive 
isolates, and pooled them with the definite HIV isolates to create a group of probable or 
definite HIV related isolates. I believed this to be reasonable since I was confident that 
1) I had identified all HIV negative isolates and 2) through cross referencing by patient 
name knew that the HIV negative isolates were not duplicated in the A-strain group 
Moreover, it is much more probable that an isolate is from an HIV infected patient than 
not and thus that A-strain isolates are from HIV positive patients. The advantage of this 
grouping was that I now had HIV and non-HIV related isolates spanning the same time- 
period, 1996 -  2009. The results o f the analysis are shown in Table 5.7 below.
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Table 5.7
________________ Linear time trend after adjusting for HIV serostatus_________
Antifungal Variable Coefficient 95% Cl P value
Amphotericin B HIV positive 1.068 0 .95-1 .21 0.29
Year 1.03 1 .02-1 .05 <0.001
Flucytosine HIV positive 1.29 1 .09-1 .52 0.003
Year 1.07 1 .05-1 .09 <0.001
Fluconazole HIV positive 1.22 0 .98-1 .51 0.07
Year 1.04 1.02-1 .07 0.002
Itraconazole HIV positive 0.80 0 .63-1 .01 0.06
Year 1.03 1 .00-1 .06 0.03
Ketoconazole HIV positive 0.82 0 .6 6 -1 .0 2 0.08
Year 1.08 0 1 <0.001
Posaconazole HIV positive 0.97 0 .7 9 -1 .1 8 0.74
Year 1.02 0 .99 -1 .0 5 0.10
Voriconazole HIV positive 0.84 0 .68 -1 .03 0.09
Year 1.03 1 .01-1 .06 0.02
The analysis shows that after adjusting for year the study characteristic (HIV positive or 
not) is not statistically significantly associated with a difference in MIC for amphotericin 
B or posaconazole (p=0.29 and p=0.74 respectively), but is associated with the MIC of 
flucytosine p = 0.003). The MICs of flucytosine were higher in general for HIV infected 
patients compared with HIV uninfected patients. For fluconazole, itraconazole, 
ketoconazole and voriconazole I did not demonstrate an influence of HIV serostatus on
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MIC after adjusting for year, although the p values approached conventional levels of 
significance (p = 0.07, 0.06, 0.08 and 0.09 respectively). The MICs of all drugs with the 
exception of posaconazole increased by year, independent of the HIV serostatus of the 
isolate source (table 5.7).
This analysis makes the assumption that the effect of year on MIC is the same for 
isolates whether or not they are from HIV infected patients. To investigate whether there 
is in fact an interaction between HIV status and time for antifungal MICs (i.e. the effect 
of year is different depending upon the HIV serostatus) I modelled an interaction 
between time and HIV serostatus. Scatter plots for the MICs of each antifungal drug by 
year according to HIV status are shown in figures 5.5 to 5.11 below.
All patients HIV negatives HIV positives/unknown
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Figure 5.5 Time trend by year in MICs of amphotericin B for the whole strain collection, and 
divided by HIV status.
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Figure 5.7 Time trend by year in MICs of fluconazole for the whole strain collection, and
divided by HIV status.
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Figure 5.8 Time trend by year in MICs of itraconazole for the whole strain collection, and 
divided by HIV status.
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Figure 5.9 Time trend by year in MICs of ketoconazole for the whole strain collection, and 
divided by HIV status..
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Figure 5.10 Time trend by year in MICs of posaconazole for the whole strain collection, 
and divided by HIV status.
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Figure 5.11 Time trend by year in MICs of voriconazole for the whole strain collection, 
and divided by HIV status.
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The blue line represents the regression line of the linear model, the red line is a lowess 
(smoother) line, and the dotted line divides the A-strain (probably HIV associated) from 
the BK (definitely HIV associated) strains. While the plots are suggestive that the effect 
of year on antifungal MIC may be different according to HIV serostatus for 
amphotericin B, flucytosine, itraconazole, ketoconazole and voriconazole, the modelling 
suggests that the effect is different only for amphotericin B (p=0.03), flucytosine 
(p=0.04), and ketoconazole (p=0.002). The p values for the other antifungals were: 
fluconazole p=0.44, itraconazole p=0.21, posaconazole p=0.63 and voriconazole p=0.17.
5.4.5 Effect of Species
Species identification was performed in 366 isolates using URA5 PCR-RFLP as 
described in Chapter Two. 350 isolates were Cryptococcus grubii (all molecular type 
VN1). 16 isolates (4.3%) were C. gattii (15 molecular type VG1 and 1 molecular type 
VG2). The results of antifungal testing according to species are shown in Table 5.8. The 
geometric mean 72 hour MICs of amphotericin and flucytosine were lower for C. gattii 
compared with C. grubii (0.632 mg/L versus 0.49 mg/L, p=0.05 and 6.09 mg/L versus 
2.46mg/L, p=0.0002 respectively). The MIC90S for each species were the same for each 
drug (1.024 mg/L for amphotericin; 16mg/ml for flucytosine). No significant differences 
in geometric mean MIC were detected for the azole drugs.
I examined the linear trends with time of MIC of amphotericin B, fluconazole and 
flucytosine by species using linear regression as described previously. The plots are 
show in figures 5.12 -  5.14 below.
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Table 5.8 M IC s by Species, ug/m L  
Antifungal
Species
C. grubii C. gattii P value
(n -  350) (n = 16) (t test)
Amphotericin B MIC 50 
MIC 90 
Range
Geometric mean 
95% Cl Geometric 
mean
N
0.512 
1.024 
0.064 -  2.048 
0.632
0 .604-0 .661
350
0.512. 
1.024 
0 .2 5 6 -  1.024 
0.490
0.381 -  0.630
16
0.05
Flucytosine MIC 50 8 2
MIC 90 8 8
Range 0 .4 8 -128 0 .9 6 -8
Geometric mean 6.09 2.46 0.0002
95% Cl Geometric
mean 5 .7 2 -6 .4 8 1.64 -  3.69
N 347 16
Fluconazole MIC 50 8.0 4
MIC 90 16 16
Range 0 .0 6 2 5 -5 1 2 2 - 1 6
Geometric mean 7.33 5.42 0.12
95% Cl Geometric mean 6 .7 4 -7 .9 8 3 .7 0 -7 .9 3
N 348 16
Itraconazole MIC 50 0.064 0.096
MIC 90 0.128 0.256
Range 0 .0 0 4 -2 .0 0 .032-0 .256
Geometric mean 0.078 0.095 0.29
95% Cl Geometric mean 0.071 -0 .0 8 6 0 .066-0 .135
N 347 60
Ketoconazole MIC 50 0.064 0.064
MIC 90 0.128 0.256
Range 0 .0 0 4 -  1.024 0 .016 -0 .256
Geometric mean 0.053 0.061 0.47
95% Cl Geometric mean 0 .0 4 8 -0 .0 5 7 0.040 -  0.095
N 347 16
Posaconazole MIC 50 0.128 0.128
MIC 90 0.256 0.256
Range 0 .0 0 8 -0 .5 1 2 0 .032-0 .512
Geometric mean 0.114 0.108 0.76
95% Cl Geometric mean 0 .106 -0 .123 0 .073 -0 .159
N 348 16
Voriconazole MIC 50 0.064 0.064
MIC 90 0.128 0.256
Range 0 .0 0 4 -0 .5 1 2 0 .032 -0 .256
Geometric mean 0.052 0.064 0.27
95% Cl Geometric mean 0 .0 4 8 -0 .0 5 6 0.044 -  0.094
N 347 16
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Figure 5.13 Year trends in flucytosine MICs by Cryptococcus species.
231
All species C. grubii C. gattii
o°
i  1 i----- 1— 1--- r
1996 2000 2004 2008
o o o
< p  o d  o  0  ( g  
® *<$ §$8$® °
%° °®S©<s>»8©«efc
o O °  OO Oo
o o _o o o
1 I I I I I I
1996 2000 2004 2008
oo
CD
C\J
o
egI
■>*i
1996 2000 2004 2008
Year Year Year
Figure 5.14 Y ear trends in fluconazole M IC s by C ryptococcus  species.
The analyses are lim ited by the small num ber o f  cases o f  C. gattii. As expected from  the 
previous analysis, yearly  trends in M IC w ere dem onstrable in C. grubii but failed to 
reach statistical significance for C. gattii Table 5.9).
Table 5.9
Changes in Geometric mean M IC of am photericin B, flucytosine and 
___________________fluconazole over 13 years by Cryptococcus species.____________
Antifungal Species
______________C. grubii____________________________C. gattii____________
Change in geometric mean M IC Change in geometric mean 
over 13 years M IC over 13 years
Coefficient 95% C l P Coefficient 95% Cl P
Amphotericin 1.52 1 .2 4 -1 .8 7 <0.001 0.64 0 .1 9 - 2 .1 4 0.44
Flucytosine 2.03 1 .5 5 -2 .6 7 <0.001 4.14 0 .6 8 - 2 5 .5 0.11
Fluconazole 1.59 1 .0 8 -2 .3 4 0.018 0.93 0 .1 4 - 6 .0 0 0.93
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5.4.6 Effect of AFLP clade on antifungal MICs
In Chapter 4, using AFLP, I showed that all cases of cryptococcal meningitis in Viet 
Nam due to Cryptococcus grubii are due to infection with 1 of 2 clades of URA5 PCR- 
RFLP molecular group 1 .1 found that HIV uninfected patients were more likely to be 
infected with strains from Clade 1 than Clade 2 (odds ratio 5.93, 95% confidence 
interval 2.4 -  16.6, pO.OOOl). I examined whether there were any differences in drug 
susceptibility according to infecting clade. The results are shown in table 5.10 below. 
There were no significant differences in antifungal susceptibility, other than a possible 
difference in the geometric mean MIC of posaconazole, which was slightly higher in 
Clade 2. However, there were no differences in MIC50 or MIC90 .
I examined the linear trends with time in MIC of amphotericin B, fluconazole and 
flucytosine by clade using linear regression. The plots are show in figures 5 .1 5 -5 .1 7  
below.
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Table 5.10 MICs by C. grubii clade, ug/mL
Clade
Antifungal
Clade 1 
(n = 67)
Clade 2 
(n = 65)
P value 
(t test)
Amphotericin B MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
1.024
1.024 
0 .2 5 6 -2 .0 4 8
0.720 
0.649 -  0.799 
67
0.512. 
1.024 
0 .0 6 4 -  1.024 
0.641 
0 .567-0 .724  
65
0.15
Flucytosine MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
8
16
2 - 1 6
6.964
6 .1 9 -7 .8 4
65
8
16
2 - 1 6
7.025
6 .1 4 -8 .0 3
64
0.923
Fluconazole MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
8.0 
16 
1 - 128 
6.64 
5 .4 7 -8 .0 7  
67
8
16
0 .125-64
7.55
6 .06 -9 .41
65
0.38
Itraconazole MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
0128 
0.256 
0 .0 0 4 -  1.0 
0.088 
0.072-0 .106  
66
0.064
0.256
0 .004-0 .512
0.068
0 .047-0 .089
64
0.13
Ketoconazole MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
0.064
0.128
0 .0 0 4 -1 .0 2 4
0.064
0 .0 5 3 -0 .0 7 8
66
0.064
0.256
0 .004-0 .256
0.057
0.046-0 .071
64
0.42
Posaconazole MIC 50 
MIC 90 
Range
Geometric mean:
95% GI Geometric mean 
N
0.128 
0.256 
0 .0 3 2 -0 .5 1 2  
0.123 
0 .1 0 5 -0 .1 4 4  
66
0.128
0.256
0 .008-0 .512
0.093
0 .076-0 .114
65
0.036
Voriconazole MIC 50 
MIC 90 
Range
Geometric mean
95% Cl Geometric mean
N
0.064
0.128
0 .0 0 4 -0 .5 1 2
0.054
0 .045-0 .065
66
0.064
0.128
0 .004-0 .512
0.053
0.043-0 .066
65
0.93
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Figure 5.15 Year trends in amphotericin B MICs by Cryptococcus grubii clade.
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Figure 5.16 Year trends in flucytosine MICs by C. grubii clade.
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Figure 5.17 Year trends in fluconazole MICs by C. grubii clade.
There were no statistically significant changes in MIC over time detected using the 
linear model (table 5.11).
Table 5.11
Changes in Geometric mean M IC of amphotericin B, flucytosine and 
fluconazole over 13 years by Cryptococcus grubii Clade
Antifungal Clade
Clade 1 Clade 2
Change in geometric mean 
MIC over 13 years
Change in geometric mean 
M IC over 13 years
Coefficient 95% C l P Coefficient 95% C l P
Am photericin 1.02 0 .5 4 - 1 .9 2 0.96 0.78 0 .2 8 - 2 .2 0 0.63
Flucytosine 0.74 0 .3 6 - 1 .5 2 0.41 0.63 0 2 0 -  1.97 0.42
Fluconazole 0.75 0 .2 3 -2 .4 8 0.64 2.24 0 .3 4 - 1 4 .4 0.40
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5.4.7 Correlation between susceptibility testing results at 48 and 72 hours
Cryptococcus neoformans is relatively slow growing compared with other yeast species 
such as Candida. While breakpoints have not been determined for Cryptococcus spp, the 
YeastOne® Sensititre® manufacturers recommend that MICs of antifungals for 
Cryptococcus are read at 72 hours. However, there is often evidence of growth in the test 
plates, with colour change and thus estimable MIC, at 48 hours. More rapid reporting of 
results would enable earlier intervention to alter therapy with potential benefit to 
patients. Therefore, I determined the correlation between MICs estimated at 48 and 72 
hours for the Cryptococcus strains tested. Table 5.12 records the numbers and 
percentage of strains where there was a change between 48 hour and 72 hour MIC. It 
was not possible to estimate the MIC at 48 hours in all isolates (hence N < 402 for all 
antifungals). Figures 5.18 -  5.20 plot the 48 hour MIC results against the 72 hour MIC 
results for all the tested isolates. The black identity line is a visual aid with intercept of 0 
and gradient of 1. The red line is the linear regression line.
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Table 5.12
Change in 48 and 72 Hour MIC results for 7 antifungal drugs
Drug No Change 
Number 
Per cent
Increased 
Number 
Per cent
Pearson
Correlation
Amphotericin B 101 270 0.53
27.2 72.8
Flucytosine 146 223 0.72
39.6 60.4
Fluconazole 153 217 0.76
41.4 58.6
Itraconazole 108 259 0.78
29.4 70.6
Ketoconazole 175 195 0.8
47.3 52.7
Posaconazole 168 202 0.78
45.4 54.6
Voriconazole 167 200 0.77
45.5 54.5
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Figure 5.18.Plots of 72 hour log2 MIC against 48 hour Iog2 MIC for amphotericin, 
flucytosine and fluconazole.
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Figure 5.19 Plots of 72 hour log2 MIC against 48 hour log2 MIC for itraconazole, 
ketoconazole and posaconazole.
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I used linear regression to determine whether it was possible to correctly predict the 72 
hour MIC from the 48 hour MIC. I looked at the absolute prediction rate, and the ability 
to predict the actual rate with an error of +/- one log2 MIC (i.e. one dilution of error). 
The results are displayed in Table 5.13.
Table 5.13
Number of 72 hour results correctly predicted from 48 hour result using the 
__________________________________regression model______________ _____________
Exact +/-1 dilution
Number Number
% %
Drug Correct Incorrect Correct Incorr
Amphotericin B 243 129 369 2
65.3 34.7 99.5 0.5
Flucytosine 226 144 364 5
61.1 38.9 98.6 1.4
Fluconazole 189 182 362 8
50.9 49.1 97.8 2.2
Itraconazole 220 147 352 15
59.9 40.1 95.9 4.1
Ketoconazole 203 167 358 12
54.9 45.1 96.8 3.2
Posaconazole 216 154 367 3
58.4 41.6 99.2 0.8
Voriconazole 197 170 358 9
53.7 46.3 97.5 2.5
The 48 hour prediction of 72 hour MIC was good to within 1 dilution, with a maximum 
error rate of 4.1%.
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5.4.8 Correlation between azole drug MICs
I examined the relationship between the MICs of different azole drugs. The scatter plots 
of the MICs o f the 4 azole drugs fluconazole, itraconazole, posaconazole and 
voriconazole are shown in Figure 5.21. The numbers are the rank correlations between 
the MICs of the different drugs. The dotted identity lines are visual aids where the 
intercept is zero and the slope is 1.
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Figure 5.21 Scatterplots of azole MICs and rank correlations for 400 strains of 
Cryptococcus spp. F -  fluconazole, I = Itraconazole, V = voriconazole, P = 
posaconazole.
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The highest correlation was between posaconazole and itraconazole, and the lowest 
between fluconazole and itraconazole. I used linear regression to predict the 72 hour 
MICs o f itraconazole, posaconazole and voriconazole from the 72 hour fluconazole 
MIC. The model predicted the actual MIC of itraconazole, posaconazole and 
voriconazole to +/- 1 dilution 90.2, 96.0 and 94.5% of the time respectively (table 5.14).
Table 5.14
Rates of Successful Prediction of Itraconazole, Posaconazole and 
Voriconazole MICs from the 72 hour fluconazole MIC
Drug N Exact Within 1 dilution
N N
 %  %
Itraconazole 398 174 359
43.7 90.2
Posaconazole 399 224 383
56.1 96.0
Voriconazole 399 225 377
56.4 94.5
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Table 5.15 lists the errors in prediction made that were greater than one dilution from the 
actual result:
Table 5.15
Number of errors in prediction by dilution fold
Antifungal N 2 dilution 3 dilution 4 dilution § dilution
error error error error
Itraconazole 398 12 5 1 0
Posaconazole 399 1 1 0 0
Voriconazole 399 5 1 0 0
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5.4.9 Influence of amphotericin B MIC on rate of clearance of yeast from CSF.
A total of 208 quantitative count measurements from 63 HIV-positive patients with 
cryptococcal meningitis were available; the median number of measurements per 
patients was 3 (range 1 to 8). Individual patient profiles of all measurements are 
displayed in figure 5.23.
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Figure 5.22 Quantitative counts from 63 HIV-positive patients with cryptococcal 
meningitis. Gray lines refer to individual patient data, the black line is a scatterplot 
smoother.
The basic model with an exponential decline determined a population intercept of 13.15 
(95% Cl [12.50, 13.81]) and slope -0.58 (95% Cl [-0.67,-0.48]) on the logarithmic scale; 
the individual patient-specific deviations around these population parameters were 
estimated to have standard deviations of 2.11 and 0.26 for the intercept and slope, 
respectively. On the original scale, the slope corresponds to a decline o f 44% per day (as 
exp(-0.58)=0.56). The extended model estimated an initial population slope o f -0.73
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(95% Cl [-0.80, -0.66]) in the first 14 days and a decline in the population slope by 0.47 
(95% Cl [0.38, 0.76]) in the time thereafter. This equates to a decline in yeast count of 
0.32 logio/day (0.73/loge10). The change in slope on day 14 was highly significantly 
different from zero (p<0.001) indicating a slower decline with increasing time of 
treatment. Figure 5.23 displays residuals versus time since treatment initiation 
suggesting that the extended model more adequately describes the data.
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Figure 5.23 Residuals versus time since treatment initiation for the model with an 
exponential decline or the extended model, respectively. The black lines are 
(lowess) scatterplot smoothers.
Amphotericin B MIC data (72 hour result) were available for 60 (95%) of the 63 
isolates. The range of MICs was narrow: 0.256 mg/L for one isolate (2%), 0.512 mg/L 
for 37 isolates (62%) and 1.024 mg/L for 22 (37%) isolates. Plots of quantitative counts 
over time stratified by amphotericin B MIC are displayed in figure 5.24. The extended 
model which postulated a linear effect o f the covariate log2-amphotericin B MIC (72
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hour result) on the initial quantitative count, the initial slope and the change in slope 
after day 14, respectively, did not significantly improve the model without this covariate 
(p[likelihood ratio test]=0.53); the effect of a 2-fold increase of the amphotericin B MIC 
on the initial slope was estimated as -0.09 (95% Cl [-0.21,0.04], p=0.19). Similarly, the 
48 hour amphotericin B MIC did not significantly affect the quantitative counts 
(p[likelihood ratio test]=0.36).
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Figure 5.24 Quantitative counts by amphotericin B MIC. Gray lines refer to 
individual patient data, the black line is a scatterplot smoother.
Fluconazole MIC data (72 hour result) were available for 60 (95%) of the 63 isolates. 
The MIC was 2 mg/L for 4 isolates (7%), 4 mg/L for 13 isolates (22%), 8 mg/L for 27 
isolates (45%), 16 mg/L for 13 isolates (22%) and between 32 and 512 mg/L for 3 
further isolates (5%). Plots of quantitative counts over time stratified by fluconazole 
MIC are displayed in figure 5.25.
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Figure 5.25. Quantitative counts by fluconazole MIC. Grey lines refer to individual 
patient data, the black line is a scatterplot smoother.
The extended model which postulated a linear effect of the covariate log2-fluconazole 
MIC (72 hour result) on the initial quantitative count, the initial slope and the change in 
slope after day 14, respectively, did not significantly improve the model without this 
covariate (p[likelihood ratio test]=0.11); the effect of a 2-fold increase of the fluconazole 
MIC on the initial slope was estimated as -0.03 (95% Cl [-0.10,0.03], p=0.40).
Similarly, the 48 hour fluconazole MIC did not significantly affect the quantitative 
counts (p[likelihood ratio test]=0.09); the trend towards significance was mainly due to a 
trend that the intercept (corresponding to the true log-quantitative count at treatment 
initiation) was estimated to increase by 0.44 (95% Cl [-0.12,1.00], p=0.13) per 2-fold 
MIC increase.
248
The joint model for longitudinal counts and survival estimated a very similar population 
slope and intercept as the longitudinal model alone: estimates were 13.37 (95% Cl 
[12.70, 14.03]) for the population intercept and -0.61 (95% Cl [-0.73,-0.49]) for the 
slope. The Weibull model indicated a decreasing hazard of death with time with a shape 
parameter of 0.60 (95% Cl [0.35,0.86]). There was no evidence that the rate of the 
quantitative count decline was associated with survival (HR=0.98; 95% Cl [0.67,1.43] 
per +0.1 more shallow slope, p=0.91). However, there was a strong trend that higher true 
initial quantitative counts were related with a worse survival (HR=4.27; 95% Cl 
[0.98,18.60] per ten-fold increase; p=0.05).
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5.4.10 Correlation with Clinical Outcome
I used the Cox regression model to examine the effect of antifungal susceptibility on 
survival in the patients described in chapter 3. All patients received treatment with 
amphotericin B (lmg/kg/day) for the first 4 weeks of therapy, followed by treatment 
with fluconazole 400mg/day. Initially I performed univariate analysis looking at both 48 
hour and 72 hour MIC estimations and the hazard o f death at 70 days. I then corrected 
for fungal load, estimated by the CSF cryptococcal antigen titre and the viable yeast 
count, and performed a multiple Cox regression analysis including the amphotericin B 
and fluconazole MICs, and the CSF cryptococcal antigen titre. The results are shown in 
table 5.16. Results are only presented for amphotericin B (AmB), fluconazole (F) and 
flucytosine (FC). No patients received treatment with flucytosine.
I found no alteration in the hazard for death at 70 days according to MICs of 
amphotericin B, flucytosine or fluconazole, whether estimated at 48 hours or 72 hours. 
Correcting for fungal burden at baseline, estimated either by log 10 quantitative count or 
log2 CSF cryptococcal antigen, had no effect, nor did correcting for fluconazole or 
amphotericin B MIC. No association was found between MICs of posaconazole, 
itraconazole, ketoconazole or voriconazole and hazard for death.
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Table 5.16 Cox 70 day survival analysis according to antifungal MICs Univariate analysis for 
48 and 72 hour MIC e s t i m a t i o n s _______________________________________
MIC Result Hazard Ratio Cl P (Wald 
Test)
N
Antifungal AmB 48 1.23 0.67-2.25 0.5 86
AmB 72 1.0 0.52-1.9 0.994 96
FC48 0.93 0.63-1.38 0.72 87
FC72 1.12 0.76-1.64 0.57 95
F48 1.07 0.75-1.52 0.71 87
F72 0.98 0.72-1.32 0.88 96
Analysis adjusted for fungal burden using CSF cryptococcal antigen titre.
Antifungal AmB 48 1.09 0.60-1.98 0.78 83
AmB 72 1.1 0.56-2.16 0.78 93
FC48 0.96 0.64-1.43 0.83 84
FC72 1.02 0.71-1.48 0.91 92
F48 1.02 0.71 -  1.46 0.92 84
F72 0.92 0.65-1.30 0.63 93
Analysis adjusted for fungal burden using CSF cryptococcal viable count.
Antifungal AmB 48 1.24 0.64-2.4 0.53 52
AmB 72 0.87 0.37-2.07 0.76 55
FC48 0.75 0.46-1.22 0.25 52
FC72 0.71 0.41 -  1.19 0.19 54
F48 0.94 0.60-1.47 0.77 52
F72 0.81 0.52-1.27 0.36 55
Analysis including both amphotericin B and fluconazole MICs at 48 or 72 hours, respectively, 
adjusted for CSF cryptococcal antigen titre
Antifungal AmB48 1.09 0.60-1.98 0.77 83
F48 1.02 0.71 -  1.47 0.91
AmB72 1.12 0.57-2.21 0.73 93
F72 0.91 0.64-1.29 0.60
251
The Cox regression model was used to analyse the effect of antifungal susceptibility on 
early death, defined as occurring within 7, 14 or 28 days. I examined only amphotericin 
B susceptibility, since this was the only treatment received by the patients during the 
first 4 weeks. I adjusted for baseline fungal burden estimated by cryptococcal antigen 
titre (using quantitative count reduced the model size by approximately half). The results 
are shown in Table 5.17.
Table 5.17
Cox regression model for early death (<28 day) by MICs of Amphotericin B at 48
and 72 hours
48 hour MIC 72 hour MIC
Survival 7 days 14 days 28 days 7 days 14 days 28 days
Hazard 3.44 2.0 1.41 0.79 0.87 0.91
Ratio
Cl 0.89-13.3 0.8-4.99 0.7-2.8 0.29-2.20 0.38-1.98 0.45-1.83
P (Wald 0.07 0.135 0.34 0.66 0.74 0.79
Test)
N 86 86 86 96 96 96
Adjusted for CSF log CrAg titre 
48 hour MIC 72 hour MIC
Survival 7 days 14 days 28 days 7 days 14 days 28 days
Hazard 2.9 1.77 1.20 0.81 0.91 1.001
Ratio
Cl 0.76-11.0 0.72-4.36 0.61 -2.37 0.29-2.3 1.03-1.41 0.48-2.09
P (Wald 0.117 0.21 0.6 0.70 0.83 1.0
Test)
N 83 83 83 93 93 93
252
The MIC for amphotericin measured at 48 hours was associated with an increased 
hazard for death at 7, 14 and 21 days, and the 72 hour estimate with a reduced hazard for 
death at the same time points. However, no result was statistically significant, although 
the effect for 48 hour MIC at day 7 was close to significance. When I corrected for 
baseline fungal burden (CSF cryptococcal antigen titre), then the effect o f MIC was 
reduced further.
Finally, I added the 48 and 72 hour amphotericin and fluconazole MIC data to the 
backward model selection developed in Chapter 3. The model examined the 6 month 
outcome. The coefficients associated with outcome at 6 months were unchanged, and 
antifungal MIC was not associated with an altered hazard for death (table 5.18).
Table 5.18
Final multivariate model for 6 month outcome after including 48 hour MICs of 
amphotericin and fluconazole for all patients with observations on the selected 
covariates (110 patients)
Variable Hazard
Ratio
Lower
95%CI
Upper
95%CI
P
Log2 Cryptococcal Antigen CSF 1.24 1.11 1.38 <0.001
GCS 0.82 0.74 0.92 <0.001
LoglO CSF white cell count 0.47 0.29 0.77 0.003
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5.5 Discussion
There are no published data on antifungal susceptibility testing for Cryptococcus from 
Viet Nam. I used the YeastOne® Sensititre® system to ascertain the susceptibilities of 
over 400 Vietnamese clinical isolates of Cryptococcus grubii and gattii to a panel of 8 
antifungal drugs. I chose the YeastOne® system because it has been shown to have good 
intra- and inter-operator consistency[167, 347]. The gold standard methodology for 
determining the MICs of antifungal drugs for yeast is the CLSI M27A broth 
microdilution method. The purpose of the CLSI methodology is to provide 
standardisation of testing systems between laboratories, and to try to ensure consistency. 
However, its use as a reference standard is problematic, not least because it has limited 
clinical utility[l70, 171, 173, 174, 178, 353-355]. Moreover, while RPMI 1640 broth is 
recommended for the assays, in fact the use o f antibiotic medium 3 (AM3) has been 
shown to be a better medium for determining amphotericin B susceptibilities for both 
Candida and Cryptococcus spp, and is preferred by some centres[l 13]. However, AM3 
is not a standardised medium, and suffers batch to batch and manufacturer to 
manufacturer variation. Different nutrient concentrations and pH are known to affect the 
estimation of MIC [337].The YeastOne® methodology has the advantages of 
consistency of both plate and medium manufacture. Correlation of the YeastOne® 
system with the M27A protocol is considered to be good, although it varies by 
antifungal and species under test (table 5.19). Particularly, agreement for amphotericin B 
and for Cryptococcus species is not as good as for azole drugs and most Candida 
species[163, 167].
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Table 5.19
Percent Agreement (within 2 dilutions) of 48 hour MICs measured by 
YeastOne® Sensititre® and CLSI M27A methods[167]
Antifungal Candida albicans Non -albicans Cryptococcus
Candida spp neoformans
Amphotericin B 97 9 2 - 9 9 76
Fluconazole 60 73-99 98
Flucytosine 56 73-100 96
Itraconazole 54 66-97 96
Ketoconazole 56 66-97 90
Lopez-Jodra reported 73% agreement for C. neoformans between 48hr CLSI 
amphotericin B MIC estimation and 72 hour YeastOne® estimation [334]. Davey found 
89% agreement for C. neoformans between 72 hour CLSI amphotericin B MICs and 48 
hour YeastOne® MICs [163]. Thus, while the CLSI method is regarded as the gold 
standard, its disappointing performance in predicting clinical outcome, other than for 
candidiasis with a limited number of drugs, suggest that methodologies without perfect 
correlation, such as the YeastOne® system, are worth evaluating. Imperfect correlation 
with the CLSI methodology does not necessarily imply redundancy.
5.5.1 MICs of Vietnamese isolates
MICs of drugs were estimable for 92.3 -  92.9% of isolates at 48 hours, and for 99.25 -  
100% of isolates at 72 hours. I found the log2 MICs of the antifungal drugs tested to be 
approximately symmetrically distributed with the exceptions of caspofungin and
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amphotericin B. The result for caspofimgin is not surprising, since Cryptococcus species 
are inherently resistant to the echinocandin drugs.
The MICs of amphotericin B were tightly clustered, with little variation in MIC detected 
using the YeastOne® method. Whether this truly reflects a narrow range of 
susceptibilities of the Cryptococcus population to amphotericin, or is a result of the 
testing system, is not clear. It is known that with the CLSI methodology, use of different 
culture media can result in differences in both the absolute MICs measured and the 
ranges detected[l 13]. However, our results are consistent with other studies [111, 115, 
185, 316, 333, 334, 352, 356, 357]. The susceptibility of Cryptococcus neoformans to 
amphotericin B seems to vary little with geography. Pfaller, using M27A methodology, 
reported MIC 90s of amphotericin of 1 mg/L for over 1800 strains from North 
America, Europe, Africa, the Pacific and Latin America, collected between 1990 and 
2004 [352]. There was no difference by geographical region. Souza reported an MIC 90 
of 1 mg/L for 110 clinical and environmental isolates of C. neoformans from Brazil
[358]. There are fewer data from Asia. Manosuthi reported a MIC90s of amphotericin B 
for Thai Cryptococcus isolates of lmg/L [182]. Sar reported MIC90s of 0.5mg/L for 402 
Cambodian isolates, using the Etest [359]. The Etest has variable agreement with the 
CLSI methodology -  if incubated for 72 hours, then the agreement with CLSI 72 hour 
MICs for amphotericin B is good (99%)[360] However, estimation of the MIC after 48 
hours incubation, as used by Sar, results in a fall o f the rate of agreement to 8.1% [159]. 
Chandenier also used the Etest, but reported 72 hour MICs of amphotericin B for 110 
Cambodian isolates [112]. These were lower, the MIC90 being 0.094mg/L. Tay used the 
ETest (72 hour incubation) and reported MICs of amphotericin B of 0.38mg/L for 48
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isolates (30 C. neoformans and 18 C. gattii) from Malaysia[361], Archibald used the 
YeastOne® system to determine the MICs of 5 antifungals against 65 blood stream 
isolates of C. neoformans from the USA (n = 20), Thailand (n = 29), and Malawi (n =
16) [356]. The MIC90 of amphotericin B after 72 hours incubation was 2mg/L. There 
were no differences between countries.
There are no published data describing flucytosine susceptibility for Cryptococcus 
strains from Cambodia or Viet Nam. The MIC90 of flucytosine for our strains was 
8mg/L at both 48 and 72 hours. The range of results was broad, varying from 0.512 
mg/L to >64 mg/L. Less than half (46.1%) of our strains would be considered fully 
sensitive if the Candida breakpoints applied - for Candida species, an MIC of 
flucytosine o f 8mg/L is considered to represent intermediate susceptibility to the drug. 
An MIC90 of flucytosine of 8 mg/L in clinical isolates is consistent with reports from 
Thailand, Malawi, Democratic Republic of Congo, North America and Northern Europe, 
but MICs of greater than 16mg/L are rarely reported [163, 334, 356]. Decreased 
susceptibility to flucytosine has been reported from Spain, where 46% of strains were 
not susceptible to 8mg/L, but in contrast, in Malaysia, the MIC of flucytosine seems 
markedly lower than elsewhere, reported as 0.023mg/L [361, 362].
Flucytosine is rarely used to treat cryptococcal meningitis in Viet Nam because of its 
cost and lack of availability. Cryptococcosis is generally not considered to be contagious 
-  Cryptococcus species are not primary pathogens of humans but live freely in the 
environment. Thus the relatively high MICs of flucytosine seen are unlikely to be the 
result o f drug-induced selection, but represent some inherent quality of Cryptococcus. 
However, flucytosine resistance is well described in human disease - it can develop
257
rapidly when used as monotherapy [363]. Despite the moderately high MICs, flucytosine 
combined with amphotericin B probably represents the most potent anti-cryptococcal 
therapy currently available (in terms of sterilising power), and there are in vitro data 
suggesting that even in the presence o f frank resistance this combination can be 
potent[99, 364].
The MIC90s of fluconazole at 48 and 72 hours were 8 and 16mg/L respectively. MICs 
across the whole range of drug dilution were detected. Aller has reported that the clinical 
outcome is worse in patients receiving fluconazole maintenance therapy if the MIC of 
fluconazole is > 16mg/L for the infecting strain ref. Over 20% of our strains had MIC’s 
> 16mg/L. However, they used dichotomised rather than continuous variables in the 
determination of significance in their analysis. While dichotomizing may result in a loss 
o f power, and thus failure to show a significance, there is also a risk of falsely attributing 
significance if the cut points are chosen adaptively (i.e. several different cut points are 
tested) [251]. Pfaller reported that North American isolates had reduced fluconazole 
susceptibility compared with those from Africa, South America and Europe[352]. This is 
plausible -  explainable by greater access to fluconazole for treatment/prevention of 
mucocutaneous candidiasis in HIV infected patients, but the spread of MICs described 
are very similar to our experience. Fluconazole primary prophylaxis for HIV patients in 
Viet Nam entered the HIV/AIDS treatment guidelines in 2006; the actual extent of 
prescribing is not known. However, the HIV positive isolates from 2004 onwards were 
all from patients entered into the RCT, for which receipt o f fluconazole primary 
prophylaxis was one of the exclusion criteria. In a small study comparing Malawian,
Thai and American isolates, Archibald found no difference in fluconazole
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susceptibilities[3 56]. Jessup reported MICs of fluconazole for 149 Ugandan isolates, and 
found them to be relatively susceptible, with no isolate requiring more than 16mg/L 
fluconazole for growth inhibition[348]. Susceptibilities reported from Malaysia are 
similar to ours (but using the Etest) [361]. Much higher MICs of fluponazole have been 
described by Sar in Cambodia (MIC90 96mg/L, Etest), and Chandenier found MICs of 
fluconazole to be higher for Cambodian isolates compared with African [112, 359].I also 
found a small number of isolates (39) that may have had reduced susceptibility to 
itraconazole. In general, our isolates were more susceptible to itraconazole than has been 
reported in a large international series, where only 80% were inhibited by lmg/L of drug 
[365]. Itraconazole has been associated with an increased risk of relapse compared with 
fluconazole, perhaps due to its relatively low CNS penetration [366, 367]. MICs of 
posaconazole and voriconazole were all low. The MIC of fluconazole was >64 mg/L for 
5 isolates; all these isolates, which were from HIV infected patients from 2005 onwards, 
had probable reduced susceptibility to itraconazole (MIC 0.256mg/L, considered a dose- 
dependent susceptibility) and flucytosine (8 -  16mg/L, considered intermediate 
susceptibility). The isolates were all baseline isolates from first diagnoses of 
cryptococcal meningitis.
5.5.2 The effect of year and HIV status
Using linear regression I found that (with the exception of posaconazole) the geometric 
mean MICs of all the drugs inextricably rose over the 13 year period. The effect was 
most marked for ketoconazole, and smallest for amphotericin B (although the 
confidence intervals of the coefficients overlapped for each drug). Where the lowess
lines suggested the relationship might not be described by a straight line, I used a natural 
cubic spline to model the effect, and found that it was highly likely that MICs were 
changing over time, including for posaconazole. The actual changes in MIC over the 13 
year period were relatively small (the largest, for flucytosine and ketoconazole, 
representing doublings of the MICs), and thus are unlikely to have any immediate 
clinical consequences. However, if the rise in MICs continues, then given the rates of 
new drug development in diseases that predominantly affect the poorer nations, these 
may eventually have clinical consequences. This rise in MICs over the 13 year period 
suggests that there is a selective pressure somewhere in the environment (clinical or 
extra-clinical) that C. neoformans var grubii inhabits.
I found statistically significant differences in geometric mean MICs of amphotericin, 
flucytosine, fluconazole and ketoconazole by the HIV serostatus of the isolate source 
(table 5.5). These differences were most marked between the HIV positive and unknown 
HIV status groups. As discussed earlier, the isolates in the unknown HIV status group 
are almost certainly from HIV infected patients. These 2 groups spanned different time 
periods. I combined these 2 groups so that I could examine for the effect of year and 
HIV status over the whole time period. After adjusting for year HIV infection was 
associated with reduced susceptibility to flucytosine (geometric mean 1.29 times higher 
than the geometric mean for HIV negative isolates). For the azole drugs, the effect of 
HIV status on MIC estimates was variable, but differences just failed to reach statistical 
significance. However, the effect of year remained significant for all drugs except 
posaconazole. I then found that the impact of time on change in MIC was different for 
isolates depending upon the HIV serostatus of the source for amphotericin B, flucytosine
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and ketoconazole -  for these drugs the rises in MIC were being seen predominantly in 
the HIV patients (figures 5 .55-5 .12). There were only 60 isolates from HIV negative 
patients, which may in part explain the differences seen. There are no published data 
specifically comparing MICs according to HIV serostatus of the isolate source. Again, 
currently the differences I have detected are unlikely to have clinical significance, but 
may point to the patient group in whom drug exposure drives resistance. The extent of 
azole drug exposure in the HIV infected patients prior to diagnosis with cryptococcal 
meningitis is unknown. Flucytosine exposure is extremely unlikely, since it is not 
generally available in Viet Nam and is expensive.
It is unclear why the MICs of the antifungals tested should rise by year. It is
conventional wisdom that infection is acquired from the environment, rather than person
to person. Cryptococcus grubii is ubiquitous; it would seem unlikely that exposure to
medicinal drug is occurring anywhere in the environment sufficient to drive selection. <
Whether cryptococcal meningitis is a result of recrudescence o f latent infection or an
acute event is a matter of debate, although the incubation period can certainly be
prolonged in C. gattii infection [73]. If the same is true for C. neoformans var grubii in
HIV infected patients, then there may be the opportunity for selection of resistance, at
least to azole drugs, through the use of primary prophylaxis or treatment of other fungal ■!
infections. However, the isolates in this series were from first episodes o f cryptococcal
meningitis, and this was frequently coincident with the diagnosis of HIV in our hospital,
so a history of azole prophylaxis would be unlikely. Additionally, this would not explain
the rising MICs of amphotericin B and flucytosine, not generally used in
chemoprophylaxis, whose mechanism of action is different to that of the azole drugs.
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Moreover, in general studies comparing drug susceptibilities of clinical and 
environmental isolates have failed to show significant differences [336, 358, 368]. 
Probably resistant (MIC >64mg/L) environmental isolates of C. grubii have been 
identified in rural and urban Spain, and the development of changing drug 
susceptibilities in sequential isolates from human infection has been described [158, 185, 
369].
However, while exposure to medicinal antifungals in the environment is unlikely, it is 
possible that the evolution of drug resistance in Cryptococcus is driven by the use of 
agrochemicals. Resistance to fungicides might result in cross-resistance to medically 
important antifungals. Numerous non-medical azoles and imidazoles, such as 
ipconazole, difenconazole, hexaconazole, tricyclazole and carbendazin, have been 
developed to control fungal plant pathogens[370]. Of note, these compounds have long 
lasting stability and can remain active in soil and water over many months [370]. The 
use of agricultural azoles has been postulated as a source of resistance to medical azoles, 
and the induction of cross resistance has been demonstrated experimentally in 
Colletotrichum graminicola, a pathogen of both maize and humans [370, 371]. The 
MIC50 of fluconazole for Cryptococcus neoformans isolated from pigeon faeces from 
farms where non-medical azoles have been used extensively have been found to be 
higher than for clinical isolates from the same area in one small study [372], Viet Nam 
has a vibrant agricultural industry -  including rice, vegetables, tropical fruit, ground 
nuts, cashews, pepper, tea and coffee. It is difficult to find data concerning the use of 
such fungicides in Viet Nam, but other agricultural pesticides have been sought and 
detected in ground water both in the north and south of the country [373-375]. Viet
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Nam’s economic restructuring (DdjJM gi) began in 1986, allowing private ownership of 
farms, and economic sanctions with the United States ended in 1994. Over the past 10 -  
15 years these 2 events are likely to have had a significant impact on the growth of the 
Vietnamese agricultural economy and access to agricultural antifungal compounds. 
Changes in antifungal susceptibility over time have not been detected by all 
investigators. Pfaller described global trends in Cryptococcus susceptibility over a 15 
year period (1990 to 2004) in 1811 isolates [352]. No trend was found over time, 
although the isolates were collected from over 100 different institutions around the 
world, and how each institution contributed temporally to the collection is not clear, 
which may have led to bias, particularly if trends in susceptibility vary by geographical 
area. Isolates were stored as water suspensions. Brandt also reported no significant 
change in MIC90s over a 6 year period in 522 isolates from the USA. However, no 
comparison was made of geometric means, and no statistical tests were applied to the 
data [185]. Davey reported no significant change in MIC90s of fluconazole in 220 UK 
strains o f C. neoformans, but again no formal statistical testing was used [376]. 
Conversely, a decrease in susceptibility over time has been reported in a short period 
from Cambodia, where the MIC 90 of fluconazole rose from 12 to 96 mg/L over 2 years
[359]. Isolates in this case were stored at -20C in 20% glycerol. Aller reported a fall in 
fluconazole MIC90s in Spain between the periods 1994-1996 (23 isolates) and 1997 -  
2005 (47 isolates); why this curious time distribution in this small study is chosen is not 
explained [377], I used a linear model to define the effects of time and HIV on 
antifungal susceptibility. I reported the geometric mean as well as MIC50s and MIC90s 
-  the geometric mean is a measure that has increased resolution compared to MIC50s
and 90s. Moreover I looked at the influence of time over the whole period rather than 
arbitrarily dichotomizing isolates into groups. I found that over 13 years there were 
statistically significant changes in this measure. These findings are consistent with the 
findings in another Southeast Asian country -  Cambodia, and thus may be real. Changes 
in geometric mean may serve as early warning markers of decreasing pathogen 
susceptibility.
Finally, it might be that the rise in MICs is a function of storage of the isolates, and that 
isolates become more susceptible as they age. This has not been reported for 
Cryptococcus, or other yeasts, and would be difficult to explain biologically since the 
isolates are frozen and therefore presumably inert. This question could only be answered 
prospectively.
5.5.3 Effect of Species
All but 16 isolates were identified as Cryptococcus grubii molecular group VN1, using 
URA5 PCR-RFLP as previously described. The remaining 16 isolates were 
Cryptococcus gattii (14 URA5 PCR-RFLP molecular group VG1 and 2 molecular group 
VG2). The geometric mean MICs of amphotericin B and flucytosine were lower for the 
C. gattii strains compared with the C. grubii. I detected no significant differences for the 
azole drugs. Again, this is unlikely to be the result of drug pressure. The differences 
between the antifungal susceptibilities of C. gattii and C. neoformans are not clear. Most 
comparative series, like mine, have small numbers of C. gattii. Initially, no differences 
were found [378]. C. gattii from both clinical and environmental sources has been 
reported to be associated with reduced susceptibility (higher geometric mean MICs) to
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antifungal drugs, including amphotericin, flucytosine and fluconazole [68, 124, 379, 
380]. Our experience, although limited by small numbers, is consistent with reports from 
Spain and Malaysia, and Thailand [361, 381, 382]. It may be that susceptibility of C. 
gattii varies by geographical area; however, reports have been contradictory even from 
within small well-defined geographical areas [379, 381]. Treatment guidelines for 
patients with C. gattii are influenced by the larger body of evidence relating to C. grubii 
/ neoformans. Given this, the lack of strong evidence of clinically meaningful reduced 
susceptibilities of C. gattii is reassuring.
In chapter 4 using AFLP I identified a clade of Cryptococcus grubii which may be more 
able to cause disease in HIV uninfected patients, suggesting relatively increased 
virulence compared with the whole C. grubii population. It is reassuring that I found no 
difference in the antifungal susceptibility of these strains compared with the general 
population.
5.5.4 Prediction of MICs.
The rate of difference between 48 and 72 hour MIC for all the drugs tested was high. 
Using linear regression I was able to predict the 72 hour MICs of all the antifungal drugs 
with high accuracy (to within 1 fold dilution) -  99.5% for amphotericin B, 98.6% for 
flucytosine and 97.8% for fluconazole. However, around 8% of strains have no 
discernible growth at this stage, but can still have what might be considered reduced 
susceptibility at 72 hours. The 72 hour results for these 32 isolates are shown in table 
5.20. Isolates with potentially reduced susceptibility are marked in bold. Whether it is 
worth trying to predict 72 hour MICs from 48 hour MICs would depend upon whether
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the 72 hour MIC has more clinical value than the 48, and whether a clinical intervention 
24 hours sooner (such as dose modification or change of drug combination) has any 
clinical benefit.
I used linear regression to try to predict the MICs of itraconazole, posaconazole and 
voriconazole from the fluconazole MIC. Since they are the same class of drug, with the 
same mechanism of action (inhibition of sterol synthesis), then it is reasonable to assume 
there may be a predictable relationship between drug susceptibilities. If it is possible to 
predict the MIC of one drug from another, then there are potential cost savings.
Prediction accuracy to within a 1 fold dilution was reasonable for voriconazole and 
posaconazole (94.5 and 96% respectively), but was less good for itraconazole (90.2%). »
The error rate for a difference of 3 or more dilutions for itraconazole predictions was 
1.5%. It may be reasonable to predict other azole drug MICs for Cryptococcus based on i
the YeastOne® fluconazole result, at least if the fluconazole MIC is of a value where a i
prediction error is unlikely to define erroneous sensitivity to the other azoles. This has i
been suggested as a strategy to identify Candida spp susceptible to posaconazole, where 
fluconazole and voriconazole MICs (using the M27A methodology) predict the MIC 
with an accuracy similar to that which I have described [383].
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Table 5.20.72 hour M ICs, ug/mL, o f 4 antifungal drugs for 32 isolates where there was 
insufficient growth at 48 hours for estimation.
Isolate* Am photericin Flucytosine Fluconazole Itraconazole
1 0.512 8 16 0.256
2 0.512 4 8 0.128
3 0.512 4 8 0.128
4 0.512 8 2 0.004
5 0.512 16 16 0.016
6 0.512 8 4 0.032
7 0.512 4 4 0.064
8 1.024 . ;;:':;4 ^ : 16 0.128
9 0.256 8 1 0.004
10 1.024 2 16 0.128
11 0.512 8 16 0.064
12 0.064 8 4 0.032
13 0.512 8 32 0.512
14 1.024 16 32 0.256
15 0.512 4 0.125 0.004
16 0.512 8 4 0.064
17 0.512 2 4 0.032
18 0.256 2 2 0.032
19 0.512 8 4 0.064
20 0.512 0.96 16 0.032
21 0.512 8 16 0.256
22 1.024 2 2 0.128
23 0.256 4 8 0.064
24 0.512 0.96 4 0.032
25 0.512 2 1 0.004
26 0.512 4 4 0.004
27 0.512 4 8 0.016
28 0.256 2 16 0.064
29 0.256 4 4 0.128
30 0.512 2 4 0.016
31 0.128 0.032
32 0.064
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5.5.5 Effect on CSF sterilisation
We examined the effect of amphotericin B MIC on the rate of decline of yeast colony 
forming units in CSF over the first 28 days of therapy. Rates o f decline in fungal 
quantitative count in CSF have been pioneered by Harrison and colleagues as a potential 
investigative tool for comparison of antifungal therapies in cryptococcal meningitis [99, 
138, 186, 205]. Sampling CSF on 4 set occasions over the first 2 weeks of treatment 
(days 1 , 3 , 7  and 14), they have demonstrated differences in the rates of decline of yeast 
colony forming units according to the treatment given[99]. They report declines in 
viable yeast counts in CSF of 0.31 logio - 0.45 logio CFUs/day over the first 14 days of 
therapy in patients receiving amphotericin B 0.7mg/kg/day monotherapy and 0.56 logio 
for patients receiving 1 mg/kg/day [99, 137]. This compares with the fall of 0.32 logio 
CFUs/day seen in the patients in this study, who were receiving 1 mg/kg/day. The 
Vietnamese patients had significantly higher baseline yeast burdens than the patients 
reported by Harrison’s colleagues, which has been associated with lower rates of 
clearance [99, 137]. More recently, Bicanic analysed a combined dataset o f 262 of their 
patients drawn from randomized controlled trials, non-randomised trials and case series, 
to investigate the influence of the rate of yeast clearance on outcome [138]. In a 
multivariate model including altered mental status at baseline, baseline fungal count and 
the rate of clearance of infection, all 3 factors were independently associated with 
mortality. Each 0.1 log 10-unit decrease in the rate of clearance in fungal load was 
associated with an increase in the hazard ratio for death of 1.34 (95% Cl 1.06 -  1.68, p = 
0.01) at 2 weeks and 1.18 (95% Cl 1.04— 1.33, p = 0.008) at 10 weeks. However, when 
the serial colony-forming unit counts were fitted as a time dependent variable, after
adjusting for baseline fungal load and mental status, an increase in the hazard ratio for 
death was seen only at 2 weeks (HR 1.82, 95%CI 1.12 — 2.96; p=0.007 at 2 weeks 
versus HR 1.13, 95%CI 0.65 -  1.32; p=0.14 at 10 weeks, for each unit increase in the 
last log 10 colony forming unit count) [138]. The combination of patients from outside 
clinical trials may have introduced bias onto this analysis. In particular, data were used 
from an observational study of 54 South African patients where the Glasgow Coma 
Scores determined treatment - all those with scores > 10 received amphotericin B, those 
with scores less than 10 received fluconazole 400mg/day monotherapy[205]. This 
treatment allocation reflected a conception that patients with coma scores less than 10 
had very poor prognoses, and therefore did not receive amphotericin which was in short 
supply. It is conceivable that this bias may have lead to difference in other aspects of 
care with adverse consequences. Sixty patients were recruited from a trial of differing 
doses o f fluconazole in Uganda[384]. The treatment allocation was not randomized. 
There were some differences between the patients in my study and those analysed by 
Bicanic. Unlike Harrison’s group, I sampled patients over the first 4 weeks of therapy, 
and looked at 6 month outcome. Notably, the median CSF yeast count at baseline in our 
patients is 10 fold higher (log 10 6.02 vs. log 10 5.4) CFU/ml, and the median CD4 
counts in our patients were lower, (median 14.5 versus 26 cells/uL). The higher fungal 
burden at baseline in our patients suggests our patients may have been generally more 
severely unwell than those in Harrison’s combined analysis.
For our data, an extended model best explained the rates of decline. We did not show 
any effect of the rate of decline of fungal cell count on the hazard for death at 6 months. 
Modelling the data at an earlier time point (such as 2 or 4 weeks) is methodologically
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difficult, since my study size is small and there are insufficient events (deaths) by these 
time-points.
We failed to show an association between amphotericin B MICs measured at either 48 
or 72 hours and the rate o f decline in yeast count. However, the range of amphotericin B 
MICs, as described earlier, was narrow. It is feasible that the yeast count methodology is 
insufficiently sensitive to detect differences in decline due to small changes in MIC. As 
would be expected, we found no association between fluconazole susceptibility and the 
rate of decline in fungal count - no patients were receiving fluconazole during the first 4 
weeks of treatment. In the future we will perform these analyses on a larger dataset.
5.5.6 Clinical Outcome
The clinical impact of yeast sensitivity testing has been disappointing in cryptococcal 
meningitis. Aller reported a small series (25 patients) in whom an MIC of >16mg/L was 
associated with therapeutic failure[183]. Therapeutic failure was defined as positive 
cultures at 10 weeks or at the time of death. Only 5 patients had therapeutic failure, and 
the small study size precluded robust statistical analysis, but those patients who died had 
higher cryptococcal antigen titres, which I have found to be the most powerful 
prognostic indicator, and were more likely to have had previous cryptococcal meningitis. 
In addition, as mentioned before, the MICs were dichotomised for analysis.
Bicanic reported 21 culture positive cryptococcal meningitis relapse patients who had 
previously been treated with fluconazole monotherapy. 14 of 21 isolates had probable 
fluconazole resistance, with MICs of fluconazole of > 64mg/L [195]. All patients were 
retreated with prolonged courses of amphotericin. Seven of the patients with resistant
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isolates died within 6 months of follow-up. The time of death in relation to the 
administration of amphotericin B is not described (i.e. it is not clear whether the patients 
died during retreatment with amphotericin). No isolates were available from the first 
episode of illness, so the antifungal susceptibilities at first presentation are not known. 
Thus it is not known whether these relapses would have been predicted by MIC testing 
at first presentation.
Witt reported 76 patients of whom 19 had therapeutic failure [349]. In a multivariate 
analysis, of 3 variables (presence of positive blood culture, flucytosine therapy and 
fluconazole MIC), the MIC of fluconazole was the least significantly associated with 
therapeutic failure (p=0.012, 0.011 and 0.039 respectively). When the serum 
cryptococcal antigen titre was used as a covariate instead of blood culture result, the 
MIC of fluconazole lost statistical significance (p=0.003, 0.005 and 0.054 respectively). 
Fluconazole MICs were measured using the M27A methodology. Conversely, numerous 
large studies have failed to show a relationship between antifungal MICs and outcome in 
cryptococcal meningitis [114, 161, 182, 348]. This contrasts with severe candidiasis, 
where the majority of studies have shown the MICs of antifungals to have some 
prognostic value [171, 173, 175, 177-180, 385]. I examined the association of antifungal 
MIC in a subset of patients (124) for whom we had extensive clinical and outcome data 
(Chapter 3). I had identified fungal load, estimated by either CSF viable yeast count or 
CSF cryptococcal antigen titre, as the factor most highly associated with an increased 
hazard of death. All the patients were treated with amphotericin B followed by 
fluconazole. Neither 48 hour nor 72 hour MICs of amphotericin B or fluconazole had 
any impact on the hazard for death at 10 weeks. I also analysed the effect of
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amphotericin B MIC on the hazard for death at the 7, 14 and 28 day time points, 
assuming that early deaths may be more likely to be due to lack of effective yeast 
killing. I failed to show a statistically significant association, although the coefficient for 
the hazard declined plausibly over the 4 week period, from 3.44 (p = 0.07) at 7 weeks to 
1.141 at 28 days for the 48 hour estimation. Interestingly, the 72 hour MIC estimation 
had no impact on the hazard for death. After correcting for fungal burden (using 
cryptococcal antigen titre in CSF), the size of the effect of the amphotericin B MIC (if 
any) was further reduced. The early predictive effect of 48 hour amphotericin B MIC 
needs to be reassessed in a larger dataset. It might be that there is a subset of patients 
who clear yeast slowly in whom I have missed an effect.
In summary, using the YeastOne® method I could detect changes in MIC over time, by 
HIV serostatus and by species for different antifungals, but I was unable to relate MICs 
to the rate o f CSF sterilization or the clinical outcome, although the results for 48 hour 
amphotericin B suggest that this should be evaluated in a larger dataset.
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Chapter 6 
Discussion
The aim of this thesis was to address the following questions:
1. Is the clinical phenotype of cryptococcal meningitis influenced by HIV 
infection?
2. What are the prognostic factors in cryptococcal meningitis?
3. What is the molecular epidemiology of human isolates of Cryptococcus 
neoformans in Viet Nam, and is this influenced by HIV serostatus?
4. Has the antifungal susceptibility of C. neoformans changed over time, do the 
susceptibility profiles of C. neoformans differ by infecting variety and immune 
status of the host, and what is the clinical utility of antifungal sensitivity testing 
in cryptococcal meningitis.
The extent to which these questions have been answered will now be discussed.
6.1 Clinical Phenotype and Prognostic Factors
I first compared the literature on the clinical phenotypes of patients by HIV infection 
status. From randomised controlled trials and descriptive studies I found clinical data 
describing a total of 2204 patients. Concatenating the data from these individual studies 
suggested that there were indeed some differences in clinical presentation according to 
HIV serostatus. Neck stiffness, confusion, focal neurological signs, visual impairment
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and nausea and vomiting were all more common features of disease in HIV uninfected 
patients. However, within each group (HIV infected or uninfected) I found that the 
patient populations were highly heterogeneous. In particular, the patients in van der 
Horst’s study, the largest ever randomised controlled trial in cryptococcal meningitis, 
and the study which forms the basis for the published treatment guidelines, had low rates 
of headache and fever compared with other study groups, suggesting that this patient 
population was significantly different to most other reported HIV infected patient 
populations with cryptococcal meningitis. As has been mentioned earlier, these patients 
seem to have had less severe disease than most patients with cryptococcal meningitis, 
probably as a direct result o f the inclusion and exclusion criteria for the study. This is 
mirrored in the relatively low death rate o f around 10%. Other reports of cryptococcal 
meningitis from the USA have reported higher death rates more in keeping with 
experience elsewhere [100, 142].
Within the HIV uninfected patients, again, marked heterogeneity was seen between the 
study populations. This is perhaps easier to explain - most reports of cryptococcal 
meningitis in HIV uninfected patients are from populations with a diverse range of 
immunosuppressing conditions including haematological malignancy, solid organ 
transplantation, connective tissue disorders and treatment with a wide range of 
immunosuppressive drugs. In addition some studies include patients with C. gattii 
infection.
3
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The heterogeneity in both the HIV positive and HIV negative study populations means 
that it is methodologically problematic to concatenate their data, and the differences that 
appear to exist between clinical phenotypes cannot be considered reliable. In addition it 
can be argued that this heterogeneity means that it is difficult to extrapolate results of 
randomised controlled trials from one patient population to another, and underlines the 
importance of minimising exclusion criteria in order to ensure that the results of clinical 
trials remain applicable to the general population. In the recent Cochrane review of 
treatment of cryptococcal meningitis, there was no attempt made to define inter-study 
population heterogeneity [386]. One conclusion drawn by the authors is that a difference 
in mortality between North American patients and those elsewhere in the world is due to 
different management of raised intracranial pressure [107, 386]. However, studies from 
less well resourced settings, such as Thailand, Papua New Guinea, and my experience 
presented here have found that raised intracranial pressure at baseline is not 
independently associated with outcome, suggesting that even in resource poor areas this 
common complication can be managed appropriately [62]. Different severities of disease 
at presentation may better explain differences in mortality rates between studies than 
management of raised intra cranial pressure, although access to treatment other than 
azole drugs is likely to be the most important factor.
At the Hospital for Tropical Diseases, cryptococcal meningitis in both HIV infected and 
HIV uninfected patients is seen. I investigated the impact of HIV on the clinical 
presentation of cryptococcal meningitis by comparing baseline historical, clinical and 
investigation findings between 2 cohorts of patients, which differed by HIV infection
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status. With the exception of disease due to C. gattii, the clinical phenotype of 
cryptococcal meningitis in HIV uninfected patients is frequently complicated by 
underlying disease with its own significant morbidities and mortalities, and this 
complicates any determination of the effect o f HIV on clinical presentation. At HTD, 
cryptococcal meningitis in HIV uninfected patients is of particular interest on two 
counts; first, most patients (81%) have no underlying disease. Of eleven patients with 
co-morbidities, the most frequent predisposing factor was corticosteroid use in 7 patients 
(one with SLE, two with nephrotic syndrome, 2 with unclassified chronic arthritides and 
two with Evan’s syndrome). Of the remaining patients, 2 had cirrhosis, one had cirrhosis 
and renal impairment, and 1 had diabetes mellitus. Whether diabetes mellitus 
predisposes to cryptococcal disease is not clear [4, 387]. The diseases seen in this series 
arguably have less impact on immune function compared to haematological malignancy 
and its therapy, and the drugs used in organ recipients. While cirrhosis, SLE and 
diabetes can all cause CNS complications, their frequency in the cohort was low. 
Secondly, as I found in Chapter 4, most HIV uninfected patients (75%) have disease due 
to infection with C. neoformans var grubii, the commonest cause of disease in HIV 
infected patients and worldwide. To define the impact of HIV on cryptococcal 
meningitis ideally requires a comparator group of HIV uninfected patients, from a 
similar patient population (i.e. the same geographical area and ethnic group), without co­
morbidities, and infected with the same species of C. neoformans. Thus, while my 
comparison was not perfect, the HIV negative cohort was closer to fulfilling these 
requirements than many other studies. I could have excluded patients with underlying 
disease, or C. gattii infection, but the power o f the comparison would have been
reduced. In the future, as more HIV uninfected patients are diagnosed, it may be possible 
to repeat this analysis excluding the C. gattii cases and those with pre-existing co­
morbidities.
I found that there were differences in the demographics between the HIV infected and 
uninfected patients, reflecting the demographics of the AIDS epidemic in Viet Nam, 
which is predominantly a disease of young male injection drug users. Duration of 
symptoms was shorter in HIV infected patients, headache was more frequent, and 
papilloedema less common, but otherwise there were few differences in the disease 
presentation by HIV serostatus. Laboratory investigations were suggestive of 
differences in the degree of inflammation within the CNS, and fungal burden was higher 
in the HIV infected patients.
The mortality was significantly higher in HIV infected patients. However, the shapes of 
the Kaplan-Meier curves were similar for both groups of patients, with most deaths 
occurring within the first 4 weeks of treatment. This suggests that in the HIV patients 
most deaths are accounted for by C. neoformans, rather than other opportunistic 
infections. It is not possible to say whether the exact causes of death (for example, 
failure of sterilisation, persistence of raised intracranial pressure) are the same between 
the groups, and this will be an area for future study.
A plethora of prognostic indicators have been defined for cryptococcal meningitis, 
which is probably a reflection of the research methodologies used. Prognostic factors 
have been derived from prospective descriptive studies, randomised controlled trials and
retrospective case series. Without predefined hypotheses concerning the prognostic 
factors, and with testing of multiple variables, there is always the risk of defining false 
associations. My work is the first systematic assessment of previously defined 
prognostic factors in cryptococcal meningitis. Of over 40 identified factors only six 
retained prognostic significance on univariate analysis. Interestingly, most factors found 
to be predictive of outcome at 10 weeks were also predictive o f outcome at 6 months. 
More variables retained prognostic significance for the HIV uninfected cohort.
The multivariate analysis identified 5 factors associated with outcome at 6 months. 
Those most highly associated with outcome were the cryptococcal burden (indicated by 
the antigen titre), the Glasgow Coma Score, and the CSF white cell count, all of which 
are biologically plausible, and relatively simple to measure. Future work will include 
determining whether these factors can be combined into a score in order to be able to 
assign patients to prognostic groups at presentation, similar to the Medical Research 
Council (UK)’s grading system in tuberculous meningitis [129].
6.2 Molecular Epidemiology
I was interested in how Cryptococcus strains from HIV uninfected patients related to 
those from HIV patients. I found that almost all cryptococcal meningitis in Viet Nam is 
due to infection with one URA5IRFLP molecular subtype of C. neoformans var grubii. 
Despite our tropical location, and the widespread presence of eucalyptus trees, infection 
with C. gattii is extremely rare.
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I used AFLP to define the relationships of the strains. AFLP has the advantages of being 
a whole genome based typing system with high resolution, and does not require any 
prior knowledge of genome sequence. A disadvantage of AFLP is that it there is an 
inbuilt variability rate due to experimental factors that cannot be completely eliminated, 
and unlike a sequence based method, cannot necessarily be detected. The consistency I 
achieved in re-typing single isolates, o f between 95 and 98%, compares favourably with 
the literature [246, 388, 389].
I used 2 primer sets, and each primer set identified a clade of C. neoformans var grubii 
with increased propensity to infect HIV uninfected patients. The structures of the trees 
were well supported with high cophenetic correlation values at the nodes defining 
clades. However, when I assigned band classes to the data, I was unable to demonstrate 
reliable nodes defining clades and sub-clusters using a bootstrap analysis. This is most 
likely because the strains are very closely related, and the differences between strains are 
defined by a large number of infrequent bands. Using a band-based analysis resulted in 
significant loss of information, and reduced resolution of the AFLP typing. This is not 
particularly concerning, because the defining of band classes is essentially arbitrary and 
open to operator bias.
Prior to this work, the hypothesis that disease in HIV uninfected patients might be due to 
infection with a sub-type of Cryptococcus neoformans of increased virulence was met 
with some scepticism, the dogma being that disease risk is determined by immune status 
[4, 64]. It is obvious, thanks to the HIV epidemic, that immune status is extremely 
important in determining the risk of disease due to Cryptococcus neoformans in most 
cases [1]. However, my work suggests that there is a clade of Cryptococcus neoformans
var grubii that has increased propensity to cause disease in immunocompetent patients. 
This clade cannot be dominant in the environment, since it is less common in HIV 
infected patients than other C. neoformans var grubii strains. The situation is analogous 
to that seen with Cryptococcus gattii. It is clear that this pathogen occurs in areas where 
there is a high incidence o f HIV infection, yet overt disease is rare [70, 85, 87, 259]. It 
seems more plausible that the frequency of disease in the HIV infected is low because a 
disease producing exposure to the pathogen is rare, rather than disease only being able to 
occur when there is also some other undefined immune deficit present. Whether the 
clade I have identified occupies a particular environmental niche is not clear, but it 
seems likely that its increased pathogenicity is a by-product of some adaptation to its 
environment. Identifying its ecological niche would be an interesting project and may 
form part of future work.
I have not been able to answer the question whether infection with the newly identified 
clade is associated with an increased risk of death or severe disease. However, I expect 
to be able to answer this question in the future, when a trial I am running in 300 patients 
with cryptococcal meningitis is completed (ISRCTN95123928, http://www.controlled- 
trials.com/ISRCTN95123928/farrark It may be that this clade is better able to establish 
infection in the first instance and, once established, disease has a similar phenotype to 
disease in C. gattii infection or in HIV patients. An increased ability to establish 
infection might simply be due to increased production of basidiospores (and thus a 
higher infective dose), or adapted basidiospores that are better able to withstand host 
immunity or invade mucosal epithelium. Alternatively, the clade may be rare in the 
environment, but undergo mating behaviour more frequently. Understanding the
prevalence of the clade in the environment in relation to other clades would help answer 
this question.
The clade may also be more pathogenic in the sense that it can cause more severe 
disease. My preliminary data do not support this -  fungal burdens in patients were no 
different by clade, although complicating the data there were more underlying diseases 
in patients affected with clade 2 isolates. Interestingly, in the HIV negative patients for 
whom clinical clade data were available, clade 2 isolates only occurred in those with 
underlying disease. A more sophisticated analysis, when more data are available, is 
needed.
Sequence based typing methods, such as multi locus sequence typing (MLST), have the 
advantage of being rather more verifiable than band based methods, where homoplasy 
reduces discrimination. In addition, the evolutionary relationship between strains can be 
better defined. I have begun 7 locus MLST typing of the isolates to confirm the findings 
of the AFLP typing [305]. If this is successful, I will develop a PCR to enable rapid 
identification of strains from clade 1. This should also help determine whether clade 2 is 
monophyletic, as suggested by the GT primer derived tree, or whether there are a 
number of other clades circulating.
The identification of the clade offers interesting possibilities to improve the 
understanding of the pathogenicity of C. neoformans. The first step would be whole 
genome sequencing of representative strains from each clade to determine the degree of 
diversity within the clades. The arrival of the latest generation sequencer platforms
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would enable this to be done at reasonable cost. A platform such as the 454 (454 Life 
Sciences, Branford, Connecticut, USA) could be used to assemble the genomes from 1 
or 2 representative isolates from each clade, and then a more economic platform, such as 
SOLiD (Life Technologies, Carlsbad, California, U S A ), could be used to sequence the 
remaining strains and determine the intra-clade diversity. The ultimate purpose of 
sequencing would be to better understand how Cryptococcus causes disease. Yeasts are 
complicated pathogens which alter their gene expression depending upon their 
environment. For example, Cryptococcus neoformans rarely produces significant 
capsule if grown on Sabouraud’s agar. Thus in vitro experiments are probably a poor 
model o f cryptococcal pathogenicity, and may be misleading. Similarly, the mouse 
model is one o f disseminated rather than central nervous system infection, and again is 
not necessarily extrapolable to human disease [390-392], However, the mouse model 
does seem to be able to reliably detect changes in virulence of mutant knockouts of 
previously identified virulence factors [393]. Because in cryptococcal meningitis 
Cryptococcus is found in significant numbers in cerebrospinal fluid, using next 
generation sequencing technology it will be possible to determine quantitative gene 
expression in human CSF. This offers the chance to confirm or refute the results of in 
vitro and animal work on virulence, to identify new virulence factors related to 
particular clinical phenotypes, and to identify new drug targets. Gene expression, 
through RNA sequencing, could be compared according to infecting species, clade and 
HIV serostatus. I plan to take this research forward through a fellowship application.
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6.3 Antifungal Susceptibility
The value of antifungal sensitivity testing in cryptococcal disease is unclear. Potential 
uses of susceptibility testing include surveillance - early warning of falling 
susceptibilities in the population prior to the development of frank resistance - and as an 
aid to treatment selection (both drug and dose) in individual patients. The value of any 
susceptibility testing method ultimately depends upon how accurately it models 
pathogen growth within the human host. So far, antifungal susceptibility testing of 
Cryptococcus neoformans has had little tangible benefit for patients.
In the first instance, I wanted to determine whether the susceptibility of Cryptococcus 
neoformans was changing with time, and whether there were differences in 
susceptibility by species and by the patient population from which the isolate came. Due 
to the spread of the HIV epidemic, and increased use of azoles for non-cryptococcal 
disease in these patients, it was feasible that there would be differences in susceptibility 
to these drugs over time, and by patient group. Additionally, I wanted to determine 
whether susceptibilities measured by the YeastOne method correlated with outcome.
American studies have found no changes in the MICs of Cryptococcus neoformans over 
the years [352]. I found that, as measured by the geometric mean MICs of a panel of 
antifungal drugs, Cryptococcus neoformans var grubii is becoming less susceptible to 
key antifungals of all classes year on year. Currently, this is unlikely to have clinical 
significance, since the MIC90s of the drugs are still comfortably within the therapeutic 
range. However, this phenomenon suggests that there is a selection pressure occurring 
somewhere within the environment of C. neoformans. This pressure, as discussed in
Chapter 5, could be present either within patients, particularly if cryptococcal meningitis 
truly represents recrudescence of latent infection, or somewhere within the natural 
environment that C. neoformans inhabits.
Cryptococcal meningitis is coincident with the diagnosis of HIV infection for most 
patients in our hospital. Thus it seems unlikely that exposure to azole drugs is occurring 
within the patient. It is also unlikely that decreased susceptibility is due to infection of a 
patient with a strain that has been previously exposed to drug within anther patient -  
cryptococcal meningitis is not thought to be contagious. It is not impossible that drug 
exposure is occurring in patients on long term suppressive therapy within sanctuary sites 
that then have access to the environment. For example, the prostate is a recognised site 
of asymptomatic infection with C. neoformans [147]. Viable yeast could presumably be 
shed in the urine and re-enter the environment. However, Cryptococcus neoformans is 
ubiquitous. It seems more likely that there is exposure to azole-type drugs occurring 
somewhere in its primary environment. In Viet Nam, this is plausible. As we have seen, 
numerous azoles are used in agriculture to control fungal pests. Viet Nam has a large 
and vibrant agricultural sector. The use o f chemicals in farming in Southeast Asia is 
believed to be widespread — Taiwan, Korea and Japan have recently banned the 
importation of Chinese fruit and vegetables because of such concerns 
(http://www.associatedcontent.com/article/625003/), and there is sufficient concern 
within Viet Nam such that there is now a fledgling indigenous organic movement 
(although whether this has health benefits is a moot point). Regulation and enforcement 
o f the use of agricultural chemicals is difficult in Viet Nam, because most tropical fruit, 
nut and rice production is done by small farms and smallholdings. There are already
experimental data that suggest that exposure of shared plant/human pathogens to 
agricultural azoles can result in reduced susceptibility to medicinal azoles [371]. 
Furthermore, the use of azoles on farms has been associated with the recovery of 
Cryptococcus neoformans from bird guano with reduced susceptibility to medical azoles 
in Brazil [372]. It would be interesting to see if this work could be repeated in Viet Nam.
Why the susceptibility of C. neoformans var grubii to amphotericin B and flucytosine is 
also decreasing might seem more difficult to explain. Amphotericin B binds to sterols in 
the fungal cell membrane. Production of these sterols is inhibited by azole drugs. The 
mechanisms of action of the drugs are thus linked, and therefore it is feasible that some 
adaptation that confers azole resistance may also impact upon the efficacy of 
amphotericin, whether that is reduced binding sites for the drug or reduced affinity. In 
fact, altered sterol metabolism has been shown to confer cross resistance between 
fluconazole and amphotericin B in both Candida albicans and Cryptococcus neoformans 
isolates from humans [394, 395].
It is less obvious, but also feasible, that azole resistance, and therefore azole exposure, 
can be linked to flucytosine resistance. It has been shown in clinical isolates of Candida 
lusitaniae that mutations in the FCY1 and FCY2 genes that encode purine -cytosine 
permeases result in cross-resistance to flucytosine and fluconazole [396-398]. This has 
not yet been described in Cryptococcus neoformans, but warrants investigation.
I did not demonstrate changes in C, gattii MICs over time. The number of C. gattii 
isolates was small, and thus I had very little power to show a change if present, but it is
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also likely to be rare in the environment and thus have less instances of exposure to drug 
pressure. C. gattii appeared to be more susceptible to amphotericin B and flucytosine 
than C. neoformans var grubii. This is similar to reports from Malaysia [361].
I could find no differences in drug susceptibility by C. neoformans var grubii clade other 
than for posaconazole.
These analyses made a large number of comparisons. The changes in MIC over time, 
while not yet clinically significant, are convincing in that there are consistent trends for 
several drugs. However, given the number of comparisons made, some of the differences 
detected may be the result o f chance. The finding of decreased susceptibility of clade 1 
isolates to posaconazole seems likely to be such a spurious finding, given that there are 
no differences between susceptibilities to other drugs, and the p value is only 0.04.
Only flucytosine susceptibility seemed to be associated with the HIV serostatus o f the 
isolate -  flucytosine MICs were higher in HIV associated cases. There was no such 
association for amphotericin or any azole drug.
Despite there being many methodologies now available which can reproducibly describe 
the MIC of a drug against a particular cryptococcal isolate, measuring antifungal 
susceptibility has not been shown to correlate consistently with clinical outcome. The 
exception is azole susceptibility in relapse isolates. The prognosis of relapsed patients is 
poor, but it has proved difficult to define this group of patients at baseline with 
sensitivity testing. Given the fact that azole resistance is potentially linked to cross­
resistance to both amphotericin and flucytosine, the ability to predict azole failure may 
have important utility in defining a group of patients who should receive a longer initial
286
duration of therapy with amphotericin and flucytosine, particularly if the period of 
treatment where cross resistance is selected is the azole phase of treatment. The 
probability of developing/selecting resistance depends upon the size of the population. 
Initial therapy that has a greater effect on reducing the biomass of pathogen in the CSF 
and brain may be key in reducing the risk of treatment failure.
I used two measures to assess the usefulness of MICs of antifungals as determined by 
YeastOne in determining outcome -  the rate o f clearance of fungal load, and survival. I 
found that the decay of yeast CFUs within the CSF over 28 days was best defined by a 2 
phase model. I was unable to detect a difference in the rate of decline of yeast CFUs in 
CSF according to amphotericin MIC. I also tested the effect of fluconazole MIC on the 
rate of decline and, perhaps as expected since no patients were receiving this drug, no 
effect was seen. The model had over 200 data points from 63 patients. If the effect of 
amphotericin MIC is small, then I may have missed an effect. Future work will include 
measuring the effect of fluconazole and flucytosine susceptibilities on fungal decay in 
patients receiving those treatments.
Finally, I looked at survival in relation to drug susceptibility. I could find no alteration in 
the hazard for death at 70 days depending upon the isolate susceptibility to 
amphotericin, fluconazole or flucytosine. However, when I examined the effect o f 48 
hour amphotericin MIC estimation at days 7, 14 and 28, it appeared that there might be a 
relationship between amphotericin susceptibility and the hazard for death. The results 
did not reach conventional levels o f significance, but the work needs to be repeated on a 
larger dataset, which is planned. O f note, most protocols recommend estimating the
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amphotericin MIC for Cryptococcus isolates after 72 hours incubation. The MIC 
measured at this time point had no relationship with the hazard for death.
6.4 Concluding Comments
The burden o f cryptococcal disease is huge, and concentrated in poorly resourced 
countries. While the vast majority of cases occur in HIV infected patients, disease is not 
limited to this group. The development of increasingly effective immunosuppressive 
treatments to manage chronic inflammatory disease and organ transplantation, and the 
ubiquity of C. neoformans means that disease in the HIV uninfected will always be 
present. It is not only the immunosuppressed who are at risk - the British Columbia 
outbreak has demonstrated that C. gattii can establish itself in new environmental niches 
and cause significant disease.
Despite the large numbers of cryptococcal meningitis patients, and the failure of any 
major advance in treatment since the advent o f fluconazole, there is little concerted 
effort to run randomized controlled trials powered to clinical endpoints. The last trial 
powered to clinical endpoints was that of van der Horst, published in 1997.1 have shown 
in this thesis that the populations of patients with cryptococcal meningitis are highly 
heterogeneous, and therefore we cannot necessarily extrapolate results from one patient 
group to another. There is a need to continue clinical research powered to meaningful 
endpoints in both HIV infected and uninfected patients.
The most exciting result of this PhD is that I have demonstrated the presence of a sub- 
clade of C. neoformans var grubii that has the ability to cause serious disease in 
apparently immunocompetent patients. While its ecological niche is not known, it is 
likely to be associated with pigeons, and there is potential for dispersal of the pathogen. 
It offers a great opportunity to better understand the pathogenesis of cryptococcal 
meningitis, which I hope to take forward in the future.
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XU THE, TRIEN VONG VA GIAI PHAP PHAT TRIEN,. 3 3 1
doanh nhan Viet Nam can phai ra nitdc ngoai hoat dong. 
Do do, luat phap Viet Nam vita phan anh du’dc ban chat 
che do xa hoi, truyen thong dan toe, ma con ca nhdng 
thong le quoc te da ditdc tat ca cac dan toe, quoc gia chap 
nhan nhii mot qui tic  dieu chinh hanh vi chung cho moi 
doanh nghiep, khong phan biet che do xa hoi. Do do, trong 
tien trinh phat trien va sit dung khu vUc FIE tiep tuc 
hoan thien he thong phap luat. Trong do, can hoan thien 
va xay dxing dong bo, nhat quan cac van ban quy pham 
phap luat lien quan den dau tof nitdc ngoai. He thong phap 
luat phai co tinh hap dan, thong thoang, ro rang, on dinh 
va mang tmh canh tranh cao so vdi cac niidc trong khu 
viic. Tiep tuc hoan chinh he thong phap luat chung ve dau 
tit va Luat Doanh nghiep thong nhat de tao moi tritdng 
kinh doanh that sii on dinh, binh ding. Tiep tuc hoan 
thien Luat ve kinh doanh bat dong san, Luat Canh tranh 
va Luat Chong doc quyen... Phai coi yeu to"phap ly vita la 
mot nhan to" quan trong trong viec thu hut v.on dau tit 
nitdc ngoai, vita la cd scl de gii3 viing quyen tit chu ve kinh 
te", chinh tri cua dat nitdc. Nghien ciiu sita doi he thong 
cac loai thue", hitdng moi no litc ve chinh sach thue" vao 
muc dlch thue day dau tit de md rong khu vitc FIE. Tritdc 
m it can hoan thien cac dao luat sau:
Thti nhat, hoan thien ve Luat Lao dong: mac du da cho 
phep DNCVDTNN trite tiep tuyen dung lao dong, nhitng 
phia Viet Nam vin  can can thiep mem deo vao van de 
tuyen dung lao dong cua ho. Trong do, can khac phuc tinh 
trang cac DNCVDTNN phai sit dung lao dong qua cac to
